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SOMMARIO  
Introduzione: ILT7 (immunoglobulin like transcript 7) è una molecola di superficie 
selettivamente espressa dalle cellule dendritiche plasmacitoidi (pDC) umane. Il 
cross-linking di ILT7 sopprime l’attivazione delle pDC e la produzione di interferoni 
di tipo I (IFN I) mediata dai recettori Toll-like (TLR)7/9. BST2 (bone marrow stromal 
cell antigen 2), identificato come un ligando naturale di ILT7, è espresso da diversi 
tipi di cellulari e regolato da IFN I. L’interazione tra BST2 e ILT7 costituirebbe un 
feedback negativo sull’attivazione delle pDC che se alterato potrebbe contribuire 
all’attivazione cronica di tali cellule mediata da HIV. Pertanto, abbiamo verificato: 1) 
se l’espressione di BST2/ILT7 nelle cellule mononucleate del sangue periferico 
(peripheral blood mononuclear cell, PBMC) fosse correlata con l'attivazione delle 
pDC mediata da HIV-1 o da TLR7/9L; 2) quali stimoli influenzassero l’espressione 
di BST2 sulle PBMC e la produzione di IFN I; 3) se l'attivazione delle pDC in 
risposta a HIV-1 e TLR7/9L fosse direttamente modulata da BST2 in vitro. 
Metodi: Le PBMC, isolate da donatori sani, sono state coltivate per tutta la notte in 
presenza o meno di imiqimod (TLR7L), CpG ODN (TLR9L), AT2-HIV1, TNFα, 
IFNγ, IL4 IL10, Anti-IFNAR2 (Interferon Alpha/Beta Receptor Chain 2) o della 
proteina di fusione BST2-GST. Le cellule T sono state stimolate con anticorpi anti-
CD3. L'effetto del blocco di BST2 e del cross-linking di ILT7 è stato testato 
utilizzando un anticorpo monoclonale (mAb)  anti-BST2 e un mAb che induce il 
cross-linking di ILT7. L’espressione di ILT7, BST2, CD83 e CCR7 è stata 
analizzata mediante citofluorimetria. Le linee cellulari 293T, transfettate con BST2
wt
 
o mutato, sono state usate per testare l’efficienza di legame di anti-BST2 mAb e in 
coltura con le pDC per testare l’effetto biologico di BST2. L’IFNα è stato 
quantificato mediante ELISA. L’analisi statistica è stata condotta con SPSS 19.0 
Risultati: ILT7 è selettivamente espressa dalle pDC, ma la sua espressione 
diminuisce rapidamente in vitro durante la maturazione delle pDC, confermata da 
cambiamenti morfologici e dall’espressione di CCR7. L’aumento di CD83, segno di 
piena maturazione e attivazione delle pDC, avviene solo in seguito alla 
stimolazione di TLR7/9. L’espressione di BST2 non è affetta da coltura in vitro. E’ 
maggiore nei monociti, nelle mDC e nelle cellule B, rispetto alle pDC e alle cellule 
T, ed è modulata da IFNα. Inoltre, l’espressione di BST2 sulle pDC è massima a 
moderate concentrazioni degli stimoli dei TLR, ma modesta a dosi elevate degli 
stessi. Questo profilo correla con quello di CD83 e con la produzione di IFNα, ma 
differisce dall’attivita’ di IDO (indoleamine-2,3-diossigenasi) a seguito di 
stimolazione con HIV. Il cross-linking di ILT7 inibisce la produzione di IFNα nelle 
PBMC esposte ad HIV o TLR7/9L. Tuttavia, il blocco di BST2 non influenza la 
produzione di IFN-I. L’ossevata mancanza di efficacia di BST2 non dipende 
dall’inefficienza dell’anti-BST2 mAb il quale, coniugato al fluorocromo PE, lega 
efficacemente le cellule 293T transfettate con BST2. Inoltre la produzione di IFNα 
non è modificata né da BST2-GST né in pDC in coltura con cellule 293T 
transfettate con BST2. La stimolazione del recettore delle cellule T contribusce 
all’aumento di BST2, ma anche quando BST2 é elevato  nei linfociti T l’anti-BST2 
mAb non altera la secrezione di IFNα. IL10 e, in parte, TNFα inibiscono la 
produzione di IFNα indotta da TLR9L, che peró non é ripristinata bloccando BST2. 
Conclusioni: I nostri dati indicano che il cross-linking di ILT7 sia un meccanismo 
omeostatico delle pDC immature circolanti, non un feedback negativo delle pDC 
attivate, e pongono dubbi sul ruolo biologico di BST2 come ligando di ILT7.  
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ABSTRACT  
Introduction: The immunoglobulin like transcript 7 (ILT7) is a surface molecule 
selectively expressed by human plasmacytoid dendritic cell (pDC). ILT7 cross-
linking inhibits Toll like receptor (TLR) 7/9-mediated pDC activation and type I 
interferon (IFNI) production. The bone marrow stromal cell antigen 2 (BST2) is a 
natural ligand for ILT7, is expressed on several cell types and encoded by an IFN I-
stimulated gene. BST2/ ILT7 interaction may provide a negative feedback for pDC 
activation. Alterations of the BST2/ILT7 negative feedback may contribute to HIV1-
induced pDC over-activation and pathogenesis. We tested: 1) if BST2/ILT7 
expression in peripheral blood mononuclear cell (PBMC) correlates with TLR-
mediated pDC activation; 2) which stimuli can influence BST2 expression and IFN-I 
production by PBMC; 3) if TLR-induced pDC activation is directly modulated by 
BST2-expressing cells in vitro. 
Methods: PBMC from healthy donors were cultured overnight with or without  
imiquimod (TLR7L), CpG ODN (TLR9L), AT2-HIV1, TNFα, IFNγ, IL4 IL10, Anti-
Human Interferon Alpha/Beta Receptor Chain 2 (IFNAR2), BST2-GST fusion 
protein. T cells were stimulated using CD3 antibody. The effect of BST2 blockade 
and ILT7 cross-linking were tested using an anti-BST2 and cross linking-ILT7 
monoclonal antibodies (mAbs), respectively. ILT7, BST2, CD83 and CCR7 
expression was analyzed by flow cytometry. 293T cell lines transfected with 
BST2
WT
, or BST2 mutants, were used to test anti-BST2 mAb efficiency of binding 
or co-cultured with purified pDC to test the biologic effect of BST2. IFNα production 
was quantified by ELISA. Statistical analyses were performed using SPSS 19.0.  
Results: pDC exclusively expressed ILT7, which was rapidly downregulated in 
vitro as part of a first step of pDC differentiation, characterized by an increase of 
the pDC morphological complexity and CCR7 expression. CD83 expression, 
indicative of full pDC activation and maturation, occurred only following TLR 
stimulation. Conversely, BST2 expression was not affected by in vitro culture; it 
was highest in monocytes, mDC and B cells compared to pDC and T cells and it 
was modulated by TLR7/9L-induced IFNα production. BST2 expression on pDC 
was highest at intermediate stimuli concentrations but modestly increased at 
maximum concentrations; a profile which correlated with CD83 expression and 
IFNα production but not with indoleamine 2,3 dioxygenase (IDO) activity after HIV 
stimulation. PBMC pre-treatment with ILT7 cross-linking mAbs reduced both 
TLR9L/HIV-induced IFNα production and HIV-induced IDO activity. In contrast, 
pre-treatment with blocking BST2 Abs did not increase IFNα production or IDO 
activity. The lack of biological effect of BST2 was not due to inefficient αBST2 Ab 
binding, as PE-labelled αBST2 Ab efficiently stained BST2-transfected 293T cell 
lines. No change in IFNα production were observed using either a soluble BST2 
protein or a co-culture system based on purified pDC and BST2
WT 
transfected 293T 
cells. T cell receptor engagement resulted in maximum BST2 expression on T 
cells, but BST2-blocking mAbs did not affect IFNα release even when BST2 
expression on T cell was enhanced. IL10 and TNFα inhibited TLR9L-induced IFNα 
production but BST2 blockade did not restored IFNα responses.  
Conclusions: Our data suggest that ILT7 cross-linking may acts as homeostatic 
mechanism on circulating pDC rather than a negative feedback for activated 
mature pDC, and argue against the role of BST2 as a biologically active ILT7 
ligand. 
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1  INTRODUCTION 
1.1 Human immunodeficiency Virus  
The Human immunodeficiency virus (HIV) is a member of the Lentiviridae 
subfamily of retroviruses affecting humans [1]. HIV has been identified as the 
causative agent of the acquired immune deficiency syndrome (AIDS) [2, 3] a 
disease characterized by variable clinical manifestations sharing an underlying 
state of severe immunodeficiency that accompanies the onset of opportunistic 
infections and cancers. No definitive cure or vaccine for AIDS is currently available.   
1.1.1 Historic overview  
The first clinical identification of AIDS dates back to 1981 when Gottlieb and co-
workers reported the case of five young men affected by rare opportunistic 
infection, Pneumocystis carinii pneumonia (PCP), associated with a severe T cell 
depletion [4]. Shortly after, cases of another rare disease, skin cancer Kaposi’s 
sarcoma (KP), emerged [5]. Both PCP and KP were usually detected in people with 
a severe impairment of the immune system caused by cancer or 
immunosuppressive drugs [6]. As cases of PCP and KP were continuously 
increasing, the U.S. Centers for Disease Control and Prevention (CDC) set up a 
task force to monitor the outbreak of infections [7, 8]. Several other unusual 
anomalies were observed in the infected patients, such as generalized 
lymphadenopathy, low CD4
+
 cell count, and high susceptibility to opportunistic 
infections [1, 5, 7]. The disease was first associated to 4 risk groups, which were 
originally referred to as the “4 H’s” as they seemed to single out Haitians, 
homosexuals, hemophiliacs, and heroin users [9]. Soon, it became clear that also 
heterosexual individuals and other intravenous drug users could be affected by the 
disease which was thus named AIDS, a term officially used by the CDC in 1982 
[10]. As the syndrome was defined, different research teams began to search for 
the causative agent. In 1983, two different groups reported that a new virus, with 
reverse trascriptase (RT) activity, was the causative agent of AIDS. The group led 
by Robert Gallo isolated a virus from the peripheral blood T cell of a patient 
diagnosed with AIDS presenting a similar morphology to the human T cell leukemia 
virus (HTLV) and recognised by antibodies (Abs) against the viral protein p19 and 
p24 [3]. Thus this virus was called HTLV-III. At the same time Barre-Sinoussi and 
Montagnier (Nobel Prize in Physiology or Medicine 2008) detected traces of RT 
activity, indicating the presence of a retrovirus, in the supernatants of T cells 
cultured with interleukin (IL) 2 and in cells isolated from the lymph node biopsy of a 
patient with generalised lymphadenopathy [2]. Moreover the labelled viral 
supernatants could not be immune precipitated with the HTLV antibodies; 
discarding the hypothesis that virus was a member of the HTLV family. Shortly 
after, the retroviral-like particles were identified by electron microscopy, and the 
virus was called lymphadenopathy-associated virus (LAV) [11]. HTLV-III and LAV 
were later recognized as being the same virus, known today as HIV. In the next 
few years Abs against HIV were indentified in individuals diagnosed with AIDS, and 
HIV was recognised as the causative agent of the syndrome. In 1984, the genome 
sequence finally defined HIV as a member of the genus Lentivirus of the family 
Retroviridae [1]. Since then, enormous progress has been made revealing the 
molecular basis of HIV infection, progression and transmission. Different drugs to 
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slow the disease progression are now available but further studies are carrying on 
in order to find a vaccine.  
1.1.2 Epidemiology 
Since 1981, the year of the first reported case of AIDS [4], over 60 million people 
have been affected and more than 25 million died of this disease [12].Thus, AIDS 
is now considered one of the greatest pandemic infections of our era. It is 
estimated that in 2010 approximately 34 million people were living with HIV, of 
whom about 23 million were in the sub-Saharan Africa. The number of newly 
infected people worldwide is gradually declining, from 3.4 million in 1997 to 2.7 
million in 2010, but large differences exist between different regions. During the 
first decade of the new millennium, the incidence of HIV infection declined in 33 
countries, of which 22 are in the sub-Saharan region of Africa. Indeed, an 
approximate reduction of 16% in the percentage of newly infected people was 
reported in sub-Saharan African countries in 2010 compared to 2001 and 26% 
compared to 1997, when the incidence of HIV peaked overall. A similar trend was 
observed in South-East Asia. However, not all countries fit in the overall trend. 
Between 2001 and 2010, an increase in newly infected people has been observed 
in the Middle East and North Africa; moreover the incidence of HIV infection has 
been accelerating again since 2008 in Eastern Europe and Central Asia [13]. 
Similarly, the global number of deaths due to AIDS is gradually declining, from the 
peak of 2.2 million observed in 2005 to 1.8 million in 2010. However, significant 
differences were observed between different regions. A reduction of AIDS-related 
deaths was reported in sub-Saharan Africa, South and South-East Asia and the 
Caribbean since 2005; which reflects the intensification of prevention efforts as well 
as increasing coverage of antiretroviral therapy (47% coverage of people eligible to 
treatment in low- middle income countries). Conversely, the number of people 
dying from AIDS increased of around 10 fold in Eastern Europe and Central Asia 
and of 60% the Middle East and North Africa between 2001 and 2010. 
Although there is a progressive global reduction in the incidence of new infections 
and AIDS-related deaths, the numbers still remain very high. Therefore the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) and  World Health 
Organization (WHO) released a five years strategy (2011-2015) that aims to reach 
zero new infections, zero discrimination and zero AIDS-related deaths for 2015. 
This strategy focuses on four main approaches: 1) optimizing prevention, diagnosis 
and treatment; 2) building sustainable health system; 3) leveraging broader health 
outcomes through HIV responses; and 4) removing vulnerability and structural 
barriers to accessing services [13]. 
1.1.3 Genetic diversity  
The HIV acronym comprises two major types of the virus: HIV type one (HIV-1) and 
HIV type two (HIV-2). Both of these viruses originate from multiple cross-species 
transmissions of simian immunodeficiency viruses (SIVs) naturally infecting African 
primates [14]. Simian relatives of HIV-1 and 2 were respectively discovered in 
Chimpanzees (SIVspz) [15] and Sooty mangabeys (SIVsm) [16]. 
HIV-1 includes four lineages (M, O, N and P) generated by distinct cross-species 
transmission events. Group M (Main group) is the major group responsible for the 
HIV pandemic infection, virtually diffused in every country. Group O (Outlier group) 
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is responsible for less than 1% of the HIV-1 infection, concentrated in Cameroon, 
Gabon, and neighbouring countries. Group N (non-M, non-O group), has been 
documented since 1998 in only 13 individuals in Cameroon. Finally, group P, 
discovered by Plantier and colleagues in 2009 and detected so far in only two 
individuals in Cameroon. Additionally, group M can be divided into 9 subtypes, 
named with letters, and sub-subtypes denoted with numbers (A1, A2, A3, A4, B, C, 
D, F1, F2, G, H, J, and K). The subtypes (or Clades) are phylogenetically linked 
strains of HIV-1 that are approximately the same genetic distance from one 
another. Moreover, the recombination between subtypes within a dually infected 
person led to the generation of unique recombinant forms (URFs) or circulating 
recombinant forms (CRFs), so called when identified in three or more people with 
no direct epidemiologic linkage [17]. 
HIV-2 is mainly spread in West Africa, with the highest prevalence rate recorded in 
Guinea Bissau and Senegal. Similarly to HIV-1, HIV-2 is divided in lineages (A-H), 
but only Group A and B have spread in humans to a considerable level [14]. 
Critical differences exist between HIV-1 and HIV-2, which provide useful 
information about the evolution and pathogenesis of HIV. The main differences 
between the two strains lie in a lower disease severity induced by HIV-2 compared 
to HIV-1, a better immune control of HIV-2 infection and a certain level of 
independence from CD4 for infection [18]. 
The data presented in this dissertation refer to HIV-1, which will be simply named 
as HIV, from now on. 
1.1.4 HIV genes and structure 
The HIV virion has an approximately spherical shape with a diameter of 100-120 
nm. The virion presents a lipid bilayer membrane (envelope) surrounding a dense 
truncated cone-shaped nucleocapside (core) that allocates the HIV genome, the 
viral protease (PR), the integrase (IN), the reverse transcriptase, and the viral 
accessory proteins Vif, Vpr and Nef (Figure 1.1A).The envelope is embedded with 
spikes of the viral Env glycoprotein, a heterodimer formed by the external 
glycoprotein (gp) 120 non covalently–linked to the transmembrane gp41 in a 
triangular symmetry [19]. Recent reports showed that the number of the Env spikes 
in HIV is about 14 ± 7 per particle (range 4 to 35) contrasting with the previous 
studies which reported a number of 72 spikes per virion [20]. The core is formed by 
4 main structural proteins: 1) the matrix proteins (MA or p17), which create a shell 
directly associated with the internal side of the envelope thanks to the N terminal 
domains; 2) the capsid proteins (CA or p24), which are assembled in an hexameric 
ring via the N-terminus  to form the capsid; 3) the nucleocapsid proteins (NC or p7), 
which stabilize the RNA dimers in the nucleocapsid assemblage; and 4) the protein 
p6 (domain of p55), which is involved in terminal steps of virion assembly and 
budding [19].  
The viral genome consists of two copies of 9.2 kb single-strand RNA. Each strand 
consists of 2 long terminal repeated regions (LTR), involved in the integration of the 
viral genome in the infected cell and in the viral replication, plus 9 genes divided in 
3 groups on the basis of the function of the encoded proteins. In particular Gag, 
Pol, Env are defined as structural genes; Tat, Rev and Nef as regulatory genes; 
and Vpu, Vpr, and Vif as accessory genes (Figure 1.1B). In details Gag encodes 
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for a polyprotein precursor (p55) which is processed by PR yielding the structural 
core proteins p17, p24, p6 and p7; Pol encodes for the viral enzymes PR (p11), RT 
(P66/51) and IN (p32). Gag and Pol are initially synthesized as one large 
polyprotein, Gag-Pol. Env encodes for the polyprotein p160, which is then 
glycosylated to produce gp160. The gp160 is cut into the envelope proteins gp120 
and gp41 which mediate the attachment and fusion of the virion to the membrane 
of the target cells and determine the viral tropism.  
 
Figure 1.1 HIV-1 structure and genome.  
A) Diagram representing the structural organisation and composition of the HIV 
virion [21]. B) Schematic representation of HIV RNA genome [22]. 
The tat, rev and nef genes encode for 3 proteins, equally named, which exhibit 
regulatory properties. Rev (p19) is a regulator of viral gene expression, which is 
also involved in the inhibition of RNA splicing; Tat (p14) is an activator of viral 
genome transcription; whereas Nef (p24), initially thought to be a negative 
regulator of transcription, was later shown to downregulate CD4 and MHC-I, 
prevent apoptosis and increase the infectivity of HIV. The HIV accessory proteins 
include: Vif (Viral infectivity factor; p23), a protein essential for correct viral 
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assembly and transmission; Vpr (Viral protein R; p15) which is mainly involved in 
the G2 cell-cycle arrest; and Vpu (Viral protein U), which induces CD4 
downregulation and influences the release of the newly formed virions [23, 24]. The 
role of Vpu is important for the purposes of my research project and it will be 
further discussed later in this dissertation.   
1.1.5 HIV Life cycle and tropism  
The replication cycle of HIV involves a series of subsequent steps, graphically 
illustrated in Figure 1.2 
 
1.2 HIV replication cycle [25]. 
Diagram summarizing the steps of HIV life cycle: binding and entry; uncoating; 
reverse transcription; integration; proteins formation; budding. 
The HIV life cycle begins with the binding of the mature virion to the surface of the 
human target cell and the consequent fusion between human and viral membrane. 
This first step is mediated by the envelope proteins and starts with the binding of 
the viral gp120 to CD4 a cellular surface glycoprotein of 58 kDa. CD4 is expressed 
by 60% of the circulating T cells, but also T cell precursors, monocytes-
macrophages, eosinophils, dendritic cells (DC), and microglia cells [26], which 
represent some of the viral cell targets. HIV replication, takes place mainly in CD4+ 
T cells but other cell types are infected by the virus such as monocytes and 
macrophages [27], Kupfer cells and hepatocytes [28], microglia [29] and circulating 
DC [30]. Moreover in vitro studies showed that also natural killer (NK) cells [31] and 
CD8+ T cells are permissive to HIV infection, probably by a mechanism 
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independent of CD4-gp120 interaction [32]. During HIV infection of CD4+ cells, the 
binding between gp120 and CD4 induces conformational changes in gp120 which 
expose co-receptor binding sites. The principal co-receptors used by HIV are the 
C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 
(CXCR4) which influence HIV tropism. In particular the macrophage-tropic (M-
tropic) strains of HIV (or R5 viruses) interact  with the β-chemokine receptor CCR5, 
mainly expressed by macrophages, CD4+ T cells and DC; the T-lymphocyte–tropic 
(T-tropic) HIV strains (or X4 viruses) instead, mainly bind the α-chemochine 
receptor CXCR4 principally expressed by primary CD4+ T cells. Dual tropic HIV 
strains (or X4R5 viruses) are able to interact with both co-receptors [26]. R5 
viruses are predominant in the in the early phases of the infection while the X4 
viruses seem to be connected to the accelerated progression of the disease and 
appear later during the course of infection [33-35].  
Upon gp120 interaction with both CD4 and co-receptor, further conformational 
changes occur in gp41 which expose an N-terminal short peptide (fusogenic 
domain) which anchors to the membrane. Subsequently the HR1 and HR2 
domains interacting with each other form a six-helix bundle structure allowing the 
membranes fusion and the consequent entry of the viral core in the cell cytoplasm 
[22]. Once in the cell cytoplasm, the viral core disassembles (uncoating) freeing the 
viral RNA and leading to the assembly of the reverse transcription complex (RTC). 
The RTC is composed by the viral genome associated with the proteins and the 
enzymes essentials for the reverse transcription, nuclear targeting and integration; 
these are RT, MA, Vpr and IN. The reverse transcription of viral RNA into cDNA 
occurs while the RTC reaches the nucleus using the cellular cytoskeleton. Once 
this process is completed, the complex is competent for the integration and is re-
named pre-integration complex (PIC); RT dissociates in order to reduce the size of 
the complex and allow its translocation into the nucleus through the nuclear pores 
[36]. Inside the nucleus, the viral IN mediates the integration of the viral DNA in the 
host cell genome. The IN acts in 3 phases: 1) it cleaves 2 nucleotides from the 3’ 
end of each viral DNA strand, forming two sticky ends; 2) it induces a staggered 
cleavage of the host chromosome; and 3) it binds together the viral and cellular 
DNA. The gaps at the 5’ end are repaired by the cellular enzymes. The viral 
genome integrated in the host DNA is referred to as provirus.  The provirus can 
remain silent for long periods of time. Upon activation of the host cell containing the 
provirus, the proviral DNA is transcribed into messenger RNA (mRNA). This 
process is mediated by the RNA polymerase II and is regulated by 5’ LTR, 
containing enhancer and promoter elements which bind transcription factors, such 
as the nuclear factor of activated T cells (NFAT) and the nuclear factor-κB (NFκB) 
[22]. The transcription process leads to the production of 3 mRNA subsets: 1) 
Multiply spliced mRNA coding for the regulatory proteins Tat, Rev and Nef. 2) 
Singly spliced mRNAs which encode for Env and the accessory proteins Vif, Vpr, 
Vpu. 3) Unspliced mRNA coding for the polyprotein Gag-Pol [37]. The regulatory 
genes are the first to be transcribed and translocated into the cytoplasm to be 
translated into proteins. The Rev protein mediates the translocation of the 
unspliced mRNAs [38]. Once in the cytoplasm the viral mRNA are translated and 
eventually cleaved by the PR to produce the viral proteins which, when assembled, 
form the new virions. In this process the two viral RNA strands associate with the 
replication enzymes and are enclosed by the core proteins forming the viral capsid. 
These molecules then migrate to the cell surface, where the process of budding 
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occurs for newly formed virions. When budding from the host cell, each virion 
incorporates part of the cellular membrane which will form the viral envelope and 
contains both viral and host cell proteins [26]. The new viruses are then ready to 
infect bystander cells thereby restarting the replication cycle. It has been shown 
that the HIV life cycle has a minimum duration of 1.2 days whilst the average 
generation time (time taken from a virion just released to infect another cell and 
produce the next generation of virions) is 2.6 days. Moreover it has been estimated 
that an average of 10.3x10
9
 new virions are produced per day in an infected patient 
[39]. 
1.1.6 Modalities of transmission   
HIV has been isolated in different biological fluids, including blood [40, 41], semen 
[42], vaginal secretions [43], milk [44] and saliva [45] at various viral 
concentrations. The concentration of HIV in the body fluids, together with the 
biological properties of the virus and the host susceptibility, influence the viral 
transmission as well as the infection outcome (AIDS-long term survival) [26]. The 
most common modalities of HIV transmission are 1) sexual (by homo/heterosexual 
intercourses; accounting for the majority of HIV infections worldwide); 2) perinatal 
(in uterus, during delivery, or postnatally via breastfeeding), and 3) parenteral (by 
blood transfusion or blood exposure through re-use or share of needles or 
syringes, mainly among intravenous drug users or during occupational health 
accidents) [46]. 
1.1.7 The clinical course of HIV infection   
Despite variations among individuals the clinical course of HIV infection seems to 
follow a common pattern of development that can be divided into 3 major stages 
[47]:  
1. Primary infection   
2. Clinical latency 
3. AIDS 
The typical course of HIV infection is shown in Figure 1.3 
The first phase is characterised by the development of a monoclueosis-like 
syndrome (acute syndrome) that affects up to 70% of patients within 3-6 weeks 
post infection [48].The typical symptoms include fever (the most common),  
headache, exhaustion, myalgia, generalized lymphadenopathy and cutaneous 
rashes [49]. A considerable viral replication occurs in this period, during which high 
levels of plasma viremia are detected [50, 51]. The peak is reached between 6-15 
days after the beginning of the acute syndrome, when the viral load varies 
approximately between 10
6
 to 10
7 
copies/ml [52].During this phase the virus also 
settles in the lymphatic tissues, which constitute the principal reservoirs where HIV 
is produced and preserved in immune complexes bound by follicular DC and 
persists in lately infected resting CD4+ T cells [53]. Concomitant with the increase 
of plasma viremia, an abrupt decline in circulating CD4+ lymphocytes is observed, 
as a consequence of both HIV-mediated apoptosis and the re-trafficking of CD4 T 
cells to lymphoid tissues or other organs [50, 51, 54, 55]. Moreover recent studies 
showed that CD4+ CCR5+ memory T cells, which preferentially reside in the 
gastro–intestinal mucosa, are rapidly depleted during HIV/SIV primary infection. 
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This results in the loss of the mucosal function characterised by the breakdown of 
the mucosal barrier which allows microbial product translocation into systemic 
circulation influencing the disease progression [56-58]. 
 
Figure 1.3 Clinical course of HIV infection 
Diagram showing phases of disease progression in relation to plasma viremia and 
CD4+T cell counts [54]. 
As the infection spreads, the immune system initiates both a cellular (peaking at 2-
3 weeks after the infection) and a humoral immune response (peaking at 12 weeks 
post infection) against HIV, resulting in a partial  and  temporary control of infection, 
during which the viral load drops and the level of CD4 T cells is partially restored 
[59-62]. Nonetheless the immune system is not able to completely clear the virus 
from the system. Plasma viremia settles to a low (but usually detectable) set point, 
the level of which is considered a predictor of disease progression [63, 64]. 
At the end of the primary infection phase, the majority of the patients enters a 
phase of clinical latency, usually asymptomatic, but delineated by the gradual loss 
of CD4+ T cells. The latency period can last for several years (generally 5-10) 
before AIDS defining symptoms are observed [54]. However significant variation 
have been observed among patients as some of them develop AIDS in less than 5 
years (rapid progressors) [65] whist others show clinical latency for more than 20 
years (long term non progressors, LTNP) [66]. Different factors have been 
associated with rate and severity of disease expression among patients, such as 
age, genetic pattern, strains of virus or co-infections [54, 55]. These variables have 
been defined “clinical illness promoting factors” [67].  
When the CD4+ T cell count in peripheral blood drops below 200 cells/μl the 
majority of patients become susceptible to opportunistic infections and develop 
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AIDS-defining symptoms (ex. generalised lymphadenopathy, PC, KS, neurological 
disorders) [68] which lead to death usually within two years [69].  
1.1.8 The immune response against HIV   
After HIV- infection, a series of immune responses against the virus are induced in 
the vain attempt to eliminate the infection.  
1.1.8.1 Cellular immune responses 
Different studies revealed the existence of an HIV-specific cytotoxic CD8+ T cell 
(CTL) response in the early phase of infection, before the actual detection of 
antibodies. This response begins in correspondence with the peak of plasma 
viremia observed during primary infection, and reaches maximum efficiency one or 
two weeks later, when the viral load drops [70]. The CTL response seems more 
efficient than HIV-specific antibodies in controlling HIV infection, as an inverse 
correlation between viral load and the number of specific CTL has been 
demonstrated using quantitative techniques [71]. Further confirmations come from 
studies on SIV-infected rhesus monkeys in which depletion of CD8+ T cells in vivo, 
using monoclonal antibodies, dramatically increased SIV viremia; leading to rapid 
progression to simian AIDS when the length of the depletion was protracted 
beyond 28 days [72].  
CTL response is HLA (MHC) restricted, antigen specific, requires cell-cell contact 
and involves the production of perforin and Fas/Fas ligand (FasL) interaction. In 
particular, the T cell receptor (TCR) on the surface of CTL binds the viral peptides 
expressed by HIV-infected cells in association with MHC class I molecules. This 
binding promotes the release of perforin, which generates holes in the membrane 
of the target cell, creating a passage for granzymes which promote apoptosis of the 
infected cells. Alternatively, the binding between Fas (on the infected cells) and its 
ligand (on CTL) may promote the apoptotic death of the HIV-infected cells. Several 
viral peptides may be recognised by CTL, which are able to induce the lysis of the 
infected cells [73, 74]. These include: RT, Env, Gag and some accessory proteins 
[75-78]. 
Additionally, it has been shown that CD8+ T cells are able to release β-
chemokines, such as MIP-1α, MIP-1β and RANTES, which are natural ligands of 
the HIV coreceptor CCR5 and are able to inhibit by R5-tropic HIV strains [79, 80]. 
Similarly other non-cytotoxic antiviral molecules, including interferon (IFN)-γ, 
tumour necrosis factor (TNF)-α, TNF-β and the soluble CD8 antiviral factor (CAF) 
can be secreted by CTL which control HIV viral infection [73, 81].  
Many indications supporting the importance of the CTL response in the control of 
HIV infection come from observations on LTNP and HIV-exposed-seronegative 
individuals (HESN). LTNP present qualitatively and quantitatively superior HIV- 
specific CTL responses compared to normal progressors, whereas HESN exhibit 
detectable levels of HIV- specific CD8+ T cells with no sign of infection or disease 
[82, 83]. 
At the same time, strong CTL responses seem to induce a selective pressure on 
the viral replication favouring the generation of virus escape mutants. The 
generation of these mutants results in a decline in the initial T cell response, which 
is followed by a second one against epitopes which escape slower or are invariant. 
This latter T cell response seems to be important for the maintenance of the 
already established viral set point [70, 84].   
 14 
 
Because CD4+ T cells are the main target for HIV infection (Section 1.1.7), the role 
of CD4+ T cell responses in controlling viral replication and disease progression is 
less clear. Nonetheless an HIV-specific CD4 T-cell response, mainly directed 
against epitopes within the Gag and Nef proteins, is detected in infected patients 
[85, 86]. However this response seems to be lower in patients with AIDS compared 
to asymptomatic ones, and it appears to become dysfunctional over time in HIV-
infected people [86, 87]. In 1997, Rosenberg and colleagues showed an inverse 
correlation between p24-specific CD4+ T cell proliferative responses and viral load 
suggesting a contribution of the CD4+T cells response in the immunological control 
of viremia [88]. Moreover, comparing non-progressive individuals and patients with 
progressive HIV infection, Wilson and colleagues, found a strong HIV-specific 
proliferative response in non progressing subjects. In contrast, the proliferative 
response was absent in progressing patients, despite the detection of IFN-γ 
producing HIV specific CD4+ T cells by flow cytometry. This suggests that the 
dysfunction observed in most HIV+ patients is likely correlated to inability of HIV 
specific CD4+ memory T cells to proliferate in response to HIV antigens, rather 
than an absolute loss of HIV specific CD4+ T cells [89]. 
1.1.8.2 Humoral immune responses 
Humoral immune responses seem to have a minor influence in the control of HIV 
infection. Antibody responses, identified as immune-complexes, begin 8 days after 
the detection of the virus in the plasma. Non-neutralising antibodies specific for 
epitopes within the Env glycoprotein are the first to be produced. In particular 23 
days after infection non neutralising Abs specific for the Env glycoprotein gp41 can 
be detected in the plasma of HIV-infected individuals. The production of non 
neutralising Abs against the Env glycoprotein gp120 require an additional 14 days. 
Neutralising antibodies (nAbs), which mediate the destruction of the virus by 
phagocytosis, start to appear only 12 weeks after HIV infection. However these 
nAbs often bind a narrow range of epitopes, usually restricted to certain virus 
isolates, favouring the generation of viral immune-escape mutants. Only later (30 
months post- infection) and only in a minority of patients, there may appear broadly 
neutralizing antibodies (bnAb), which  bind conserved  regions of HIV, and  are 
able to  neutralize a wider range of isolates (from different subtypes or from diverse 
geographical regions). However, this response is usually not associated with the 
control of viremia [70, 90]. Thus only nAbs, rather than the total amount of the 
specific Abs produced, seem to play a role in the defence against viral infection.  
The humoral immune response mounted against HIV during primary infection does 
seem to be less efficient compared to that observed in response to other viral 
infections. This impairment may be due to a number of different reasons. First, the 
generation of nAbs against HIV is delayed, probably due to the B cell impairment 
induced by the virus itself. Thus, HIV has been shown to promote the lysis of 
follicular B cells, B cell apoptosis and loss of 50% of the germinal centres, therefore 
delaying the generation of nAbs [91, 92]. During this period, and before nAbs are 
generated, the initial burst of HIV viremia has already been contained [93]. 
Additionally, different studies showed that Abs in the sera of HIV infected 
individuals are not able to significantly diminish viral infectivity in vitro [94], probably 
due to the generation of viral escape mutation (usually in the conformation or in the 
glycosylation pattern of gp120) [95, 96]. Moreover no association has been 
identified between the amount of maternal HIV specific nAbs in infected pregnant 
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women and the rate of vertical transmission [97] However studies conducted in 
rhesus macaques and chimpanzees demonstrated the protection against chimeric 
SHIV by the passive transfer of HIV nAbs, debating the role of humoral responses 
in the control of HIV replication [98-100]. 
1.1.8.3 Innate immune responses 
Recently, the role of the innate compartment of the immune system in the control of 
HIV infection has been reconsidered [101]. Thus, during primary infection, an 
increased level of acute phase proteins, such as serum amyloid A, has been 
detected. Acute phase proteins levels further increase in parallel with cytokine 
responses and viral replication [70]. The increase of viremia during acute HIV 
infection has been linked with the increase of some cytokines and chemokines 
such as IFNα, IL15, IL18, TNFα, and late-peaking rise in levels of the 
immunoregulatory cytokine IL10 [102]. The production of these cytokines, may 
participate in the control of viral replication during primary infection, but may 
contribute to HIV immunopathology during chronic infection and prolonged 
systemic inflammation. The cellular source of these cytokines has not been clearly 
identified, but may consist of a multitude of cell types including infected 
CD4+CCR5+ T cells, monocytes, activated DC, macrophages, NK cells, NKT cells 
and HIV‑specific T cells [70]. 
In particular, DC and NK cells seem to play an important role in the control of HIV 
infection. The DC subset is particular important for the purpose of my research and 
it will be widely discussed in Section 1.2 of this chapter; the role of NK cells is 
briefly described below. 
During primary infection, NK cells are activated and seem to proliferate before the 
peak of viremia [103]. Similar to CTL, NK cells control viral replication through 
cytolytic or cytokine-mediated mechanisms. Furthermore, similar to CD8+ T cells, 
NK cells secrete β-chemokines (MIP-1α, MIP-1β and RANTES) which block HIV 
infection by competing for CCR5 [104]. Moreover, in vitro studies demonstrated the 
ability of NK cells to kill HIV-infected cells directly or through antibody‑dependent 
cell‑mediated cytotoxicity (ADCC) [105, 106].  ADCC, rely on HIV specific gp120 
Abs present in the serum or at mucosal level, and it appears to negatively correlate 
with the progression of disease [107, 108]. The importance of NK cells in the 
control of primary HIV infection was established by the analyses of a cohort of 
intravenous drug users HESN, in whom NK cells showed both a higher cytolytic 
activity and an increased CC-chemokines production, compared to HIV infected 
patients and healthy controls [109]. However, several studies pointed out the 
quantitative and qualitative impairment of this cell subset during the course of HIV 
infection. In particular, it has been shown that CD4+, CXCR4+ and CCR5+ NK 
cells may constitute an important viral reservoir in chronically HIV infected 
individuals receiving antiretroviral therapy [110]. In addition, HIV replication and NK 
cells counts appear to be negatively correlated in HIV+ patients [111, 112]. 
Moreover, NK cells appear to be dysfunctional and unable to respond to stimulation 
with certain cytokines in HIV-infected individuals [113]. Finally, the expression of 
inhibitory (KIR2DL2, KIR2DL1, KIR3DL2, LIR1) and activating (ex. NKp30 and 
NKp44) receptors on NK cell surface was altered by HIV. NK cells from HIV+ 
patients seem to upregulate the expression of inhibitory receptors, whist a 
downmodulation of activating receptors has been described in untreated HIV-
infected people [113-115]. 
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1.1.9 Host immunity elusion and immune-suppression mechanisms 
1.1.9.1 HIV variability and immune-avoidance 
Despite the several mechanisms put to use by the human immune system in order 
to control and eliminate the viral infection, HIV is able to establish a chronic 
infection that gradually leads to the destruction of the immune system itself, 
eventually leading to the death of the infected individuals. The ability of HIV to 
overcome the host immune defence mechanisms is mainly related to its high 
variability. A property which is a result of 3 main HIV features: 1) the “error-prone” 
activity of the HIV RT, which lacks proof-reading property and introduces on 
average one mutation for each viral genome transcribed [116]; 2) the high rate of 
viral replication (average of 10.3x10
9
 new virions/day per patient) [39]; and 3) the 
chances of recombination events within 2 or more viral subtypes in the same 
individuals [17].  
The genetic variability of HIV allows for the generation of viral mutants which 
escape the surveillance mediated by CTL [70, 84] or nAbs [95, 96]. However, many 
other mechanisms are used by HIV to elude the host immune surveillance. An 
example of these consists in the down regulation of MHC class I molecules from 
the surface of infected cells; which are necessary for the antigen presentation to 
CTL and the subsequent lysis of the infected cells.  CTL avoidance by MHC class I 
downmodulation, is mainly mediated by the viral accessory protein Nef. Nef diverts 
the viral-peptide loaded to MHC I to the endosomal pathway, from where they are 
brought back to the trans-Golgi network, thus preventing the expression of the 
complex on the cell surface [117, 118]. Additionally, the accessory protein Tat may 
contribute to this process by reducing the transcription of MHC class I molecules in 
HIV infected cells [119]. HIV also escapes NK-mediated surveillance, usually 
enhanced by MHC class I downregulation, by selectively reducing the surface 
expression of HLA-A and HLA-B, but not the inhibitory ligands for NK receptors 
HLA-C and HLA-E [120]. 
Moreover, HIV establishes a lifelong latency in the host, which allows a prompt 
increase of viremia upon the interruption of therapy. Several cellular and 
anatomical reservoirs have been proposed in which continuous low level HIV 
replication may take place. Microglia cells, male urogenital tract, macrophages, 
follicular DC, memory or naïve T cells are some examples. Two forms of latency 
have been identified in resting CD4+ T cells:  labile preintegration latency, and 
stable postintegration latency. Additionally, different studies have shown that viral 
replication might continue in patients on antiretroviral therapy, even when the HIV 
RNA levels in the plasma are below detectable levels. Recent studies have also 
demonstrated the persistence of HIV in the gut-associated lymphoid tissue (GALT) 
in patients on therapy for 10 years. Thus, the presence of virus reservoir 
constitutes the major barrier to virus eradication [121]. 
1.1.9.2 HIV mechanisms of immune system impairment   
In parallel to the avoidance of immune surveillance, HIV gradually destroys the 
immune system inducing a strong CD4+ T cell depletion as well as a general 
dysfunction of the immune responses. HIV utilizes several direct and indirect 
mechanisms to induce immune dysfunction.  
The main ones include: 
 compromising the membrane integrity after the exposure of envelope 
fusogenic domains [122]; 
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 cytotoxicity caused by the accumulation of non integrated viral RNA or 
DNA [123, 124];  
 compromising the protein synthesis apparatus, which mainly produces 
viral proteins; 
 caspase-mediated apoptosis induced by the accessory protein Vpr [125]; 
 bystander apoptosis mediated by the accessory protein Nef [126]; 
 ADCC of non infected cells mediated by the Abs binding to soluble gp120 
attached to CD4 receptor of non infected cells [47];  
 alteration of CD4+ T cell function and activation through TCR 
downregulation [127]. 
1.1.10 Highly Active Antiretroviral Theraphy  
The association between viremia and disease progression led to the development 
of a series of drugs able to reduce viral replication. Potentially, all the phases of the 
viral life cycle constitute targets for antiretroviral therapy (ART). Currently six 
classes of antiretroviral drugs are available: 
1. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI).  
These consist of nucleoside or nucleotide analogues lacking the hydroxyl 
group in 3’ of the ribose, which compete with natural nucleoside for RT and 
inhibit the reverse transcription of the viral genome (ex. Zivoudine, 
Didanosine, Abacavir, Tenofovir). 
2. Non nucleoside reverse transcriptase inhibitors (NNRTI).  
These agents induce alteration in the RT active site, decreasing the 
binding of natural nucleotides (ex. Nevirapine, Delaviridine, Efavirenz). 
3. Protease inhibitors (PI). 
They mimic the Gag-Pol cleavage site and compete with it for PR. This 
prevents the generation of mature and infectious virions (ex. Saquinavir, 
Ritonavir Atanazavir). 
4. Fusion inhibitors. 
Binding the HR1 region of gp120, these peptides block the fusion of viral 
and cellular membrane (ex. Enfuvirdide). 
5. CCR5 antagonists. 
They block entry of the virus in the CD4+ T cells by binding the co-receptor 
CCR5 (ex. Maraviroc). 
6. Integrase inhibitors 
They block the action of the enzyme IN And prevent integration of the 
proviral DNA (ex. Raltegravir) [19, 22, 128] 
The current therapeutic strategy, Highly Active Antiretroviral Theraphy (HAART), is 
based on the concurrent use of at least 3 drugs from 2 of the above categories. 
Several studies showed the efficiency of HAART in reducing plasma viremia and 
delaying disease progression and time to death. However, the development of 
severe side effects (ex. cardiovascular complication, lopodystrophy syndrome) and 
the development of drug resistance (mainly due to poor patient’s adherence, which 
favours the generation of escape mutants) highlight the urgency for the 
development of more efficient therapies, a cure and/or an effective vaccine. The 
genetic variability of HIV and the high number of strain variations represent 
considerable obstacles to the development of a vaccine. In the past decades, 
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several approaches have been considered (including live attenuate vaccines, 
subunit vaccines and live recombinant vaccines), however no vaccine has been 
produced which was able to induce a neutralizing humoral response against HIV 
[19, 128]. 
1.2 The role of pDC in HIV infection: a new hypothesis of 
immunopathogenesis   
1.2.1 Plasmacytoid DC cell 
Dendritic cells are bone marrow derived cells, which act as professional antigen-
presenting cells (APC) with a particular ability to stimulate naïve T cells and initiate 
primary immune response [129]. In humans, two distinct DC subsets are found in 
peripheral blood: myeloid DC (mDC) and plasmacytoid DC (pDC), which differ on 
the basis of their origin, microbial pathogen identification, phenotypic markers 
expression and type of immune and adaptive response induced [130]. In particular, 
pDC were first identified in 1958 by Lennert and Remmel, who described a new cell 
population with plasma-cell morphology, but lacking of the B cell and plasma cell 
markers [131]. These newly characterized cells were particularly abundant in the T 
cell areas of the lymphoid organs, hence the name “T-cell associated plasma cells” 
[131]. Studies carried in the 1980s led then to the identification of a small group of 
cells (0.1-0.5% of blood mononuclear cells), which were MHC II positive but distinct 
from T cells, B cells, monocytes and NK cells. These cells were able to secrete a 
large amount of type I IFN, a known potent antiviral factor, in response to viruses, 
and were therefore denoted “natural type I interferon producing cells” (NPIC) [132-
135]. In 1999, a number of studies suggested that T-cell associated plasma cells 
and NPIC were in reality the same cell type actually known as pDC [136, 137]. 
Thus, pDC play an important role in antiviral immune response and constitute a 
bridge between innate and adaptive immunity. They are phenotypically defined as 
positive for CD4, CD45RA, CD123 and ILT3 but negative for ILT1, CD11c and 
lineage markers including CD3, CD14, CD16, CD19, CD20, and CD56. 
Furthermore, two additional markers appear to be restricted to human pDC in 
peripheral blood and bone marrow: BDCA2, a C-type lectin transmembrane 
glycoprotein that can internalize antigen for presentation to T cells; and BDCA4, a 
neuronal receptor that is also a co-receptor for the vascular endothelial growth 
factor A [138]. Circulating pDC are immature lymphoid-derived DC which are able 
to capture and process antigens and present peptides to T cells in the context of 
MHC molecules [139]. Upon activation, they upregulate CCR7 and CD62L, and 
migrate through the high endothelial venules (HEV) to the lymph nodes. During this 
process they mature becoming able to act as proper APC [136, 140]. The ability of 
pDC to respond to viral pathogens is associated to the expression of specific 
pattern recognition receptors (PRR) known as Toll-like receptors (TLR). TLR are a 
family of conserved trans-membrane molecules composed by an ectodomain of 
leucine-rich repeats, a trans-membrane domain and intracellular domain, know as 
Toll/IL1 receptor (TIR) domain. In particular the expression of endosomal TLR7 and 
TLR9 confers pDC sensitivity to single-stranded RNA and unmethylated CpG-rich 
DNA respectively, which are characteristic of most viral genome [138, 141]. 
Following exposure to viruses or nucleic acid, these two receptors relocate from 
the endoplasmic reticulum (ER) of the pDC to the endosome where the interaction 
 19 
 
with the RNA or DNA antagonist occurs. Subsequently TLR undergo 
conformational changes which activate the myeloid differentiation primary-
response gene 88 (MyD88). Activated MyD88 binds the complex formed by TNF 
receptor-associated factor 6 (TRAF6), Bruton’s tyrosine  kinase  and IL1 receptor-
associated kinase 4 (IRAK4) inducing 3 different signal transduction cascades 
(Figure 1.4) which leads to the production of: 1) type I IFN (IFN I: IFNα, IFNβ, IFNλ, 
IFNω); 2) proinflammatory cytokines, such as IL6 and TNFα; and 3) co-stimulatory 
molecules, such as CD40, CD80 and CD86 which promote T cell activation [142]. 
 
Figure 1.4 TLR7 and TLR9-mediated pathways in pDC 
Diagram showing the 3 main transduction cascades induced by TLR7 and TLR9 
after the interaction with TLR7 or TLR9 agonists and nucleic acids from necrotic 
cells [142].  
The antiviral properties of IFN I rely on its ability to create a cellular environment 
which is hostile to the virus. Thus, IFN I limits the uptake of nutrients from the 
extracellular compartment, promotes RNA degradation, and induces anti-
proliferative or pro-apoptotic mechanisms in different cell types including T cells 
[143]. Several studies showed the ability of IFN I to activate double-stranded RNA 
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activated protein kinase R (PKR), which promotes cell death by blocking protein 
synthesis or acts in combination with NFκB to favour Fas/FasL interaction and 
increasing TNF-related apoptosis-inducing ligand (TRAIL) production [144]. 
The ability of pDC to produce large quantities of IFN I and cytokines makes them a 
key factor in the connection between innate and adaptive immunity. Thus, besides 
directly inhibiting viral replication, IFN I promotes the antiviral functions of NK cells, 
mDC, B and T cells. Several antiviral activities have been attributed to pDC-derived 
IFN I in the literature, which include: 1) activation of NK cell and CD8+ T cell 
cytotoxicity [132]; 2) maturation of mDC into APC [145]; 3) increased production of 
IL12, IL15, IL18 and IL23 by mDC [146]; 4) promotion of differentiation, maturation 
and immune-regulatory properties of DC [146]; 5) the regulation of T cell functions 
inducing the expression of the activation marker (CD69), long term survival, IFN-γ 
secretion and the differentiation of naïve T cells into T helper type 1 (TH1) cells) 
[147]; 6) induction of the nuclear protein p53 which regulates apoptosis in cycling 
cells [148, 149]; 7) the differentiation of B cells into immunoglobulin-producing 
plasma cells in combination with IL6 [150, 151].  
Recently, it has been shown that pDC also exert a negative regulatory activity on T 
cells. Following TLR stimulation, pDC upregulates the expression of indoleamine-
2,3-dioxygenase (IDO). IDO catabolises the essential amino acid tryptophan (trp) 
into N-formyl-kynurenine, which is rapidly converted into kynurenine (kyn). The 
combination of trp depletion and accumulation of downstream bioproducts of the 
kyn pathway exert a potent inhibitory effect on T cell proliferation and activity [152, 
153]. IDO plays an important role in the maintenance of immune tolerance in 
particular conditions, for example by protecting the fetus from maternal T-cell 
immunity during mammalian gestation [153, 154], and as a protective negative 
regulator in autoimmune disorders[153, 155-157]. In chronic diseases, such as 
cancer or persistent infections, IDO appears to contribute to the maintenance of the 
chronic condition by preventing the development of an efficient immune response 
[158-161].   
Moreover, IDO modulates the activation of regulatory T cells (Treg). In particular, 
Fallarino and colleagues showed bidirectional interplay between IDO and Treg. 
Thus, Treg activate IDO through the engagement of CTLA4 with B7 on APC,, thus 
suppressing immune reactions by inducing trp catabolism. Conversely, in 
conditions of Trp depletion and/or of high amounts of its catabolites, naïve CD4+T 
cell can be forced to differentiate into Treg rather than effector T helper cells [162, 
163].  
1.2.2 Plasmacytoid DC and HIV immunopathogenesis 
According to the general accepted hypothesis of HIV immunopathogenesis, HIV 
induces a state of chronic immune activation, recognizable for example by the 
increase of some T cell activation markers (HLA-DR, CD38). This condition 
contributes to the depletion of CD4+ T cells and to the exhaustion of immune 
responses which characterizes the progression to AIDS [164-168]. In 2008, Boasso 
and Shearer proposed a new hypothesis of HIV-mediated-pathogenesis in which 
the virus leads firstly to a chronic activation of the host innate immune 
compartment which leads secondarily to the impairment of T cell function, despite 
the maintenance of the activated phenotype. Consequences of this process are the 
gradual depletion of the T cell compartment, as a result of pro-apoptotic cytokines, 
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and the gradual T cell dysfunction due to suppressive mechanisms. The role of 
pDC seems to be particularly relevant in this setting as they play an important role 
in the antiviral defence, but they may lead to the progressive T cell suppression 
when chronically activated, as observed during HIV infection, contributing to 
disease progression [164]. 
Different studies have shown that both frequencies and activity of pDC are reduced 
during HIV chronic infection; characteristics that correlate with disease progression 
[169-173]. However, it remains unclear whether the diminished proportion of 
circulating pDC in HIV positive individuals is due to HIV-mediated cytopathicity and 
apoptosis, or is secondary to their recruitment to lymph nodes [164].  
There is evidence that pDC are susceptible to HIV infection. Thus, pDC express 
CD4, CXCR4 and CCR5 which are necessary for virus entry. Furthermore, it has 
been shown that pro-viral DNA can be detected in pDC cultured with X4 or R5 HIV, 
supernatants from infected pDC can infect CD4+ T lymphocytes [174]. 
Nonetheless, whether HIV infection of pDC occurs in vivo and causes cell death is 
still debated. Recent studies failed to detect efficient HIV replication, and 
consequent cell death, in purified pDC from healthy donors exposed to HIV, unless 
the cell were matured with CD40L [175]. Moreover Hardy et al demonstrated that 
both, infectious or inactivated HIV and IFNα have no cytopathic effect on pDC but 
rather induce metabolic activation and promote pDC survival [176]. Conversely, a 
study, conducted by Meyers et al, showed that pDC undergoes apoptosis when 
cultured in presence of HIV infected cell lines [177]. Additionally studies conducted 
in both humans and monkeys were not able to detect pDC markers in the lymph-
nodes, arguing in favour of pDC depletion [178, 179]. In particular, Brown and 
colleagues showed a parallel loss of both mDC and pDC from blood and lymphoid 
tissue in simian AIDS [178]. Similarly Biancotto and co-workers reported a dramatic 
depletion of this cell subset in lymph nodes of HIV infected patients [179]. 
However, more recently, Sabado and colleagues provided direct in vivo evidence 
for the increase of pDC migration to secondary lymph nodes during primary HIV 
infection. In detail, the authors reported that both mDC and pDC rapidly decline 
during acute infection of HIV but those that remain in circulation keep their function, 
are able to induce allogeneic T cell responses, upregulate the expression of 
maturation markers (CCR7, associated with the migration to lymphoid tissues, 
CD40, and CD86 involved in the interaction with T cells) and produce different 
cytokine/chemokines (including IFNα) in response to stimulation with TLR7/8 
agonists. The analysis of gene expression also confirmed the activation profile of 
pDC during HIV infection in vivo, suggesting a role for pDC in promoting chronic 
immune activation [180]. These data corroborate the well reported increase of 
IFNα, IDO activity and CCR7 expression following HIV-mediated pDC activation in 
vitro [145, 181, 182]. Furthermore, the two hallmarks of pDC activation IFNα and 
IDO activity can be measured in the serum of chronically infected individuals and in 
the lymphoid tissues during HIV/SIV infection [183-187].  
The importance of chronic innate immune activation in the progression of disease 
during HIV infection is highlighted by studies on natural disease-resistant host of 
HIV/SIV. Thus, in the natural host of SIV (Sooty mangabeys or African green 
monkeys), infection does not results in simian AIDS despite the high level of viral 
load [164-166, 188-191]. In these animals the dynamics of the immune response 
follow a typical profile, with a transient activation of innate immune responses 
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which is replaced by an adaptive antigen-specific immune response within 3-4 
weeks from infection (Figure 1.5 Top) [164]. 
 
 
Figure 1.5 Innate immune activation in HIV/SIV natural and susceptible hosts.    
Graphs showing the magnitude of immune responses and viremia in (top) natural 
HIV/SIV hosts (as chimpanzee and sooty mangabeys respectively) or in (bottom) 
susceptible host (as humans and macaques respectively) 
 
In natural host, in fact, it not possible to detect an impairment of T cell responses or 
signs of chronic activation markers [164, 166, 190, 191]. Additionally, a study 
showed that HIV/SIV is not able to induce pDC activation in natural hosts in vitro 
[192]. Conversely, in disease-susceptible hosts pDC are activated early during 
infection and markers of pDC activation (IFNα and IDO) are visible throughout the 
course of the infection. Thus, Boasso and colleagues, proposed a new model of 
immunopathogenesis which is summarised in the bottom graph of Figure 1.5. The 
authors hypothesized that in susceptible hosts HIV/SIV infection induces a 
persistent activation of the innate immune response which results in the induction 
of T cell activation markers (CD38 and lymphoadenophathy – LAS); progressive 
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loss of T cell subsets due to apoptotic mechanisms; and functional T cell 
impairment through mechanisms mediated by IDO/Treg and programmed death 
ligand 1 (PDL1) [164].  
When chronically activated by HIV, pDC can contribute to the detriment of the 
immune system and to the consequent progression of the disease in different 
ways. First, pDC continue to produce high amount of IFN I which has been shown 
to induce TRAIL-mediated apoptosis of CD4+ T cells in both HIV+ individuals and 
SIV+ macaques [193, 194]. IFN I has also been reported to enhance the 
expression of PDL1 on monocytes and T cells during HIV infection, thus favouring 
the induction of another mechanism which contributes to immune suppression 
[195]. Moreover IFN I upregulates T cell activation markers, such as CD69 and 
CD38 [196, 197]. CD38 expression, in particular is directly correlated with disease 
progression, showing a better prognostic value than plasma viremia [168]. Chronic 
activation of pDC may also contribute to HIV immunopathogenesis by increasing 
IDO activity, which mediates the suppression of T cell responses and the 
imbalance of the Th17/Treg equilibrium [182, 197, 198]. Different stimuli have been 
reported to contribute to IDO-mediated trp catabolism. The main ones include HIV 
virions as well as the viral accessory protein tat and nef, which upregulate IDO 
expression and activity in both pDC and macrophages. Similarly, the CTLA4/B7-
mediated pathway stimulates the development of an IDO-dependent 
immunosuppressive phenotype in different cell subsets, including pDC and CD4+ T 
cells [199]. IDO+ pDC suppress both CD8 and CD4 T cell responses [199]; the 
importance of the immunosuppressive IDO activity during HIV infection, has been 
demonstrated in an animal model of HIV encephalitis, in which the inhibition of IDO 
by 1-methyl-D-tryptophan (1-MT) increases the generation of HIV-1-specific CTL 
and strongly reduces the frequency of HIV-1-infected monocyte-derived 
macrophages in the brain [200]. Interestingly, it has also been shown that IDO and 
CTLA4+ Treg co-localize in lymphoid tissues in both HIV+ individuals and SIV+ 
macaques, contributing to the impairment of antiviral immune responses [186, 187, 
201-203]. The interplay between IDO and Treg suggested by Fallarino and 
colleagues [162, 163] (Section 1.2.1), may be enhanced during HIV infection [199]. 
Indeed, HIV directly induces Treg survival by interacting with CD4. At the same 
time, HIV promotes IDO expression in pDC and macrophages. Therefore HIV, IDO 
and Treg may interact with each other in a circle leading to inefficient antiviral 
responses characterized by the inability of T cell to respond to recall antigens, allo-
antigens and mitogens [199]. Finally, a study performed in an SIV-macaque model 
showed that mucosal pDC contribute to recruit CD4+ T cells to the infection site 
through the production of CCR5+ cell-attracting chemokines. This phenomenon 
may be critical for the systemic spread of HIV in the host [204].  
 
 24 
 
 
Figure 1.6 pDC-mediated immunopathogenesis    
Diagram showing the different mechanisms by which chronic activation of pDC 
contributes to the impairment of the immune system.    
An indirect proof that pDC over-activation is one mechanism used by HIV to 
escape adaptive immunity by exhausting adaptive immunity comes from two study 
on murine models. In detail, it has been reported that mice daily injected with 
cytosine-phosphate-guanosine (CpG)-oligodeoxynucleotides (ODN), which activate 
pDC through TLR9 engagement, presented alteration in the morphology and 
architecture of lymphoid tissues, as well as functional alterations of both T and B 
cell responses, comparable to that observed in patients with AIDS [205]. A more 
recent study achieved similar results using a ligand for TLR7 [206]. These 
alterations were not observed in mice with impaired IFN I signalling. 
Recently, we provided a direct evidence of HIV-mediated T cell impairment through 
overstimulation of pDC. We altered the stability of the binding between viral gp120 
and cellular CD4, necessary for the HIV/pDC interaction, creating a model for the 
study of virus effect on pDC activation and antigen specific T cell responses. This 
was achieved by depleting cholesterol from the HIV envelope to different degrees 
using different concentrations of 2-hydroxy-propyl β-cyclodextrin (βCD). 
Cholesterol depletion impairs the functionality of the micro-domain of the HIV 
envelope which is responsible for cell-virus interaction. We thus generated virions 
which presented alteration in the envelope organization or permeabilized viruses 
which lost viral RNA and p24. Our data showed that partial cholesterol withdrawal 
reduced the ability of HIV to activate pDC, probably due to the alteration in their 
physical interaction. Furthermore, we found that APC activation can be dissociated 
from IFN I secretion and IDO activity. Thus, the permeabilised virus was able to 
upregulate the costimulatory molecule CD80 on pDC even in absence of IFN I and 
suppressive/proapoptotic mechanism (IDO, PDL1, TRAIL). This suggests that pDC 
activation occurs in different phases, characterized by an initial upregulation of 
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costimulatory molecules followed by induction of immunosuppressive mechanisms. 
Moreover, we showed that permeabilised, but not its intact counterpart, elicited 
memory CD8 T cell responses in HIV-exposed seronegative individuals, 
demonstrating that HIV directly inhibits antiviral T cell responses via pDC over-
stimulation.  We also proposed a double threshold model of pDC activation during 
viral infection. The first threshold, represented by upregulation of costimulatory 
molecules, is reached by basal stimulation. The second one is reached during 
acute infection, leading to full pDC activation, antiviral activity and promotion of 
primary T cell responses. Normally, pDC stimulation is rapidly reduced below the 
second threshold in order to maintain APC activity, thus favouring T cell responses 
and clearance or long term control of the infection. However, during HIV infection 
pDC activation is uncontrolled (preventing the contraction of the responses below 
the second threshold) thus undermining the preservation of memory T cell 
responses and promoting viral persistence [207]. Further details are available in 
Appendix 1. 
1.3 ILT7 and BST2 interaction 
1.3.1  ILT7 
Immunoglobulin-like transcripts (ILT) are a superfamily of receptors which are 
differentially expressed on myeloid and lymphoid cell subsets. These receptors, 
also named leukocyte Ig-like receptors (LILR), or monocyte/macrophage Ig-like 
receptors (MIR), are encoded by genes mapping on human chromosome 19q13.4, 
in close linkage with cytogenetic loci for the KIR genes, the gene encoding for the 
Fc receptor for Igα (FcαR) and the one for leukocyte-associated inhibitory receptor 
(LAIR). All the ILT receptors present 2 or 4 homologous extracellular 
immunoglobulin (Ig)-like domains (C-2 type), but differ in the transmembrane and 
intracellular domains [208-210]. Thus, on the basis of the latter two, we can 
distinguish 3 main subsets of ILT receptors: 
1. Inhibitory receptors (ILT2, ILT3, ILT4, ILT5 and LIR8), characterized by a 
long intracellular tail which presents 6-amino acid sequences known as 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The consensus 
sequence for ITIM is (Ile/Val/Leu/Ser)-X-Tyr-X-X-(Leu/Val), where X 
indicates any amino acid. After the interaction with the ligand, the receptors 
cluster causing phosphorylation of tyrosine residues, usually by Src family 
kinases. Phosphorylated tyrosines form docking sites for Src homology 2 
(SH2) domain-containing phosphatases such as SHP-1 and SHIP, which 
then transduce inhibitory signals [208-210]. 
2. Stimulatory receptors (ILT1, ILT1-like protein, ILT7, ILT8 and LIR6), 
characterised by a short cytoplasmic domain, thus lacking of the docking 
residues for the signal transduction. However, they present a positively 
charged arginine residue within the transmembrane domain, which allows 
the association of these receptors to the gamma chain of Fc receptors 
(FcRγ), containing immunoreceptor tyrosine-based activation motif 
(ITAMs). Thus, in association with FcRγ, stimulatory ILT receptors 
transduce signals by recruiting protein tyrosine kinases through ITAM (Tyr-
X-X-Leu/Ile sequences spaced by 6-8 amino acids) [208-210]. 
3.  Soluble receptors (ILT6), which lack of the transmembrane domain [208-
210]. 
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Figure 1.7 ILT7 structure 
Schematic representation of ILT7 structure, characterized by 4 extracellular Ig-like 
domains, a short cytoplasmic tail and a transmembrane domain containing a 
residue of arginine which associates with FcRγ containing ITAM. 
The Immunoglobulin-like transcript 7 (ILT7), also known as CD85g or leukocyte 
immunoglobulin-like receptor subfamily A member 4 (LILRA4), is a protein of 499 
amino acids which presents the typical morphology of ILT stimulatory receptors 
(Figure 1.7) [208-211].  
In order to characterize genes which were selectively expressed by human pDC, in 
2002 Rissoan and colleagues used a polymerase chain reaction (PCR)–based 
subtraction technique on cDNA from human tonsils pDC, using cDNA from 
monocyte-derived DC (mDDC) as competitor. Subtractive hybridization revealed 
that ILT7 was selectively expressed by pDC in comparison to mDDC [212]. 
Subsequently, Ju and colleagues showed that the mRNA of ILT7 was a specific 
marker of pDC by using microarray analysis of RNA isolated from different DC 
subsets, ex vivo amplified CD34
+
 progenitor cells and B cells [213]. Few years 
later, two groups independently confirmed that ILT7 mRNA was specifically 
expressed by human pDC [214, 215]. Cao and colleagues showed that the 
expression of ILT7 was restricted to pDC by screening human leukocyte gene 
expression databases and quantitative reverse transcription (RT)-PCR [214]. The 
data was validated by Cho et al. through the serial analysis of gene expression 
(SAGE) libraries constructed on human pDC [215]. The expression of the protein 
by human pDC was further demonstrated in flow cytometry by both groups, which 
independently generated anti-ILT7 monoclonal Ab (mAb) in mice [214, 215]. 
However, when pDC were activated by CpG ODN, HSV (TLR agonists) or IL3, 
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ILT7 was rapidly downregulated from the cell surface [214, 215], corroborating the 
observed reduction of ILT7 transcripts [212, 213].    
Because ILT7 protein presents a positively charged arginine within the 
transmembrane region, Cao and colleagues speculated that ILT7 could be 
expressed on the cell surface in a heterodimer with one adapter FcRγ family. Using 
an “adapter trap” reporter cell system based on the transfection of murine BaF/3 
pro–B cells with the 3 adapters expressed by pDC (FcεRIγ, DAP12, or DAP10) 
they demonstrated that ILT7 was able to stabilize only the surface expression of 
FcεRIγ. Likewise FcεRIγ increased the cell surface expression of ILT7; plus the 
complex ILT7/FcεRIγ could be coimmunoprecipitated from the lysate of BaF/3 cells 
transfected with the two genes [211, 214]. The stable association between ILT7 
and the ITAM- bearing adapter FcεRIγ was further confirmed by Cho et al [215].  
Cao et al also showed that the cross-linking of FcεRIγ-ILT7 complex on freshly 
isolated pDC induced stimulatory signals. Indeed, both Src family kinases, and Syk 
family kinases, usually involved in the signal transduction cascade mediated by 
ITAM, were phosphorylated following ILT7/FcεRIγ cross-linking. Additionally, ILT7/ 
FcεRIγ cross-linking caused a conspicuous mobilization of intracellular calcium, 
one of the typical downstream events of the ITAM-mediated cascade. However, 
ILT7 negatively regulated TLR responses. Indeed, when pDC were stimulated with 
the TLR9 agonist CpG ODN, ILT7 cross-linking reduced IFNα and TNFα 
production as well as IFN I transcription [214]. These results are in agreement with 
other studies showing inhibition of TLR-mediated pDC activation through the 
signalling induced by ITAM adapters [216-218]. Thus, the authors proposed that 
ILT7/FcεRIγ cross-linking activates a signal transduction cascade, which may 
involve different kinases (ex. B lymphoid tyrosine kinase- BLK, Lyn kinase, Syk, 
surprisingly expressed by pDC) and cell type specific adapter molecules (ex. 
BLNK, BCAP), leading to the suppression of TLR7/9-mediated IFN I and 
proinflammatory cytokines production (TNFα, IL6), minimally affecting pDC 
maturation (CD80, CD86) [211, 214].  
The importance of ILT7 in regulating IFN I production was confirmed by Cho et. al. 
In this study, using different ILT7 mAb clones (37D and 26E), the authors obtained 
contrasting results on calcium mobilization and IFN I production. The clone 37D 
increased calcium mobilization in ILT7 transfected pDC CAL-1 leukemic cells and 
reduced IFN I production in CpG ODN/Influenza virus stimulated pDC. Conversely, 
the clone 26E upregulated IFN I production and did not affect calcium mobilization. 
These differences may depend on the different binding sites and affinity showed by 
the two Abs [215]. 
1.3.2  BST2 
The bone marrow stromal antigen 2 (BST2) was first cloned in 1995. It was 
identified as a human membrane protein, expressed on bone marrow stromal cell 
lines and synovial cells, potentially involved in pre-B-cell growth [219]. An identical 
protein, but named HM1.24, was also detected on terminally differentiated human 
B cells and considered as a potential anticancer target for multiple myeloma [220]. 
This protein, later renamed CD317 [221], was shown to be strongly stimulated by 
IFN, due to interferon response elements and a binding site for the transcriptional 
factor STAT3 in the promoter region of its gene [222]. Nonetheless, the IFN-
induced upregulation of the protein appears to be cell-type-dependent [223].  
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Only recently, BST2 has been identified as a new element of the innate immune 
response to enveloped viruses. The first indication of its antiviral activity came from 
a study which suggested that BST2 is targeted by the viral ubiquitin-ligase K5 of 
Kaposi’s sarcoma-associated herpes virus (KSHV) [224]. However, its role as 
proper host restriction factor (host defence proteins that directly inhibit viral 
replication) was demonstrated in 2008 when the ability of BST2 to inhibit the 
release of Vpu-defective HIV particles was shown [225, 226]. Thus, BST2 was 
renamed Tetherin because of its ability to tether nascent HIV-1 particles to the cell 
surface [225, 226]. It is now well known that Tetherin inhibits the release of 
different enveloped viruses by targeting the host cell-derived lipid bilayer [227].  
In the present dissertation the term BST2 will be used to indicate the protein known 
as BST2, HM1.24, CD317 or Tetherin protein.  
In humans, BST2 is encoded by a single copy of the bst-2 gene located on 
chromosome 19p13.2 [219, 228]. BST2 orthologues have been found in placental 
mammals [228]. Several cell types, such as monocytes/macrophages, B cells, T 
cells, pDC and cancer cell lines constitutively express BST2 [228, 229].   
 
 
Figure 1.8 BST2 structure 
Schematic representation of BST2 monomer, characterized by a short cytoplasmic 
tail and a transmebrane, an extracellular coil-coled domain and a GPI anchor 
BST-2 is an atypical type II transmembrane protein which localizes to the lipid rafts 
of the plasma membrane, to the trans-Golgi network (TGN) and to early and 
recycling endosomes. It is characterized by a short N-terminus intracellular domain, 
a transmembrane region, an ectodomain (which forms coiled coil in BST2 dimers) 
and an extracellular C-terminus modified by a glycosyl phosphatidyl inositol (GPI) 
membrane anchor (Figure 1.8). The particular BST2 topology determines its 
antiviral activity. The double anchor is involved in the inhibition of viral particle 
release, possibly because one of the anchor is inserted in the cellular membrane 
whilst the other in the viral membrane; Three extracellular cysteines (C53, C63, 
C91) mediate disulphide bonds, resulting in the formation of BST2 dimers; 
alterations in this 3 residues has been shown to prevent dimer formation, reducing 
BST2 antiviral properties. The intracellular tail induces BST2 endocytic recycling, 
interacting with clathrin adaptors AP1 and AP2. In polarized epithelial cells, 
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instead, this cytoplasmic tail connects BST2 to subapical cortical actin filaments 
[227, 230]. 
BST2 is incorporated in the newly formed virions during HIV budding. However, the 
exact mechanism by which BST2 retains the virions on the cellular membrane is 
still unclear. Different models have been proposed. Biochemical and structural 
evidences suggest that parallel BST2 dimers form physical cross-links between 
either the cellular and viral membrane or the membranes of other virions thanks to 
the dual anchor, thus promoting the accumulation of virions on the cell surface and 
the consequent endocytic uptake, which potentially leads to the degradation of the 
viruses [227, 231]. 
In primates, the immunodeficiency viruses HIV-1, HIV-2 and SIV encode viral 
proteins which counteract BST2 activity. These proteins are Vpu, Env and Nef for 
HIV-1, HIV-2 and SIV, respectively [227].  
Vpu is a 16 kDa protein translated from a Rev-dependent vpu–env bicistronic viral 
mRNA. Because it is translated during the late stage of HIV-1 infection, Vpu was 
originally thought to be carried into mature virions. However, studies investigating 
the presence of Vpu in cell-free virus have given contrasting results. Vpu consists 
of a 27 amino acid transmembrane domain at the N terminus, followed by a 54 
amino acid intracellular region consisting of two α-helices [231]. The crystal 
structure of Vpu has not yet been deciphered; different biochemical and genetic 
evidence lead to the hypothesis that the transmembrane domain may be critical for 
Vpu multimerisation in order to form ion channels. However, the role played by the 
ion channel in the antiviral function of Vpu is still unclear [232]. Vpu is well known 
for its ability to downregulate CD4 expression on the endoplasmic reticulum, 
preventing the premature binding of viral gp160 with CD4. In particular, the 
intracellular tail of Vpu recruits the β-transducin repeat containing protein (β-TrCP), 
that is part of the E3 ubiquitin ligase complex, promoting polyubiquitination and 
proteasomal degradation of CD4 [233]. 
Through the interaction of the respective transmembrane domains, Vpu has been 
shown to downregulate BST2 from the plasma membrane. Similar to the 
mechanism of CD4 downregulation, Vpu recruits β-TrCP promoting the 
proteasomal degradation of BST2. Several studies also suggested that Vpu may 
induce lysosomal degradation of BST2, promoting the retention of the protein in the 
endolysosomal system. Finally, different studies reported that the inhibition of 
BST2 antiviral activity is achieved by Vpu even if BST2 is not degraded. Thus, the 
sequestration of BST2 to the endosomal compartment may be sufficient to 
withdraw BST2 from the plasma membrane where its activity is exerted. This may 
occur through trapping of newly synthesized BST2 proteins within the TGN or by 
preventing the return of endocytosed proteins to the cellular surface [228, 231]. 
Despite the important role of BST2 in preventing virus release, it seems unlikely 
that the only function of BST2 is related to its activity as host restriction factor. 
Recently, BST2 has been discovered as the natural ligand of ILT7, suggesting its 
possible involvement in the regulation of the innate immune response [234]. The 
scientific steps leading to this discovery and the importance of the pathway 
mediated by the interaction between BST2 and ILT7 will be discussed in the next 
section.    
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1.3.3 ILT7 and BST2 interaction. 
In 2009 Cao and co-workers showed that the biological ligand for ILT7 is not a 
member of the MHC class I molecules, and rather corresponds to the host 
restrictor factor BST2. In this study, the authors co-cultured ILT7 reporter cell lines 
with different human breast carcinoma cell lines and several other cancer cell lines, 
in order to identify one or more ILT7 ligands (ILT7L). They found that T47D breast 
cancer line was the most efficient in triggering ILT7. Thus, they used the T47D-
ILT7L+ cell line, plus the ILT7L- breast cancer line MDA- MB-231, to immunize 
mice, obtaining different hybridoma clones secreting mAbs able to bind exclusively 
to T47D cells. The screening of these clones on the basis of their ability to prevent 
the T47D-mediated ILT7 reporter activation lead to the identification of two mAbs 
clones which recognise ILT7L: 26F8 (IgG1) and 28G4 (IgG2a)[234]. A subsequent 
cDNA library screening revealed that both the mAbs were able to bind the BST2 
protein. Additionally the researchers provided 3 main evidences in support of the 
idea that BST2 is ILT7 ligand [211, 234]: 
1. The recombinant (r) ILT7 molecule was able to directly and exclusively 
engage rBST2- glutathione-S-tranferase (GST) fusion protein in a dose-
dependent manner. Plus BST2-Fc/ILT7-Fc interaction presented an affinity 
of approximately 10
-6
M, by surface plasma resonance measurement, and 
was totally neutralized by 26F8 mAb.  
2. rBST2-GST fusion protein was able to induce a vigorous activation of ILT7 
reporter cells through BST2/ILT7 direct interaction 
3. BST2 on HEK293 promoted the expression of GFP only in ILT7 NFAT-
GFP reporter cells and not in ILT7 negative reporter cells.  Moreover, this 
effect was inhibited by blocking ILT7 or BST2 using specific antibodies. 
Once determined that BST2 was able to bind ILT7, Cao and colleagues verified 
weather BST2/ILT7 interaction was able to mediate the biological effects observed 
following ILT7 cross-linking. First, they reported that rBST2 protein promoted 
calcium mobilization in primary pDC via an ITAM-mediated pathway, similar to 
what observed with anti-ILT7 mAb. Moreover, pDC stimulated with CpG ODN or 
influenza virus showed a reduction in the TLR7/9- mediated production of IFNα and 
TNFα when they were pre-incubated with plate-bound rBST2-Fc protein. A similar 
reduction was observed in the transcription of IFN I subtypes and IL6. Conversely, 
BST2 did not cause any change in the expression of co-stimulatory markers (CD80 
and CD86). Additionally the authors showed that, when co-cultured with HEK293 
cell expressing HA-tagged BST2, pDC stimulated with influenza virus produced 
less IFNα. Thus, BST2 interaction with ILT7 appeared to modulate TLR-mediated 
IFN I production by pDC [234].  
Finally, corroborating the data in the literature [222, 223], an increase of BST2 on 
the surface of different cell lines (embryonic kidney, dermal fibroblast, umbilical 
vein endothelial and keratinocytes cell lines) was observed when the cells were 
treated with IFNα. Conversely, despite the high levels of BST2 transcripts, freshly 
isolated or TLR- stimulated pDC presented low levels of the protein. By transducing 
ILT7 and FcεRIγ in human Burkitt lymphoma cell lines, which express endogenous 
BST2, Cao et al. found that ILT7 and BST2 can also interact in cis, causing BST2 
internalization [234].  
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Taken together these results suggest that BST2 induces ILT7 cross-linking in pDC, 
thereby activating a negative regulatory pathway which suppresses TLR-mediated 
production of IFN I and pro-inflammatory cytokines.     
The negative feedback mediated by BST2 and ILT7 may be very important in the 
regulation of the immune response. Numerous disorders have been associated 
with an alteration of pDC activation and IFN I production. These include 
autoimmune diseases such as systemic lupus erythematosus and psoriasis, and 
chronic infections such as HIV, in which prolonged pDC activation and IFN I 
production have been observed [211, 235-237]. Moreover, pDC have been 
detected in several tumours where they can interact with cancer cells [211]. In 
breast cancer, for example, pDC infiltrates correlate with the progression of the 
disease. Thus, IFNα is known to inhibit the growth of primary tumours, however 
infiltrating pDC in breast cancer secrete less IFN in response to TLR agonists, 
[211, 238, 239], which may directly depend on BST2/ILT7 signalling. Concurrently, 
BST2 expression in cancer may contribute to the tumour invasion, as a 
consequence of NFkB induction [211].  
Thus the dynamics and consequences of ILT7/BST2 interaction during innate 
immune responses need to be further investigated to determine the role and 
importance of this system in chronic conditions. In the present research work, the 
ILT7/BST2 negative feedback will be analysed in relation to HIV infection.    
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2 HYPOTHESIS AND AIMS 
The persistent activation of pDC can paradoxically lead to harmful consequences 
for the immune system in both murine models [205, 206] and humans [153, 159, 
164, 240]. In particular, during HIV-1 infection, pDC play an essential role in the 
transition between the acute and the chronic phase of the infection [164]. 
We hypothesise that upon activation, pDC produce high levels of IFN-I which may 
induce BST2 expression in surrounding cells. BST2 may then interact with ILT7-
expressing pDC causing downregulation of IFN-I and return to the original resting 
condition, thereby providing a negative feedback for pDC activation. Alterations of 
these mechanisms may drive HIV-induced pDC over-activation. 
Accordingly, the specific aims of this project are: 
1. to test  whether BST2/ILT7 expression in peripheral blood mononuclear 
cells (PBMC) correlates with HIV- or TLR7/9L-mediated pDC activation;  
2. to investigate which stimuli (pro or anti-inflammatory) can influence BST2 
expression and modulate IFN-α production by PBMC 
3. to evaluate whether pDC activation in response to HIV-1 and TLR7/9L is 
directly modulated by BST2-expressing cells in vitro. 
The finding of the present work are described and discussed in the Chapter 4, 
while conclusion and future works are presented in Chapter 5.    
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3 MATERIALS AND METHODS  
3.1 Cell culture media and buffers  
PBMC and pDC culture media (CM) consisted of RPMI 1640 (PAA Laboratories, 
UK) supplemented with 10% heat inactivated foetal bovine serum (FBS) (Sigma-
Aldrich, Poole, UK) and 1% Penicillin-Streptomycin and 1% L-Glutamine (Sigma-
Aldrich).  
293T cells culture medium (293T-CM) consisted of Dulbecco’s modified Eagle’s 
medium (DMEM) high glucose (PAA) supplemented with 10% FBS and 1% 
Penicillin-Streptomycin. 
293T transfected cells culture medium (293T/ts-CM) consisted of 293T-CM 
supplemented with Hygromycin B (Invitrogen, Paisley, UK) diluted 1:500. 
FACS buffer was purchased from BD bioscience, Oxford, UK. 
MACS buffer consisted of phosphate-buffered saline (PBS) (PAA Laboratories) 
with 2 mM ethylenediamine tetra-acetic acid (EDTA) (Invitrogen) and 2% FBS. 
50% Percoll gradient solution was prepared according to the following steps:  
1) A Percoll mix solution was prepared by mixing 60 ml of 10x PBS with 176 ml of 
sterile distilled water (Sigma-Aldrich) 
2) A 70% Percoll solution was made by adding 145 ml of Percoll (Sigma-Aldrich) to 
85 ml of Percoll mix. 
3) A 50% Percoll solution was prepared by adding 107 ml of 70% Percoll to 43 ml 
of Hanks balanced salt solution (Sigma-Aldrich). 
3.2 Samples 
PBMC were isolated from blood samples obtained from healthy donors, aged 20 - 
40 years old, after informed consent. Blood samples were collected in Vacutainer 
blood collection tubes (BD biosciences, Oxford, UK) containing Heparin as 
anticoagulant. Alternatively, PBMC were recovered from leukoreduction system 
chambers (LRSCs) of Trima Accel aphaeresis devices (Gambro BCT, Lakewood, 
CO) after routine donor plateletpheresis procedure [241]. LRSCs held 
approximately (1.88 ± 0.40) x10
9
 fully functional and viable PBMC [242].LRSCs 
were purchased from the North London Blood Transfusion Service (London, UK). 
The two source of PBMC were indiscriminately use for all the experiments as no 
significant differences were observed between them. 
3.3 Mononuclear leukocytes isolation and culture 
PBMC were separated from whole blood or LRSCs by density gradient 
centrifugation. Thus, whole blood obtained from healthy donors was diluted 1:3 in 
PBS; blood obtained from LRSCs, instead, was diluted 1:15 in PBS supplemented 
with 2% FBS, because as consequence of the plateletpheresis procedure the 
blood is more concentrated and free of serum.  Subsequently, 35 ml of the diluted 
blood were under laid with 10 ml of Histopaque 1077(LSM; PAA laboratories) and 
centrifuged at 895 Relative Centrifuge Force (RCF) for 20 minutes with no brake. 
PBMC formed an opaque interface between the Histopaque 1077 layer and the 
plasma (Figure 3.1). 
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Figure 3.1 Diagram representing the PBMC separation 
 by density gradient   
PBMC were then harvested and washed twice with PBS (or PBS-2% FBS if 
isolated from LRSCs), by centrifugation at 503 RCF for 10 minutes, to remove any 
residual Histopaque. Cell pellets were resuspended in 50 ml of the same buffer and 
the numbers of cells determined. Cells were then cultured in CM, at 2x10
6
 cells/ml, 
at 37
o
C 5% CO2 in a humidified environment. 
3.4 Cell counts 
The number of cells isolated from whole blood was determined using a dye 
exclusion method based on Trypan blue solution (Sigma-Aldrich). Trypan blue 
traverses the damaged membrane of the dead cells which appear blue under a 
microscope. 
A volume of 50 µl of the cells suspension was diluted 1:2 in Trypan blue solution 
and 10 µl of the resulting dilution was dispensed in a disposable counting chamber 
(KOVA Glasstic® Slide 10, Hycor, US). Cells were counted within 10
4
 dilution 
coefficient squares and the number of cells in the starting suspension was 
calculated as follow: 
N° of Cells = Cell count x DF x V x DF of the chamber
 
DF= Dilution factor of the cell suspension in trypan blue 
V= volume of the cells suspension  
DF of the camber = 10
4  
3.5  Isolation and culture of pDC 
PBMC were isolated from LRSCs as described. Cells were resuspended in 40 ml 
of PBS 2%FBS and further separated into high and low density fractions by 50% 
Percoll gradient centrifugation. A volume of 4 ml 50% Percoll solution (section 3.1) 
was added in five 15 ml centrifuge tubes (Corning, US), overlaid with 8 ml of the 
cell suspension, and centrifuged at 300 RCF for 30 minutes with no brake. The thin 
layer at the interface between the Percoll and the buffer which contained the 
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monocyte/DC enriched fractions, were harvested and washed twice in 10 ml MACS 
buffer (section 3.1) by centrifuging at 1500 rpm for 10 minutes, to remove any 
residual Percoll. Plasmacytoid DC were then magnetically isolated from the above 
fraction using a CD304 (BDCA-4/Neuropilin-1) MicroBead kit (Miltenyi Biotec, 
Germany) in accordance with the manufacturer’s protocol. Thus, the monocyte/DC 
enriched fraction pellet was resuspended in 300 µl of MACS buffer per 10
8
 total 
cells. A volume of 100 µl of FcR blocking reagent and an equivalent volume of 
BDCA-4 microbeads (Miltenyi Biotec) were added to the cell suspension and 
incubated for 15 minutes at 4 
o
C. Cells were washed in MACS buffer and 
centrifuged at 300 g for 10 minutes (MSE Mistral 3000i). The pellet was 
resuspended in 500 µl of MACS buffer and added to an LS column (Miltenyi 
Biotec) pre-washed with MACS buffer and installed on a magnetic support. Cells 
were allowed to flow through the columns, which were then washed 3 times with 
3ml of MACS buffer. Plasmacytoid DC retained in the column were eluted by 
removing the column from the magnetic field and flushing with 5 ml of buffer. This 
cell fraction was then passed through a pre-washed MS column (Miltenyi Biotec) to 
increase cell purity. This purified pDC fraction was eluted by removing the column 
from the magnetic field and flushing with 1 ml of CM.  
Isolated pDC were counted and used for the co-culture experiment with 293T cells 
described in the Results and Discussion chapter and in Section 4.3.6.2. 
3.6  Cell lines: description and culture 
pDC-293T cell co-culture and BST2 antibody affinity experiments, described in the 
Results and Discussion Chapter and in Section 4.3.6.2 and 4.3.5. respectively, 
were conducted using human embryonic kidney (HEK) 293T cell lines (from now 
on referred to as 293T cells for simplicity) kindly donated by Dr. Stuart Neil (King’s 
College, London, UK). We used 293T cells (CTRL) or  293T cells that were stably 
transfected (ts) with the human wild-type bst2 gene (BST2-293T) or bst2 bearing 
mutations in the extracellular coiled-coil region (L123P), in the extracellular anchor 
(ΔGPI), in the dimerisation site (3CA) or in the intracellular region (Y6,8A and 10-
12A). 293T wt and 293T ts cells were cultured in 75 mm
2
 flask (for maintenance) or 
24/48 well cell culture cluster plates (for the experiments) in 293T-CM and 293T/ts-
CM respectively. Cells were maintained in culture at 37
o
C supplemented with 5% 
CO2 in a humidified environment. Cells cultured in flasks were passaged two to 
three times a week depending on their confluence. During each passaging step, 
adherent 293T cells were washed twice with 5 ml of PBS; then treated with 2ml of 
the serin-protease Trypsin (Invitrogen) for 3 minutes at 37
o
C, to allow cells to 
disassociate from the plastic surface of the flask. When cells were detached, 
Trypsin was inactivated by adding 8 ml of the appropriate culture media. A volume 
of 2 ml of the suspension was then added into a new flask and cells were 
maintained in culture adding 8 ml of fresh 293T-CM or 293T/ts-CM. The cell lines 
were maintained in culture throughout the course of experiments and stored in 
liquid nitrogen when not needed. 
3.7  Cryogenic storage of 293T cell lines 
293T cells were trypsinised, washed twice in 293T-CM, counted and resuspended, 
at a concentration of 4x10
6
 cells/ml, in FBS containing 10% dimethylsulphoxide 
(DMSO, Sigma Aldrich). The cell suspension was then aliquoted into cryovials 
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(Fisher Scientific, UK). The cryovials were placed in a Nalgene cryofreezing 
container (Jencons, Leighton Buzzard, UK) containing 2-isopropanol (Sigma 
Aldrich) which was then placed in a -80
o
C freezer overnight (o/n). The cryovials 
were finally transported in dry ice and placed into liquid nitrogen for long term 
storage.  
Recovery of the cells was achieved by rapid thawing in a 37
o
C water bath. Warm 
293T-CM was then added in a drop-wise fashion. Cells were washed twice in the 
293T-CM and resuspended in 293T-CM. Cells were then plated in 25 mm
2
 flask 
(Corning). When cells reached confluence, they were passaged in the 75 mm
2
 
flask and cultured in the appropriated media (293T-CM or 293T/ts-CM). 
3.8 Stimulation of PBMC  
PBMC were cultured in presence or absence of specific stimuli for different periods 
of time, depending on the experimental setting, as described in the Results and 
Discussion Chapter. 
3.8.1 Stimulation of PBMC with TLRs agonist and HIV 
The TLR9 ligand (TLR9L) CpG ODN type A (InvivoGen, San Diego, CA, USA) was 
tested at different concentration (0.025-7.5 μM) and used at 0.75 µM final 
concentration. 
The TLR7 ligand (TLR7L) R848 (Imiquimod; InvivoGen) was tested at different 
concentrations (0.16-5 μg/ml) and used at 5 µg/ml final concentration. 
HIV-1MN/CEMx174 was originally obtained from the AIDS and Cancer Vaccine 
Program (SAIC-NCI at Frederick).HIV-1MN was inactivated with aldrithiol-2 (AT-2) 
as previously described by Rossio JL and colleagues [243] and kindly donated by 
Dr. D.Graham. AT-2 is an oxidizing reagent that renders HIV reverse transcription-
deficient, thereby eliminating the infectivity of HIV while preserving its structure and 
ability to activate innate and adaptive immunity [243]. AT-2 HIV was tested at 
different concentration (3-1000 ng/ml p24 equivalents) and it was added to PBMC 
cultures at 100 ng/ml p24 equivalents final concentrations. 
3.8.2 Stimulation of PBMC with cytokines 
PBMC were stimulated for 2 hours by pre-incubation with the following cytokines: 
IFNγ, IL10, TNFα (all from Miltenyi Biotec) and IL-4 (R&D Systems, Abingdon, UK).  
TNFα and IL10 were used at 10 ng/ml final concentration, whereas IFNγ and IL4 
were used at 1000 U/ml final concentrations.  
3.8.3 Stimulation of PBMC with T cell receptor agonists 
The CD3-specific antibody (Ab) HIT3a (BD biosciences, Oxford, UK) was used at 1 
µg/ml final concentration as a mitogenic stimulus for T cells. 
The CD28-specifc antibody CD28.2 (BD biosciences) was used as a control (1 
µg/ml final concentration). 
3.8.4 Stimulation of PBMC with anti-IFNI Receptor 
Anti-Human Interferon Alpha/Beta Receptor Chain 2 (IFNAR2), Clone MMHAR-2 
(PBL Interferonsource, Piscataway, NJ, USA) was used at 10 µg/ml final 
concentration.  
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3.8.5 Stimulation of PBMC with soluble BST2-GST fusion protein 
Soluble BST2-GST fusion protein (Abnova, Taipei city, Taiwan) was used at 5 
µg/ml final concentration.  
Soluble Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-GST fusion protein 
(Abnova, Taipei city, Taiwan) was used as control (5 µg/ml final concentration) 
3.9 ILT7 cross-linking and BST2 blockade 
The effects of BST2 blockade and ILT7 cross-linking were tested using an 
anti/blocking-BST2 monoclonal antibody (αBST2 mAb; clone 26F8 eBioscience, 
California, USA) and a cross linking-ILT7 mAb (XL-ILT7, clone 17G10.2 
eBioscience). PBMC were incubated with XL-ILT7 mAb at 10 μg/ml final 
concentration or with the αBST2 mAb at 1.25 µg/ml, 5 μg/ml or 10 μg/ml final 
concentration for 30 minutes before stimulation with TLR7/9L or AT-2 HIV. After o/n 
incubation the quantity of IFNα was evaluated by an immune-enzymatic assay as 
describe in Section 3.10 
3.10 Enzyme-Linked Immunoabsorbent Assay (ELISA) 
The levels of IFNα in cell culture supernatants were quantified by human IFNα 
multi subtype ELISA kit (PBL Interferonsource) following the manufacturer’s 
instruction. The kit is based on an ELISA with anti-secondary antibody conjugated 
to horseradish peroxidase (HRP) and Tetramethyl-benzidine (TMB) is the 
substrate. All the reagents, buffers antibodies and substrate, necessary to develop 
the assay, are included in the kit. 
Briefly, volumes of 100 μl of Human IFNα Standards, Samples (supernatants 
diluted 1:5 in the Dilution Buffer) and Blanks (Dilution Buffer alone) were plated in 
duplicate in the wells of a Pre-coated microtiter plate. The plate was then covered 
and incubated for 1 hour at room temperature. At the end of the incubation the 
contents of the plate were emptied and wells were washed one time with diluted 
Wash Buffer, using an automated plate washer (Asys Atlantis microplate washer, 
Biochrom, US). A volume of 100 μl of diluted antibody solution was then added to 
each well; the plate was covered and incubated for another hour at room 
temperature. After the incubation the contents of the plate were emptied and the 
wells washed 3 times with diluted Wash Buffer. A volume of 100 μl of diluted HRP 
solution was then added to all wells; the plate was covered and incubated for 1 
hour at room temperature. At the end of the incubation the contents of the plate 
were emptied and the wells washed 4 times with diluted Wash Buffer. A volume of 
100 μl of TMB substrate was finally added to the wells and the plate incubate in the 
dark for 15 minutes. A volume of 100 μl of STOP solution was then added to each 
well and the plate was read within 5 minutes using a microplate reader (Anthos 
microplate reader Biochrom, USA) set at 450 nm absorbance. 
Interferon titer (pg/ml) was calculated by plotting the optical densities (OD) using a 
4-parameter fit for the standard curve. 
3.11 Tryptophan and kynurenine measurement 
Tryptophan and kynurenine were detected in culture supernatants using high 
performance liquid chromatography (HPLC) [244]. Volumes of 400 μl of 
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supernatants were frozen at -80ºC and shipped overnight in dry ice to the 
Innsbruck Medical University, Austria where the experiments were performed by 
Prof. Dietmar Fuchs and collaborators. 
3.12 Phenotypic analysis 
The surface phenotypic analysis was performed using anti-human monoclonal 
antibodies purchased from the following companies: eBioscience (Hatfield, UK), 
Biolegend (London, UK), BD Bioscience (Oxford, UK), or Miltenyi Biotec 
(Germany). The antibodies used are listed in the Table 3.1. 
Cells were incubated for 20 min at room temperature with 3 µl of appropriate 
fluorochrome-conjugated antibodies according to the gating strategies described in 
the Result and Discussion Chapter. Cells were washed twice with 2 ml of staining 
buffer (BD Bioscience) and fixed with 200 μl of 1X BD cytofix buffer (BD 
Bioscience). FACS analysis was performed on an LSR-II flow cytometer using 
FACSDiva software (BD Bioscience). FlowJo software (Treestar, Ashland, OR) 
was used for data analysis. Fluorescence minus one (FMO) controls were used to 
establish positivity thresholds.   
3.13 BST2 staining of IFNα- treated 293T-wt and 293T-ts cells 
To verify the specificity of the 26F8 antibody for BST2, we used PE-conjugated 
26F8 (Table 3.1) to stain confluent 293T cells which had been treated or not with 1 
ng/ml of universal type I IFN (PBL Interferonsource) overnight and 293T cells which 
were stably transfected with the human wild-type bst2 gene or bst2 bearing 
mutations as described in section 3.6. Cells were cultured in 24 well cell culture 
plates until confluence in 293T-CM (293T wt) or 293T/ts-CM (293T ts). Confluent 
cells were treated with 200 µl of trypsin (Invitrogen) and washed twice. Staining 
and flow cytometry analysis were performed as described in Section 3.12. 
3.14 pDC and 293T cell co-cultures 
To test whether ILT7/ BST2 interaction may be induced in vitro, we set up a co-
culture experiment between pDC and BST2-293T cells, using pDC alone and 293T 
wt as controls. BST2-293T and 293T wt cells were cultured in 250 µl of 293T-CM, 
in 48 well cell culture plates, until confluence. pDC were isolated as described in 
section 3.5 and resuspended in CM.  A volume of 250 µl of the pDC suspension 
was then added to the 293T confluent cultures. The co-cultures (or the pDC alone) 
were then stimulated with TLR9L in the presence or absence of anti- BST2 
blocking Ab as described in the Results and Discussion chapter. An IgG1 Isotype 
Ab was used as control for 26F8. After o/n incubation cell supernatants were 
collected and the IFNα levels were measured as described in Section 3.10  
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Antibody Clone Conjugate Supplier 
CD317 (BST2) 26F8 AlexaFluor 488 eBioscence 
CD317 (BST2) 26F8 PE eBioscence 
CD19 HIB19 APC-eFluor 780 eBioscence 
CD85g (ILT7) 17G10.2 PerCP-Cy5.5 eBioscence 
CD3 UCHT1 PE-Cy7 eBioscence 
CD1c (BDCA1) L161 PerCP-eFluor 710 eBioscence 
CD83 HB15e PE eBioscence 
CD4  RPA-T4 PE eBioscence 
CD8 SK1 APC eBioscence 
CCR7 3D12 FITC eBioscence 
CD123 6H6 PE-Cy7 Biolegend 
CD14 6MPφ9 APC-H7 BD Bioscience 
CD14 6MPφ9 APC BD Bioscience 
CD141 (BDCA3) AD5-14H12 FITC Miltenyi Biotec 
CD303 (BDCA2) AC144 APC Miltenyi Biotec 
Table 3.1. Antibodies used for flow cytometry.APC, Allophycocyanin; 
PerCP, Peridinin Chlorophyll Protein; FITC, Fluorescein 
isothiocyanante PE, Phycoerythrin. 
3.15 Proliferation assay 
T cells proliferation, in response to the mitogenic stimulus CD3 Ab (HIT3a) in 
presence or absence of TLR9L (see Section 3.8.1 and 3.8.3), was evaluated using 
a flow cytometry-based intracellular dye dilution proliferation assay, based on the 
Violet Proliferation Dye 450 (VPD450; BD Bioscience). VPD450 is a violet laser 
excitable dye that allows monitoring of cell divisions by flow cytometry. The non-
fluorescent VPD450 dye passively diffuses across cell membranes and is cleaved 
by esterase only in viable cells, becoming highly fluorescent. Not viable cells 
remain not fluorescent. As viable cells divide, the dye is uniformly distributed 
between daughter cells; each daughter cell retains approximately half of the 
VPD450 fluorescence intensity of its parent cell.  
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VPD450 staining has been carried out according the manufacture’s protocol. 
Briefly, PBMC were isolated as described in section 3.3, transferred in 15 mL 
polypropylene centrifuge tubes and washed twice in PBS, to remove any residual 
serum proteins. Cells were then resuspended at a concentration of 10-30x0
6
/mL in 
PBS. A volume of 1 μL of 1 mM VPD450 stock solution was added to 1 mL of cell 
suspension, for a final VPD450 concentration of 1 μM. Cells were vortexed and 
incubated in a 37ºC water bath for 10-15 minutes. Cell were washed first with 9 ml 
of PBS and then with 10 ml of CM. The stained PBMC, were then resuspended in 
CM and cultured o/n or for 5 days in the presence of TLR9L, CD3 Ab, CD28 Ab, 
and in presence or absence of the blocking BST2 Ab, as described in the “Results 
and Discussion” Chapter.    
At the end of the incubation, cells were stained with PE-conjugated CD4, APC-
conjugated CD8 APC, and AlexaFluor 488-conjugated BST2 as described in 
section 3.12.  
3.16 Statistical analyses  
Statistical analyses were performed using SPSS 19.0 software (SPSS Inc., 
Chicago, IL, USA). Pairwise comparisons between control and stimulated cells 
were performed using non-parametric Wilcoxon sign rank test. Changes in 
measured parameters over time in kinetic experiments were analyzed using 
Friedman’s two-way analysis of variance (ANOVA) by ranks, and pairwise 
comparisons were subjected to Dunn’s post-hoc correction for multiple analyses. 
P-values lower than 0.05 were considered statistically significant. 
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4 RESULTS AND DISCUSSION 
4.1 Overview 
Plasmacytoid DC are IFN I producing cells that play a key role during viral 
infections, promoting innate and adaptive immune responses [138]. Activated pDC 
also exert a powerful immunoregulatory activity and are important in the in the 
maintenance of immune tolerance, through the expression IDO [152]. However, the 
persistent activation of pDC can paradoxically lead to harmful consequences for 
the immune system, resulting in inhibition of T cell proliferation and promotion of 
cell death. In particular, it has been recently shown that pDC overactivation 
contributes to the dysregulation of adaptive immunity and antiviral immune 
responses during HIV-1 infection [194-197]. Thus, studying the mechanisms that 
regulate IFN-I production by pDC is essential to understand the molecular basis of 
HIV-1 disease. Thus, we focused our attention on ILT7, a surface molecule 
selectively expressed by human pDC which potently suppress TLR7/9-induced 
IFN-I, and its ligand BST2, better known as Tetherin due to its ability to interfere 
with the release of enveloped viruses [211, 214, 225, 234, 245, 246]. Upon pDC 
activation, BST2 may be upregulated by IFN-I in the surrounding cells. This may 
favour BST2 interaction with ILT7, providing a negative feedback that may prevent 
deleterious pDC overactivation. Consequently, studying the regulation and activity 
of the ILT7/BST2 pathway may aid a better understanding of HIV 
immunopathogenesis.  
4.2 ILT7 expression and modulation following in vitro culture 
4.2.1 ILT7 expression is limited to pDC and is downregulated during 
in vitro culture 
We evaluated the expression of ILT7 and BST2 in different cell types, in the 
presence or absence of HIV or TLR7/9L stimulation, in order to identify possible 
correlations with pDC activation. The phenotypic analysis was conduct by flow 
cytometry (Chapter 3, section 3.12) on freshly isolated primary PBMC from healthy 
donors or recovered from LRSCs (Chapter 3, section 3.3). Briefly 2x10
6
 PBMC 
were stained with the appropriate fluorochrome-conjugate antibodies and acquired 
on a flow cytometer. The gating strategy used to identify the different cell 
populations (pDC, mDC, monocytes, B cells and T cells) is indicated in Figure 4.1. 
The live gate was determinate on the basis of the combination of Forward Scatter 
(FSC) and Side Scatter (SSC) (Figure 4.1A and B). FSC is associated to the size 
of the cells, whereas SSC correlates with the granularity of cells, which varies 
depending on different cellular characteristics such as: the amount and type of 
cytoplasmic granules, the shape of the nucleus or the membrane roughness. As 
shown in panel A, monocytes were identified as CD14+ cells in the “Live gate”, 
whereas pDC were defined within the CD14- cells as BDCA2 and CD123 double+ 
cells. Panel B shows the gating strategy used to define B cells, T cells and mDC. In 
particular, B cells were selected within the CD14- and CD19+ population in the 
“Live gate”, then defined as CD19+ and CD3- cells; T cells were defined in the 
“Live gate” within the CD14 and CD19 double negative gate as CD14- and CD3+ 
cells; finally mDC were characterized by selecting the CD14 and CD19 double 
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negative cells in the “Live gate”, then excluding the CD3+ cells, and selecting both 
BDCA1 and BDCA3+ cells.  
 
 
Figure 4.1 Phenotypic characterizations of pDC, mDC, monocytes, B cell and T 
cells. 
 Flow cytometry zebra plots showing the gating strategy used to identify: A) pDC 
(CD14-BDCA2+CD123+) and monocytes (CD14+); and B), B cells (CD14-CD3-
CD19+) T cells (CD14-CD19-CD3+) and mDC (CD19-CD14-CD3-
BDCA1/BDCA3+). 
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Figure 4.2 ILT7 expression and downregulation during in vitro culture. 
A) Flow cytometry histogram from experiments conducted on one representative of 
N=6 independent donors showing ILT7 expression on different cell populations 
(pDC, mDC, monocytes, B and T cells) gated as shown in figure 4.1.Black lines 
indicate FMO controls, red lines indicate ILT7 staining. B) Frequency of ILT7+pDC 
overtime (0-6 hours). Dots correspond to the median of N=5 donors for each time 
point. Thick line indicates linear regression of medians; thin lines indicate linear 
regressions of interquartile ranges (IQRs). ** P<0.01 compared to 0 hours 
(Friedman’s test with Dunn’s correction for multiple pairwise comparisons). C) 
Frequency of ILT7+ pDC (red dots and lines) and CD83+ pDC (black diamonds 
and lines) in function of time, in absence (dashed lines) or in presence of TLR9L 
CpG ODN (thin lines) or AT-2 HIV (thick lines).Dots and diamonds indicate 
medians of N=3 donors for specific time point; P values in legend indicate 
Friedman’s test results for changes overtime in each condition. 
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Figure 4.2A illustrates an example of flow cytometry histograms showing ILT7 
expression on different cell populations in freshly isolated PBMC stained as 
described in Figure 4.1. The red lines, indicating ILT7 staining, presented a positive 
shift in comparison to the FMO controls (in black) only for the pDC population. 
Therefore, in agreement with the work of Cao et al. [211, 214, 234], our results 
confirmed that ILT7 was exclusively expressed by pDC. 
ILT7 expression, however, was negatively affected by in vitro culture (figure 4.2B-
C). PMBC isolated from 5 healthy donors were cultured in CM, at the concentration 
of 2x10
6 
cells/ml, at 37
o
C 5% CO2 in a humidified environment. PBMC were then 
stained for ILT7 (PerCP-Cy5.5) at regular intervals of 1 hour, for a total of 6 hours. 
The linear regression of the frequency of ILT7+pDC overtime is presented in figure 
4.2B. The graph shows a linear (R
2
=0.9625) progressive reduction of ILT7 during 
the first 6 hours of in vitro culture, with a drop of about 40% in ILT7+pDC after 6 
hours. Friedman’s test with Dunn’s correction for multiple pairwise comparisons 
showed a significant reduction of ILT7 expression in pDC after 5 hours (p=0.002) 
and 6 hours (p=0.003) compared to 0h. Moreover ILT7 expression was 
dramatically reduced in pDC after overnight culture (Figure 4.2C and 4.3). In order 
to investigate ILT7 downregulation following in vitro culture in conjunction with pDC 
activation, PBMC were isolated from an additional N=3 healthy donors or LSRCS. 
PBMC were cultured in CM at the concentration of 2x10
6 
cells/ml, in absence 
(CTR) or presence of TLR9L (0.75 µM final concentration) or AT-2 HIV (100 ng/ml 
p24 equivalents final concentration). PBMC were then stained for ILT7 (PerCP-
Cy5.5) and CD83 (PE) after 0, 3, 6 and 18 hours of in vitro culture. The frequency 
of ILT7+pDC in function of time in different conditions is illustrated in Figure 4.2C. 
Our data confirmed the progressive reduction of ILT7+pDC over the time with a 
drastic drop to about 10% after overnight incubation (p=0.029, Friedman’s test). 
Stimulation with TLR9L and AT-2 HIV did not prevent ILT7 downregulation, despite 
promoting pDC activation as measured by the upregulation of the activation marker 
CD83 (Figure 4.2C), IFN-α production and IDO activity (discussed later in Figure 
4.8 and Figure 4.9). As shown in Figure 4.2C no significant increase in the 
frequency of CD83+pDC, was observed following in vitro culture in the absence of 
stimuli (black dashed lines), whereas a significant upregulation of CD83+pDC (up 
to about 40%) was observed in response to stimulation with either TLR9L 
(p=0.042, Friedman’s test) and AT-2 HIV (p=0.042, Friedman’s test). 
A further confirmation of ILT7 downregulation by in vitro culture is presented in 
Figure 4.3, where frequency and Mean Fluoresce Intensity (MFI) of ILT7 on pDC 
were tested in N=15 blood samples from independent healthy donors or LRSCs. In 
detail, the frequency of ILT7+pDC significantly decreased after overnight 
incubation in the absence of stimuli from 75% (FRESH) to 11% (CTR) (Figure 
4.3A). No significant differences were observed between unstimulated PBMC 
(CTR) and PBMC stimulated with AT-2 HIV (100 ng/ml p24 equivalents final 
concentration), TLR9L (0.75 µM final concentration) or TLR7L (5 µg/ml final 
concentration) after overnight incubation (Figure 4.3A). As shown in Figure 4.3B, 
the MFI of ILT7 on pDC followed the same trend; in fact, a significant reduction 
from the FRESH (MFI 1440) to the CTR (MFI 306) condition was observed, but no 
substantial changes were detected between unstimulated (CTR) and stimulated 
(AT-2 HIV, TLR9L, TLR7L) PBMC, after overnight incubation. 
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Figure 4.3 ILT7 downregulation after overnight in vitro culture. 
A) Frequency ILT7+ pDC  and B) MFI of ILT7 on pDC, in PBMC, freshly isolated 
(FRESH) or overnight cultured , in absence (CTR) or presence of  AT-2 HIV, 
TLR9L  or TLR7L. In panel A and B medians with IQRs of N=15 independent 
donors are shown. Whiskers denote: Min to Max values. *p<0.05, **p< 0.01, 
***p<0.001(Wilcoxon sign rank test) 
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Collectively our data corroborate the findings reported in the literature, defining 
ILT7 as an exclusive pDC marker. Nevertheless, they also indicate that the surface 
expression of this receptor is strongly affected by in vitro culture, and its expression 
is not restored by exposure to HIV or TLR ligands. Consequently, any regulatory 
activity mediated by ILT7 may need to be triggered within the first hours of in vitro 
culture. 
4.2.2 ILT7 downregulation is associated with the differentiation of 
blood pDC precursors 
Circulating pDC, are precursors of the immature lymphoid- derived DC [247, 248] 
which, upon activation, can migrate directly from blood into the draining lymph 
[249]. After migration to the lymphoid tissues, the maturation process is completed 
and the mature pDC can act as proper antigen presenting cells (APC) [142, 241]. It 
has been observed that freshly isolated pDC spontaneously differentiate into 
immature pDC when cultured in vitro, then further mature into APC in response to 
adequate stimulation [247, 248]. We verified whether the changes in ILT7 
expression on pDC were related to the differentiation of freshly isolated pDC in 
vitro. For this purpose we evaluated the changes in the morphology and in the 
surface expression of activation and migration markers, in relation to ILT7 
modulation. 
A first indication of the correlation between ILT7 downregulation and pDC 
differentiation in vitro, was suggested by the flow cytometry analysis of the ILT7 
expression in relation to the SSC properties of pDC.  Representative contour plots 
from one donor are presented in Figure 4.4A. The data showed both a reduction in 
ILT7 expression and an increase in SSC property in pDC from PBMC cultured 
overnight (red contours in all plots) in comparison to freshly isolated PBMC (black 
contours in all plots). Both a leftward shift along the X-axis (ILT7 expression) and 
an upward displacement along the Y-axis (SSC property) of the red contours in 
comparison to the black one was observed. These changes, indicating both an 
increase of the inner complexity of the pDC and ILT7 downregulation, occurred 
independently of weather PBMC were cultured with control media alone (CTR) or 
stimulated with AT-2 HIV (100ng/ml p24 equivalents) TLR9L (0.75µM), or TLR7L 
(5µg/ml). However, when the frequency of ILT7+ pDC and the fold change in SSC 
in function of time were considered (Figure 4.4B), TLR7L appeared to induce a 
more rapid downregulation of ILT7 which was significantly lower than untreated 
(p=0.043, Wilcoxon sign rank test), TLR9L- (p=0.046, Wilcoxon sign rank test) and 
AT-2 HIV-treated (p=0.042, Wilcoxon sign rank test) cells after 6 hours culture. 
Conversely, TLR9L and AT-2 HIV, but not TLR7L, induced a more rapid increase in 
SSC compared to media alone, as indicated by significantly higher SSC after 6 
hours culture (for both AT-2 HIV and TLR9L p=0.028, Wilcoxon sign rank test)  
(Figure 4.4B). 
 
 49 
 
 
Figure 4.4 ILT7 downregulation correlates with pDC differentiation in vitro. 
 
 
 50 
 
Figure 4.4 ILT7 downregulation correlates with pDC differentiation in vitro. 
A) Flow cytometry contour plots showing ILT7 expression in relation to the SSC 
properties of pDC, in freshly isolated PBMC (black contours in all plots) and in 
PBMC cultured overnight (red contours in all plots) in  absence or presence of AT-2 
HIV ,TLR9L or TLR7L; the contour plots represent one example of experiments 
performed on N=6 independent donors.  B) Summary graphs showing (from top to 
bottom) frequency of ILT7+ pDC, fold change in SSC, frequency of CCR7+ pDC 
and frequency of CD83+ pDC in function of  time (0, 6, 18 hours). For each 
parameter,  PBMC cultured in control media alone (CTR, black) or in presence of 
AT-2 HIV (red),TLR9L (blue) or TLR7L (green); SSC were normalized against 
measurements on fresh cells; medians and IQRs are shown (N=6); * P<0.05 and ** 
P<0.01 (Friedman’s test with Dunn’s correction for multiple pairwise comparisons); 
§ P<0.05 compared to untreated control at the same time point (Wilcoxon sign rank 
test). 
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It has been shown that the expression of the chemokine receptor CCR7 on 
circulating lymphocytes represents an essential factor for lymph node (LN) entry 
via HEV [250, 251]. In the literature, there is contrasting evidence regarding CCR7 
expression on human pDC. Some evidence suggests high level of CCR7 
expression on circulating pDC, which however do not confer responsiveness to 
CCR7 ligands [140, 252]. Conversely, other reports showed low expression levels 
of CCR7 on resting pDC [253-255]. However, it has been observed that, upon 
stimulation with TLR ligands, both human and murine pDC upregulate CCR7 
expression, resembling the mDC activation profile [252, 256, 257]. As shown in 
Figure 4.4B, our data confirmed a significant increase in the frequency of the 
CCR7+ pDC upon stimulation with AT-2 HIV, TLR9L and TLR7L compared to 
control after 6 hours incubation. Similar results were observed after 18 hours 
incubation, with the only exception that the increase in CCR7+ pDC compared to 
control remained significant only for AT-2 HIV and TLR9L, but not TLR7L. 
Nevertheless, when PBMC were cultured in media alone (CTR), we noticed a 
spontaneous significant increase of CCR7 on pDC (up to 20%; 0h-18h p=0.004, 
Friedman’s test, with Dunn’s correction for multiple pairwise comparisons), albeit 
lower than what observed in presence of stimuli. Conversely, when analysing the 
frequency of pDC expressing the activation marker CD83 over time, we observed 
only a transient increase (up to 17%) after 6h incubation in unstimulated PBMC 
(CTR) (0h-6h;6h-18h p=0.028 Friedman’s test, with Dunn’s correction for multiple 
pairwise comparisons). The increase in CD83 expression was instead higher and 
persistent in pDC stimulated with AT-2 HIV (100 ng/ml p24 equivalents), TLR9L 
(0.75 µM) and TLR7L (5 µg/ml). After 18 hours, we observed a significant increase 
in the frequency of CD83+ pDC (up to 49%, 0h-18h p= 0.012 Friedman’s test, with 
Dunn’s correction for multiple pairwise comparisons) in AT-2 HIV treated PBMC; 
whilst TLR9L- and TLR7L- treated PBMC showed a significant upregulation to 63% 
and 44%, respectively (0h-6h p= 0.004 Friedman’s test, with Dunn’s correction for 
multiple pairwise comparisons) (Figure 4.4B). 
In summary, our results suggest that ILT7 downregulation is associated with 
differentiation of circulating pDC, characterized by increased morphological 
complexity and CCR7 expression, but not with activation and full maturation, 
epitomized by increased CD83 expression, which occur only following TLR 
stimulation. 
4.2.3 Summary and discussion 
ILT7 is a surface molecule selectively expressed by human pDC. The cross linking 
of this receptor activates a signal transduction cascade which potently suppresses 
TLR7/9-mediated IFN-I production by pDC [214]. Therefore, achieving a more 
detailed knowledge of ILT7 expression, modulation and interaction with its ligand, 
may help understanding the function of a new pathway involved in the negative 
regulation of pDC activation. In this result section we confirmed that ILT7 is 
exclusively express by human pDC, as previously described by Cao and 
colleagues [211, 214, 234]. However, we also showed that ILT7 is rapidly 
downregulated upon in vitro culture, decreasing of about 40% within the first 6 
hours, independently of stimulation with AT-2 HIV or TLR7/9L. A possible 
explanation for ILT7 downmodulation may be the differentiation of freshly isolated 
pDC in immature pDC. In 1994, O'Doherty et al [247] defined the CD11c
-
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peripheral blood (PB)-DC, known today as pDC, as functionally immature cells that 
required monocyte-derived cytokines in order to develop into typical DC. A few 
years later, Kohrgruber and colleagues [248] demonstrated that CD11c
- 
PB-DC 
resembled the pDC previously identified in T cell-rich areas of tonsils and lymph 
nodes, not only by their surface Ag expression profile but also by their peculiar 
ultramorphology. Moreover, they showed that IL3 and TNFα controlled some of the 
CD11c
-
 PB-DC functions (i.e. survival and maturation), in the transition from 
circulating precursors to an advanced maturational stage, such as: induction of a 
highly dendritic phenotype; MHC class II relocation to the plasma membrane; 
upregulation of costimulatory molecules and switch from a high Ag-processing to a 
low Ag-processing/potent accessory cell mode. Therefore, when cultured in an in 
vitro system, the circulating pDC differentiate into immature pDC, before they 
develop into fully functional APC in presence of adequate stimulation [257]. 
Our data corroborate these findings and suggest that the downregulation of ILT7 is 
part of the freshly isolated pDC differentiation process. We observed that ILT7 
downregulation was indeed accompanied by an increase in both SSC property and 
CCR7 expression. The enhancement of SSC reflects the changes in the cells 
morphology, related to an increase in their granularity; whilst the upregulation of 
CCR7 indicate an increase of the lymph node homing properties. These 
characteristics together seem to support the hypothesis of a partial PB-pDC in vitro 
maturation.  The expression of CCR7 is known to increase on pDC in response to 
appropriate stimuli via TLRs pathway, a process which in vivo is responsible for 
driving pDC migration to the T cells area within secondary lymphoid tissues [247-
249]. However, flow cytometry analysis of CD83, a surface marker that 
differentiates immature and mature human dendritic cell populations [258, 259], 
showed only a transient increase on the pDC surface when PBMC were cultured in 
media only. Conversely, the frequency of CD83+ pDC was highly increased when 
pDC were activated by TLR ligands or HIV. Therefore, circulating pDC appears to 
be subject to a two step differentiation process in vitro. The first one, characterized 
by spontaneous changes in the morphology and partial acquisition of lymph node 
homing properties, leading to the generation of immature pDC; the second step, 
triggered by TLR7/9 stimulation, promotes full maturation and IFN-α production. 
4.3 BST2 expression and regulation following in vitro culture 
4.3.1 BST2 is upregulated in different cell types a consequence of 
IFNα stimulation via TLR- mediated pathway 
Hitherto the only natural ligand known for ILT7 is BST2, also known as Tetherin 
[211, 234]. BST2 a protein encoded by an IFN-I-stimulated gene [234, 245]and it is 
better known for its ability to  prevent  the release of newly formed virus; activity 
counteracted  by the  HIV-1 accessory protein Vpu [225, 226, 246]. We 
hypothesised that, following pDC activation, BST2 may be upregulated in PBMC as 
a consequence of IFNα production, thus favouring BST2-ILT7 interaction that may 
negatively regulate pDC activation. Consequently, we tested the expression of 
BST2 on PBMC which were freshly isolated or cultured overnight in presence or 
absence (CTR) of AT-2 HIV (100ng/ml p24 equivalents), TLR9L (0.75µM) or 
TLR7L (5µg/ml). AT-2 HIV and TLR7/9 ligands directly activate pDC causing the 
secretion of IFNα [138, 142]. As illustrated in Figure 4.5A, the highest frequency of 
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BST2+ cells among freshly isolated PBMC was observed in monocytes; 
approximately 90% of monocytes were BST2+. To follow, 64 % of mDC and 44 % 
of B cells were BST2+, whereas less than 20% pDC and T cells tested BST2+. 
However, looking at PE-MFI of anti-BST2 Ab staining (Figure 4.5B), mDC showed 
the highest BST2 expression levels (MFI=4218) followed by monocytes 
(MFI=2046), B cells (MFI=1419), pDC (MFI=527) and T cells (MFI=715). This data 
suggested that, despite a lower frequency of BST2+ cells, mDC expressed a 
higher number of BST2 molecules per- cell on their surface compared to 
monocytes. However we cannot exclude that mDC are simply more auto-
fluorescent and that the higher BST2 MFI is an artefact due to higher fluorescence 
background. Therefore, the frequency of positive cells, which takes into account a 
cell-specific background, may be a more reliable parameter to compare BST2 
expression in different cell types.    
Differently from ILT7, BST2 expression was generally unaffected by in vitro culture 
in the absence of stimuli; only mDC showed a significant reduction from 64% to 
16% (p=0.025 Friedman’s test) of BST2 expression when PBMC where cultured 
overnight in absence of stimuli (compare Figure 4.5A and C). Moreover, a 
significant upregulation of BST2 was observed after o/n culture of PBMC with AT-2 
HIV or TLR7/9L, at different degrees, in all cell types (Figure 4.5C). In particular, 
the frequency of BST2+ pDC increased from 32% in absence of stimuli (black 
bars), to 77-78% after overnight stimulation with TLR9L (blue bars) and AT-2 HIV 
(red bars) (p=0.0002 and p=0.0001, Wilcoxon sign rank test) and to 92% after 
overnight stimulation with TLR7L (green bars, p=0.0001, Wilcoxon sign rank test) 
(Figure 4.5C). Despite showing a reduction in BST2 expression following in vitro 
culture in the absence of stimulation, mDC also showed a high significant 
upregulation of BST2 expression after overnight culture in the presence of AT-2 
HIV, TLR9L and TLR7L, compared to the untreated control (for all p=0.043, 
Wilcoxon sign rank test; Figure 4.5C). B cells modestly upregulated BST2 (of 
approximately 35-40%) when PBMC were treated with either AT-2 HIV or TLR7/9L 
(for both p=0.043, Wilcoxon sign rank test; Figure 4.5C). T cells, instead, showed 
minor alterations of BST2 expression, which tested significant only after stimulation 
with AT-2 HIV or TLR9L (p=0.025 and p=0.05 respectively, Wilcoxon sign rank 
test) (Figure 4.5C). The frequency of BST2+ monocytes approached 100% in both 
freshly isolated and overnight cultured PBMC even in the absence of stimulation 
(Figure 4.5A and C). Consequently, when the frequency of BST2+ cells was 
considered, no differences could be revealed in the presence or absences of 
different TLR agonists (Figure 4.5C). However, by analysing the PE- MFI of anti-
BST2 Ab staining, we observed a significant increase in BST2 expression per-cell 
on monocytes following PBMC treatment with AT-2 HIV (p=0.022, Wilcoxon sign 
rank test) or TLR7/9L (p=0.007 and p=0.005 respectively, Wilcoxon sign rank test) 
(Figure 4.5D). In all other cell types the changes in MFI followed the same trends 
described for the frequencies of BST2+ cells (Figure 4.5A and C). These data are 
consistent with the regulation of BST2 expression by IFN-I produced by TLR7/9-
stimulated pDC [234, 245]. 
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Figure 4.5 BST2 expression in different cells types. 
 A) Frequency of BST2+ cells, and B) PE-Mean Fluorescence Intensity (PE-MFI) of 
BST2 on pDC, mDC, Monocytes, B and T cells, in freshly isolated PBMC. C) 
Frequency of BST2+ cells, and C) PE-MFI of BST2 on pDC, mDC, Monocytes, B 
and T cells following overnight culture, in absence (CTR) or presence of  AT-2 HIV, 
TLR9L or TLR7L. In all panels pDC, mDC, Monocytes, B and T cells were gated as 
shown in Figure 4.1; medians and IQRs of experiments from at least N=5 
independent donors or LRSCs are shown. 
 *p< 0.05, **p<0.01, ***p<0.001 (Wilcoxon sign rank test) 
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Figure 4.6 Effect of IFNAR2 on BST2 expression. 
PBMC from two independent LRSCs (Samples 1 and 2) were cultured overnight in 
the presence or absence (CTR) of TLR9L, TLR7L or AT-2 HIV (agonist) and pre-
treated or not with Anti-Human IFNAR2, clone MMHAR-2.The expression of BST2, 
was then evaluated by flow cytometry in different cells types (pDC, mDC, 
Monocytes and B cells) gated as shown in Figure 4.1. The percentages of positive 
cells for each sample (circles and squares) are shown. 
A further confirmation of BST2-IFN-dependent expression is presented in Figure 
4.6 where frequency of BST2+ cells on PBMC was tested in blood samples from 
N=2 LRSCs (dots and squares) in the presence (empty symbols) or absence (solid 
symbols) of Anti-Human IFNAR2, clone MMHAR-2. In detail, PBMC were either 
untreated or pre-treated with 10µg/ml of IFNAR2 and cultured overnight with or 
without 100 ng/ml p24 equivalents of AT-2 HIV (in red), 0.75 µM of TLR9L (in blue) 
and 5 µg/ml of TLR7L (in green). In Figure 4.6, the frequency of BST2+ cells for 
each sample and for each condition are reported for the different cells types 
analyzed (pDC, mDC, Monocytes and B cells). In agreement with the finding 
reported in the literature [234, 245], our data confirmed that BST2 expression is 
regulated by IFNα. Thus, in all cell types analyzed and in response to all stimuli 
tested (total 12 cell-stimulus combinations for each donor), blocking IFNα receptor 
induced different degrees of BST2 downregulation compared to TLR- stimulated 
PBMC (with the exception of 3/24 cell-stimulus combinations: donor 1, B cells and 
mDC both in response to TLR7L; and donor 2, B cells in response to TLR9L). 
In summary our data showed that BST2 is expressed at different level on the 
surface of pDC, mDC, Monocytes, B and T cells, without being dramatically 
affected by in vitro culture. Only the frequency of BST2+ mDC underwent a 
significant reduction after overnight incubation when PBMC were cultured in media 
only. Moreover, corroborating the data reported in the literature, we showed that 
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BST2 expression is IFNα-dependent, showing increases in the frequency of BST2+ 
cells and/or in BST2 MFI in all the cell types after stimulation with TLR agonist, 
which could be reversed by blocking IFNAR2 receptor.   
4.3.2 Effect of TLR- agonists titration on BST2 expression and pDC 
activation. 
In the previous section we reported that pDC, similar to other PBMC, express and 
can upregulate BST2 in response to TLR-stimulation (Figure 4.5 and 4.6). This 
suggests that ILT7 and BST2 interaction may happen not only in trans between 
pDC and other cells, but also in cis within the pDC population, depending on the 
pDC activation status. Therefore, we tested the effect of pDC overstimulation or 
suboptimal stimulation on the dynamics of BST2 expression by pDC. In Figure 4.7, 
PBMC from 6 independent donors or LRSCs were stimulated overnight with 
different concentrations of AT-2 HIV (in red) TLR9L (in blue) or TLR7L (in green) 
and the MFI of BST2 (top) was measured and compared to other pDC activation 
markers such as (from top to bottom) CD83 expression, IFNα production and IDO 
activity. We observed a significant up-regulation of BST2 expression by pDC after 
stimulation of PBMC with low-medium concentrations of HIV (p=0.028 for 100 
ng/ml p24 equivalents; Friedman’s test with Dunn’s correction for multiple pairwise 
comparisons) and a similar trend was noted after TLR7L stimulation, despite not 
reaching statistical significance. Conversely, when high concentrations of HIV or 
TLR7L were used, we observed only a modest increase in BST2 expression 
(Figure 4.7). Conversely, when cells were stimulated with TLR9L, a significant 
upregulation of BST2 on pDC was observed in response to high doses of TLR9L 
(with 15 and 50 µg/ml of TLR9L, p=0.044 and p<0.001 respectively; Friedman’s 
test with Dunn’s correction for multiple pairwise comparisons). The profile of BST2 
up-regulation by pDC observed after HIV and TLR7L stimulation generally followed 
that of CD83 and IFN-α production. Indeed, CD83 expression on pDC significantly 
increased when PBMC were stimulated with 100 ng/ml p24 equivalents HIV 
(p=0.004; Friedman’s test with Dunn’s correction for multiple pairwise 
comparisons) or with 0.075 μM and 0.25 μM TLR7L (p=0.018, p=0.044 
respectively; Friedman’s test with Dunn’s correction for multiple pairwise 
comparisons). Similarly, IFNα concentration was higher in the supernatants of 
PBMC treated with 100 or 300 ng/ml HIV p24 equivalents (p=0.02; Friedman’s test 
with Dunn’s correction for multiple pairwise comparisons), with 1.6 and 5μg/ml 
TLR9L (p=0.018, p=0.01 respectively; Friedman’s test with Dunn’s correction for 
multiple pairwise comparisons) or with 0.075 μM TLR7L (p=0.022; Friedman’s test 
with Dunn’s correction for multiple pairwise comparisons). Whist, only modest 
levels were observed when PBMC were treated with high concentration of the 
abovementioned stimuli (Figure 4.7). 
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Figure 4.7 Effect of TLR-agonist titration on pDC activation. 
Summary graphs showing (from top to bottom) MFI of BST2 on pDC, MFI of CD83 
on pDC, IFNα production and IDO activity (ratio Kyn: Trp) in function of different 
concentrations of AT-2 HIV (0-1000ng/ml; in red), TLR9L (0-50μg/ml; in blue) and 
TLR7L (0-7.75μM; in green). PBMC from N=6 independent donors or LRSCs were 
cultured overnight in presence of difference concentration of the agonists; pDC 
were then stained for BST2 and CD83 whilst the supernatants were used for 
evaluation of IFNα production by ELISA and measurement of Kyn: Trp by HPLC. 
*P<0.05, ** P≤0.01, ***P<0.001 (Friedman’s test with Dunn’s correction for multiple 
pairwise comparisons) compared to concentration 0.  
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Finally, we noticed a similar trend in IDO activity, measured by HPLC as ratio 
between Kynurenine and Tryptophan (Kyn: Trp) [244], only in response to TLR9L 
and TLR7L. These results suggested that overstimulation of pDC may result in 
hypo-responsiveness, possibly caused by regulatory mechanisms such as BST2-
mediated ILT7 cross-linking. However, IDO activity did not decrease when PBMC 
were exposed to elevated concentrations of AT-2 HIV. Thus, the Kyn: Trp ratios in 
culture supernatants were higher after overnight stimulation of PBMC with 300 or 
1000 ng/ml p24 equivalents of AT-2 HIV (p=0.011 and p<0.001 respectively 
Friedman’s test with Dunn’s correction for multiple pairwise comparisons) (Figure 
4.7). 
Therefore these data suggested that IDO activity may be differentially regulated 
upon HIV-mediated pDC stimulation, or that the suppression of IDO activity is 
specifically dysfunctional in response to high concentration of HIV.  
4.3.3 BST2 expression is not sufficient to suppress IFN-α production 
via ILT7 cross-linking. 
It has been shown that the cross linking of ILT7 on pDC causes a reduction in their 
ability to secrete IFNα [211, 214]. Furthermore, we demonstrated that BST2 
expression is increased on the surface of different cell types upon exposure of 
PBMC to TLR agonists (Section 4.3.1). Based on both these findings we 
hypothesized that, upon pDC activation, ILT7/BST2 interaction may be favoured 
and IFNα production negatively regulated. Therefore, we tested the effect of a 
cross-linking ILT7 Ab (XL-ILT7; clone 17G10.2) and one anti-BST2-specific Ab 
(αBST2; clone 26F8) on the TLR-mediated IFNα production by PBMC (Figure 4.8A 
and B). Clone 17G10.2 has been used in plate-bound form to cross-link ILT7 and 
suppress pDC activation [214], whereas 26F8 was reported to block BST2-ILT7 
interaction [234]. Figure 4.8A illustrates the levels of IFNα in the supernatants of 
PBMC, isolated from N=11 independent donors or LRSCs, cultured overnight in 
media only (black bars) or in the presence of AT-2 HIV (100 ng/ml p24 
equivalents), TLR9L (0.75 µM) or TLR7L (5 µg/ml) and pre-incubated for 30 
minutes or not (white bars) with 10 µg/ml of XL-ILT7 Ab (light blue bars) or 5 µg/ml 
αBST2 Ab. As expected, we reported a statistically significant increase in the IFNα 
concentration after the stimulation of PBMC with AT-2 HIV (p<0,0001; Wilcoxon 
sign rank test), TLR9L (p<0.0001; Wilcoxon sign rank test) and TLR7L (p=0.004; 
Wilcoxon sign rank test) compared to the untreated cells; consistent with the ability 
of TRL- agonists to induce pDC activation [138, 142] (Figure 4.8A). Congruous with 
the finding of Cao et al. [211, 214], pre-treatment of PBMC with the XL-ILT7 Ab 
caused a significant inhibition of AT-2 HIV- and TLR9L-mediated IFNα production 
(for both p<0.0001; Wilcoxon sign rank test), but did not affect the already low 
levels of IFNα induced by the TLR7L (Figure 4.8A). Conversely, the αBST2 (26F8) 
had no detectable effect on IFNα production (Figure 4.8A). In Figure 4.8B PBMC 
were cultured overnight as described for Figure 4.8A, but pre-treated (light blue 
bars) or not (white bars) with 10 µg/ml (final concentration) of αBST2 Ab. No 
significant changes in IFNα levels were observed even when αBST2 Ab was used 
at higher concentration (Figure 4.8B), indicating that the observed lack of effect 
was not connected to the dosage of the Ab used. Moreover, the αBST2 Ab did not 
affect the production of IFNα induced by TLR9L over time. In detail, Figure 4.8C 
illustrates the fold changes in TLR9L-induced IFNα in function of time when PBMC 
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were pre-incubated with 10 µg/ml of XL-ILT7 Ab (light blue bars) or 5 µg/ml αBST2 
ab. The data showed that, whilst XL-ILT7 Ab inhibited IFNα already at 6 hours after 
stimulation of PBMC with TLR9L (p=0.034 Friedman’s test with Dunn’s correction 
for multiple pairwise comparisons), the αBST2 Ab did not modulate IFNα at any of 
the time points considered. Consequently the inability of BST2-blocking Ab to 
regulate IFNα production by pDC was not associated to a different kinetic of action 
of the antibody. 
Collectively, these data confirmed the role of ILT7 cross-linking in the 
downregulation of IFNα production after pDC activation [211, 214]. However, they 
also argue against the involvement of BST2 in the regulation of pDC activation 
[211, 234]. Indeed, blocking of BST2 did not increase the levels of IFNα in 
supernatants of TLR-stimulated PBMC. This effect was independent of the dose or 
the kinetic of action of αBST2 Ab. 
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Figure 4.8 ILT7/ BST2 pDC-regulatory activity. 
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Figure 4.8 ILT7/ BST2 pDC-regulatory activity. 
A) ELISA measurement of IFNα production in culture supernatants from PBMC 
cultured overnight in the presence or absence (CTR) of TLR9L, TLR7L or AT-2 HIV 
(agonist) and pre-treated or not with 10 µg/ml XL-ILT7 Ab (17G10.2) or 5 µg/ml 
αBST2 (26F8); medians and IQRs of experiments from N=11 independent donors 
or LRSCs are shown. *p< 0.05, **p<0.01, ***p<0.001 (Wilcoxon sign rank test)  B) 
ELISA measurement of IFNα production in culture supernatants from PBMC 
cultured overnight as in A, but pre-incubated or not with 10 µg/ml of αBST2 (26F8); 
medians and IQRs of experiments from N=3 independent LRSCs are shown. C) 
Fold changes in TLR9L-induced IFNα in PBMC cultures after pre-treatment with 
XL-ILT7 (light blue dots and lines)or αBST2 (blue squares and lines) over time (6, 
9, 18 or 48 hours); all values were normalized against TLR9L-stimulated cells, 
indicated by the black dashed line; For each time point, medians (dots/squares) 
and IQRs of experiments from N=3 independent donors or LRSCs are shown.   
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4.3.4 BST2 expression is not sufficient to inhibit IDO activity 
It is known that activated pDC, besides secreting type I IFN, also upregulate the 
expression of IDO, an immunosuppressive enzyme which inhibits cell proliferation 
by catabolising the essential amino acid tryptophan into kynurenine [152, 153, 
182]. Therefore, we verified whether ILT7 cross-linking or BST2 blockade were 
involved in the regulation of TLR7/9L- and AT-2 HIV-induced IDO activity.  
 
Figure 4.9 IDO regulation by the ILT7/BST2 pathway. 
Ratio between Kyn and Trp measured by HPLC in supernatants from 
PBMC cultured overnight in the presence or absence (CTR) of TLR9L, 
or AT-2 HIV (agonist) and pre-treated or not with the XL-
ILT7(17G10.2) or the αBST2 (26F8); medians and IQRs of 
experiments from N=11 independent donors are shown.  
*p<0.05, **p<0.01, ***p<0.001 (Wilcoxon sign rank test) 
Figure 4.9 shows the results obtained for IDO enzymatic activity when PBMC were 
cultured overnight in the presence or absence (black bars) of HIV (100 ng/ml p24 
equivalents), TLR9L (0.75 µM) or TLR7L (5 µg/ml). After being pre-treated or not 
(white bars) with 10 µg/ml of XL-ILT7 Ab (light blue bars) or 5 µg/ml αBST2 Ab. 
The ratio between Kyn and Trp (Kyn: Trp), a well accepted marker of IDO activity 
[244], was then measured by HPLC in culture supernatants. Similar to what 
observed for IFNα, we found statistically significant increases in IDO activity after 
stimulation with AT-2 HIV (p=0.004, Wilcoxon sign rank test), TLR9L (p=0.028, 
Wilcoxon sign rank test) and TLR7L (p=0.003, Wilcoxon sign rank test). 
Interestingly, XL-ILT7 Ab pre-treatment induced a significant downregulation of  
AT-2 HIV-induced IDO activity (p=0.01, Wilcoxon sign rank test), whereas no 
significant change was observed in TLR9/7L-induced IDO activity.  
 63 
 
Moreover, no effect on IDO activity was reported after pre-incubation with 5µg/ml 
(final concentration) of αBST2 Ab. 
We conclude that whilst the cross-linking of ILT7 was partially capable to regulate 
IDO activity, at least in response to AT-2 HIV-, BST2 did not affect IDO enzymatic 
activity. These findings support the hypothesis that BST2 is not involved in the 
regulation of pDC activity. 
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4.3.5 BST2 antibody efficiency of binding 
Since we did not observe any effect of BST2 blocking on pDC activity, we tested 
whether the lack of biological activity was due to a defect in the efficiency of 26F8 
binding to cellular BST2. 
 
Figure 4.10 anti-BST2 antibody efficiency of staining. 
A) Diagram showing five different mutations (10-12A; Y6,8A;ΔGPI; 3CA;L123P) on 
the BST2 protein. The details of the mutation are given in the text. B) HEK 293T 
cells were stained with PE-labelled 26F8 anti-BST2 antibody; the first panel shows 
FSC and SSC properties of 293T cells; all other panels show staining of untreated 
and rIFNα-treated 293T CTR, as well as 293T cells transfected with wild-type (WT) 
or mutated (10-12A; Y6,8A;ΔGPI; 3CA;L123P) BST2; numbers in the plots indicate 
% BST2+ cells (in red) and BST2-PE MFI (in blue). 
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To this purpose we adopted a controlled in vitro system based on the use of 293T 
cell lines which were transfected or not (CTR) with wild-type (WT) BST2 or BST2 
bearing specific mutations, or 293T cells lines which were treated with rIFNα to 
increase BST2 expression (Figure 4.10). Figure 4.10A illustrates a diagram 
showing the position of different mutations on BST2 protein. In detail, BST2
10-12A
 
and BST2
Y6,8A
 bear mutation in the intracellular region of the protein, likely affecting 
the BST2-mediated intracellular pathways; BST2
ΔGPI
 mutant presents a disruption 
in the extracellular membrane anchor;  BST2
3CA
  bears a mutation in the disulfide-
bonds that join the two monomer of the dimeric BST2, thus resulting in a 
monomeric protein; and BST2
L123P
 is mutated in the coiled-coil extracellular region. 
To test the reactivity of the BST2 Ab with the extracellular portion of BST2, we 
stained the above cell lines with the PE-conjugated BST2 Ab (clone 26F8) and we 
detected BST2 expression by flow cytometry. As shown in Figure 4.10B, PE-
conjugated- BST2 Ab efficiently stained rIFNα treated 293T cells (31.8% BST2+; 
MFI = 5,228) and 293T cells transfected with BST2
WT
 (96% BST2+; MFI = 37,500) 
but not the 293T CTR cells. Efficient staining was also observed in 293T cells 
transfected with BST2
10-12A
 (84% BST2+; MFI = 10,700), BST2
Y6,8A
 (94% BST2+; 
MFI = 12,600) and  BST2
ΔGPI
 (89% BST2+; MFI = 32,300). 293T cells transfected 
with monomeric BST2
3CA
 stained positive for 26F8-PE but presented a reduction of 
staining on a per cell basis as measured by MFI (79% BST2+; MFI = 6,385). 
Finally, no staining was detected in BST2
L123P
–transfected 293T cells, in which 
BST2 is mutated in the coiled-coil extracellular portion of BST2, presumably the 
region responsible for ILT7 binding (Figure 4.10B). 
In light of these observations, we deducted that the lack of biologic effect of BST2 
blockade is not related to the inefficiency of reactivity of the αBST2 antibody with 
the extracellular portion of BST2. 
4.3.6 BST2 is not involved in the regulation of IFNα production by 
pDC  
We tested whether the apparent lack of BST2 biological effects was associated 
with the lack of BST2-ILT7 interactions in vitro. Therefore, we used two 
independent experimental systems in order to favour the interplay between ILT7 
and BST2 in vitro: 1) a soluble BST2 protein to stimulate PBMC; and 2) a co-
culture system in which isolated pDC were incubated with 293T cells lines 
transfected with BST2
WT
. 
4.3.6.1 Soluble BST2 did not affect IFNα production 
We verified whether pre-treatment of PBMC with a soluble form of BST2 was 
sufficient to regulate the secretion of IFNα by activated pDC. In Figure 4.11, PBMC 
isolated from 3 healthy donors were pre-treated or not with 5µg/ml of soluble 
BST2-GST fusion protein or soluble GAPDH-GST fusion protein. GAPDH was 
used as a control (BST2 predicted mw=19.7kDa; GAPDH predicted mw=36.1kDa; 
GST predicted mw=25kDa). Importantly, the BST2-GST fusion protein contains 
only a monomer of BST2, and may not fully reflect the physiologically relevant 
conformation of the protein. After pre-treatment with BST2-GST or GAPDH-GST, 
pDC were activated by stimulating PBMC overnight with AT-2 HIV (100 ng/ml p24 
equivalents; in red) or TLR9L (0.75 µM; in blue).  
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Figure 4.11 Effect of soluble BST2 protein on IFNα production. 
IFNα levels in supernatants from PBMC isolated from N=3 independent donors, 
cultured overnight in the presence or absence (CTR) of AT-2 HIV (in red) or TLR9L 
(in blue) and pre-treated or not with soluble BST2-GST soluble GAPDH-GST fusion 
proteins. IFNα concentrations for each donor (circles, diamonds and stars) in each 
condition are shown. 
Consistent with our previous observations, we did not find any change in the IFNα 
production by pDC in the presence of soluble BST2-GST protein (Figure 4.11), 
supporting the notion that BST2 may not be involved in the regulation of pDC 
activation. 
4.3.6.2 BST2 did not affect IFN-α production in an in vitro co-culture system 
BST2 is normally expressed on the surface of cells as a homodimer [260, 261]. 
However the soluble protein used in the experiment described in Section 4.3.6.1 
was in a monomeric form; thus it could be argued that the lack of effect of BST2-
GST was due to its non-natural monomeric form. For this reason, we used a model 
in which the effect of cell-bound dimeric BST2 could be analysed. Isolated pDC 
were co-cultured with 293T cells transfected with BST2
WT
 as described in section 
3.14 of the Material and Methods Chapter. In this system, BST2-ILT7 interaction 
may be facilitated as ILT7-expressing pDC, isolated from the total PBMC, may 
interact with BST2 dimers which are abundantly and stably expressed by the 293T 
cell lines. Figure 4.12 shows the levels of IFNα in the supernatants of pDC co-
cultured alone (in orange) or with BST2
wt
–transfected 293T cells (in green) or 293T 
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CTR cells (in violet), stimulated or not with TLR9L (0.75µM) and pre-incubated or 
not with 5µg/ml of αBST2 Ab (clone 26F8) or the respective isotype control Ab. As 
expected, our data showed a significant increase in IFNα production when pDC 
were stimulated with TLR9L, regardless of whether they had been cultured alone 
(p=0.046; Wilcoxon sign rank test) or co-cultured with BST2
wt
-293T cells or 293T 
CTR cells (p=0.028 in both conditions; Wilcoxon sign rank test). 
 
 
Figure 4.12 Effect of pDC and 293T CTR or BST2
wt
 cell lines co-cultures  
on IFNα production 
Plasmacytoid DC, magnetically isolated from N=6 independent LRSC, were 
cultured overnight alone (orange bars) or in combination with 293T CTR (green 
bars) or BST2
wt
 cell lines (violet bars) in presence or absence of TLR9L and pre-
treated or not with the αBST2 (26F8); or isotype as indicate by +/- symbols 
underneath the X-axis. ELISA IFNα measurements in supernatants of the different 
cells culture are shown. Whiskers denote: Min to Max values. *p< 0.05, (Wilcoxon 
sign rank test). 
 
However, in both co-culture systems, no differences in the IFNα levels were 
observed when cells were also pre-treated with αBST2. When pDC were cultured 
alone, αBST2 significantly reduced IFNα production rather than enhancing it, but a 
similar effect was observed in presence of the isotype control (p=0.028 and 
p=0.043 respectively; Wilcoxon sign rank test) suggesting a non-specific alteration 
of IFNα production cause by the addition of antibodies.  
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Taken together, these data suggest that BST2 was not able to modulated IFNα 
secretion. This inefficacy was likely not due to technical issues related to the in 
vitro culture system, but more likely to the intrinsic inability of BST2 to negatively 
modulate pDC activation.  
4.3.7 Summary and discussion  
Cao and colleagues showed that XL-ILT7 Ab (clone 17G10.2), suppressed pDC 
activation when used in plate-bound form [214]; they also demonstrated that 
αBST2 Ab (clone 26F8) inhibited green fluorescence protein (GFP) induction, in 
ILT7 reporter cell lines in response to the ILT7 surface ligation induced by co-
culture with human breast cancer cell lines [234]. Moreover they observed a 
reduction in the TLR9L- mediated IFNα production when pDC where pre-incubated 
with plate-bound rBST2-Fc protein; which was prevented by blocking anti-ILT7 
mAb [234]. These findings led to the idea that when BST2 interacts with ILT7, an 
intracellular signal cascade is triggered, which negatively regulates pDC activation. 
To verify this hypothesis we tested the expression of BST2 in circulating PBMC 
and we tried to induce the cross-linking of ILT7 and to block the interaction with its 
ligand using the same clones of Ab used by Cao and colleagues in more 
physiological setting, represented by unsorted human PBMC. 
Corroborating the findings presented in the literature, our data confirmed the 
presence of BST2, on the surface of untreated PBMC, albeit with different levels 
depending on the cell types, and with the most prominent expression on 
monocytes [229]. With the exception of mDC, BST2 expression was not affected by 
in vitro culture, different from what reported for ILT7 (Section 4.2.1). Furthermore, 
in agreement with data reported in the literature, BST2 expression was found to be 
modulated by IFNα [234, 245]. A significant upregulation of BST2 was observed in 
all cell types after TLR7/9L stimulation of PBMC, especially in pDC with the highest 
increases at low and medium concentration of HIV and TLR7L, rather than at the 
highest concentration tested. A profile of expression, that followed that of CD83 
and IFNα, suggesting that the overstimulation of pDC may results in 
hyporesponsiveness, possibly caused by BST2-mediated ILT7 cross-linking. 
However, IDO activity was found to be higher after stimulation with the maximum 
doses of HIV, suggesting a different modulation or a dysregulation of IDO activity at 
high concentration of HIV  
Nevertheless, our findings collectively cast doubt on the role of BST2 in regulating 
pDC activity. Thus, we were unable to increase IFNα production and IDO activity 
by blocking BST2 in primary human leukocytes with the αBST2 Ab (clone 26F8) as 
shown by Cao and colleagues in an ILT7-reporter system [234]. Different 
hypotheses were considered to explain this absence of biological effect. We 
excluded the possibility of poor efficiency of αBST2 Ab binding, as 96% of cells in 
(BST2
WT
) – HEK 293T transfected cell lines showed positive staining for PE-
labelled 26F8 αBST2 Ab. Moreover, the lack of staining in BST2
L123P3
-293T cells, 
confirmed the binding of the αBST2 Ab to the extracellular coiled-coil region of the 
molecule, which is likely the region of interaction with ILT7. We also discarded the 
idea that deficit in the biological effect of BST2 was related to poor BST2-ILT7 
interactions in vitro. Indeed, no changes in the production of IFNα were revealed 
even when the possibility of interaction between ILT7 and BST2 were optimized 
using either a soluble BST2 protein or a co-culture system using purified pDC and 
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HEK 293T cells expressing BST2
WT.
 Therefore, it is likely that BST2 is not involved 
the negative regulation of pDC activation in primary leukocytes. 
On the other hand, in agreement with the findings of Cao and colleagues [214], 
pre-treatment of PBMC with XL-ILT7 Ab (clone17G10.2) inhibited IFNα production 
and IDO activity of AT-2 HIV and/or TLR9L- stimulated pDC. These data, combined 
with the previous results showing ILT7 downregulation in vitro as part of the pDC 
differentiation process (Section 4.2), led us to speculate that ILT7 cross-linking may 
act as a homeostatic mechanism on immature circulating pDC rather than a 
negative feedback for activated mature pDC. This could be particularly relevant for 
HIV pathogenesis, during which partial or incomplete pDC maturation is observed 
[247, 248]. It has been recently shown that ILT7 expression on circulating pDC is 
reduced in HIV-infected patients in which viral replication is not efficiently controlled 
by HAART [262]. Therefore it is possible that ILT7 downregulation is a 
consequence of the partial or incomplete pDC differentiation caused by chronic 
stimulation during HIV infection. Accordingly Sabado et al. reported that pDC and 
mDC may relocate to lymphoid tissues already during primary HIV infection, and 
this redistribution persists throughout the course of disease [180]. However, 
whether and how ILT7 downregulation may contribute to chronic pDC activation 
during HIV infection remains unknown. 
4.4 BST2 expression on T cells 
In Section 4.3, we showed that BST2 is unlikely to be involved in the regulation of 
pDC activation as we were unable to alter IFNα production and IDO activity using a 
specific αBST2 Ab (clone 26F8). We postulated that the absence of BST2 
biological effect may have been associated with the difficulty to favour the BST2-
ILT7 interaction in vitro. However, we were unable to inhibit IFNα secretion by pDC 
using either a soluble BST2 protein or a co-culture system based on purified pDC 
and HEK293T cells expressing BST2
WT
. 
Nevertheless, it can be argued that both systems described above do not represent 
the physiological conditions in which BST2 may be expressed on the surface of 
PBMC. Thus, these artificial in vitro systems may lack additional complementary 
signals between cells that may influence BST2 activity. Therefore, we tested 
whether other signals may influence BST2 expression and its interaction with ILT7 
in a more physiological system. In particular, T cells interact closely with pDC 
during the immune response, and pDC can either induce T cell tolerance or 
contribute to the initiation and modulation of T cell responses [263, 264]. T cells 
showed the lowest expression of BST2 among the cell subsets considered in 
PBMC, even after stimulation with AT-2 HIV or TLR7/9 agonists (Figure 4.5). Thus, 
we hypothesised that, during antigen (Ag) presentation to T cells by activated pDC, 
the combination of signals triggered by IFNα and TCR may induce BST2 
upregulation and subsequent ILT7-mediated pDC suppression. Therefore, we 
tested whether BST2 expression on T cells was regulated by T cell activation via 
TCR engagement, and whether T cell activation may affect pDC-mediated IFNα 
production in a BST2-dependent manner. 
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4.4.1 TLR9L-mediated BST2 expression is enhanced by T cell 
receptor engagement. 
To test whether BST2 expression on T cells is upregulated following direct TCR-
dependent stimulation, PBMC from 3 different LRSCs were cultured in control 
media (CTR) or stimulated with TLR9L (0.75 µM final concentration) and pre-
incubated or not for 30 minutes with 1 µg/ml CD3-specific antibody (αCD3 Ab; 
clone OKT3), used as mitogenic stimulus for T cells; CD28-specifc antibody 
(αCD28 Ab; clone CD28.2) was used as control. Prior to stimulating T cells with the 
above conditions for up to 5 days, PBMC were stained with Violet Proliferation Dye 
450 (VPD450) in order to monitor the efficiency of the mitogenic stimulus. As 
described in Section 3.15 of the Materials and Methods Chapter, VPD450 is a 
violet laser excitable dye that passively diffuses across cell membranes, becoming 
highly fluorescent. When parental cells divide, VPD450 is uniformly distributed 
between daughter cells allowing the monitoring of cell divisions which can be 
visualized by flow cytometry as a reduction in the VPD450 fluorescence intensity. 
The gating strategy used to identify CD4+/CD8+T cells subsets is illustrated in 
Figure 4.13. 
 
 
Figure 4.13 Phenotypic characterization of CD4+ and CD8+T cells. 
 Flow cytometry pseudocolour chart showing the gating strategy adopted to 
identify CD4+ T cells (CD4+ and CD8- within the Lymphocytes gate) and 
CD8+ T cells (CD4- and CD8+ within the Lymphocytes gate). It is important 
to note that the Lymphocytes gate has been intentionally extended to 
higher FSC and SSC to account for possible changes in size and 
granularity of proliferating T cells.   
 
As expected, CD4+ and CD8+T cells showed no sign of proliferation after 24 hours 
of culture in any of the conditions analysed (CTR; TLR9L; αCD3 Ab;  αCD3 Ab + 
TLR9L; αCD28 Ab + TLR9L), as epitomized by the lack of reduction in VPD450 
fluorescence intensity. In Figure 4.14A, flow cytometry histograms are shown for 
VPD450 staining (X axes) of CD4+ T cells (in grey) and CD8+ T cells (in blue) in 
PBMC that were cultured in media alone (CTR) or stimulated with αCD3 Ab alone 
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for 24 hours. No staining was detected in the VPD low region (orange arrows), 
defined as the area showing a reduction in VPD450 fluorescence intensity 
compared to Generation 0 (undivided cells), demonstrating the absence of cell 
proliferation. Similar histograms were obtained in all the other conditions of PBMC 
stimulation (TLR9L; αCD3 Ab + TLR9L; αCD28 Ab + TLR9L) after 24 hours. These 
data confirmed that 24h were not sufficient to induce T cell proliferation even in 
presence of a mitogenic antibody. Conversely, five days after stimulation we 
observed consistent T cell proliferation, in both the CD4+ and CD8+ T cell subsets, 
when PBMC were treated with αCD3 Ab alone (Figure 4.14B). Figure 4.15 shows 
the proliferation of CD4+ T cells (in grey) and of CD8+ T cells (in blue), expressed 
as the reduction in VPD450 fluorescence intensity (X-axes), after 5 days of PBMC 
culture in the presence of media alone (CTR), TLR9L alone, αCD3 Ab alone, αCD3 
Ab + TLR9L and αCD28 Ab + TLR9L. The number of peaks in the VPD low region 
(orange arrows) is associated with the number of cell divisions. Thus, as expected, 
[265] αCD3 Ab efficiently induced T cells proliferation at 5 days. 
Conversely TLR9L alone or in combination with aCD28 was unable to induce T cell 
proliferation, as no peaks were observed in the VPD low region. A statistical 
evaluation of the proliferation, at 5 days, is presented in Table 4.1 where the 
median (in bold) and Min and Max values (in brackets) of Proliferation and Division 
Indices of both CD4+ and CD8+ T cell subsets in all conditions of stimulation are 
shown. The “Division Index” represents the average number of cell divisions that a 
cell in the original population has undergone (including the undivided peak). 
Conversely, the “Proliferation Index” corresponds to the ratio between the total 
number of divisions and the number of cells that underwent division (thus 
considering only the cells that underwent at least one division) [266]. Therefore, the 
Proliferation Index provides information on the biology of the responding cells, 
whereas the Division Index describes the effect of the treatment on the entire 
system, including both responding and resting cells. Both these indices were 
calculated using FlowJo software (Tree Star, San Carlos, CA) which uses a 
mathematical model based on the construction of a series of Gaussian curves, the 
sum of which equals the distribution found in the data file. The evaluation of 
Proliferation and Division indices supported what was observed in the flow 
cytometry histograms shown in Figure 4.15, confirming the high efficiency of αCD3 
Ab as a mitogen. Indeed, in both CD4+ and CD8+ T cells subsets, the Proliferation 
index as well as the Division index were higher when PBMC were stimulated with 
αCD3 Ab rather than in association with TLR9L; conversely TLR9L, alone or in 
combination with aCD28, was unable to induce proliferation (Table 4.1). Thus, for 
example, in CD4+ T cells the proliferation index decreased from 1.52 in presence 
of αCD3 Ab alone to 1.25 when PBMC were treated with αCD3 Ab in combination 
with TLR9L, whilst it is equivalent to 0 (no proliferation) when PBMC were cultured 
for 5 days in media alone (CTR), TLR9L or αCD28 Ab+ TLR9L (Table 4.1). A 
similar trend was reported for Division Index in CD4+T cells and for both 
Proliferation and Division Indices in CD8+T cells (Table 4.1). 
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Figure 4.14 T cell proliferation after 24 hours and 5 days.  
Flow cytometry histograms showing proliferation of CD4+ and CD8+T cell (in grey 
and blue, respectively), measured as reduction of VPD450 staining (VPD low) after 
24 hours (A) and 5 days (B) of PBMC culture in media (CTR) or αCD3 Ab (clone 
OKT3).The number of peaks in the VPD low region (orange arrows) corresponds to 
the number of cell divisions. Histograms are shown from one representative 
sample of an experiment performed on N=3 different LRSCs. 
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Figure 4.15 T cell proliferation after 5 days. 
Flow cytometry histograms showing CD4+ and CD8+T cell (in grey and blue 
respectively) proliferation measured as reduction of VPD450 staining (VPD low) 
after 5 days of PBMC culture in presence or absence (CTR) of TLR9L and pre-
treated or not with αCD3 Ab (clone OKT3) or αCD28Ab (clone CD28.2). The 
number of peaks in the VPD low region (orange arrows) corresponds to the 
number of cell divisions. Histograms are shown from one representative sample of 
an experiment performed on N=3 different LRSCs. 
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CTR 
 
TLR9L 
 
αCD3 
 
αCD3+ 
TLR9L 
 
αCD28+ 
TLR9L 
 
CD4 
Prolif. 
index 
0 
 
0 
 
1.52 
(1.36-1.63) 
1.25 
(1.25-1.51) 
0 
 
CD4 
Division 
index 
0 
 
0 
 
0.42 
(0.27-0.43) 
0.20 
(0.17-0.39) 
0 
 
CD8 
Prolif. 
index 
0 
 
0 
 
1.59 
(1.58-1.67) 
1.56 
(1.27-1.66) 
0 
 
CD8 
Division 
index 
0 
 
0 
 
0.53 
(0.39-0.54) 
0.51 
(0.23-0.25) 
0 
 
Table 4.1 Proliferation and Division Indices in CD4+ and CD8+T cells. 
PBMC isolated from N=3 LRSCs were stained with Violet Proliferation Dye 450 
(VPD450) and cultured for 5 days in media alone (CTR) or stimulated with TLR9L. 
Cells were also pre-treated or not with αCD3 Ab (clone OKT3) or αCD28Ab. The 
table shows Median (in bold) and Min and Max value (in brackets) of the 
Proliferation and Division Indices, calculated using FlowJo software,  in CD4+ and 
CD8+T cells after 5 days of culture in the different conditions of stimulation. 
 
Once the efficiency of αCD3 Ab (clone OKT3) to stimulate TCR and induce T cell 
proliferation was confirmed, we verified whether it also influenced the expression of 
BST2 on T cells, and whether its expression was associated with the degree of T 
cell proliferation itself. Therefore we measured BST2 expression on T cells in the 
same experiments described to monitor the proliferation at 24h and 5 days after 
different stimulation conditions. Cells were stained with AlexaFluor488-conjugate 
BST2 antibody, in order to evaluate the expression of BST2 on both CD4+ and 
CD8+ T cells subsets (Figure 4.16). In detail, Figure 4.16 illustrates the frequencies 
of BST2+ cells in CD4+ T cells (in grey) and in CD8+ T cells (in blue) after 24 
hours (Figure 4.16A) and after 5 days (Figure 4.16B) of stimulation in the 
conditions described above. Confirming the previous data (Figure 4.5C), BST2 
expression was found to be very low in unstimulated T cells (CTR) (1% and 2% in 
CD4+T cells and CD8+T cells, respectively) and was modestly upregulated after 
overnight incubation with TLR9L, increasing up to 7% and 25% in CD4+T cells and 
CD8+T cells respectively (Figure 4.16A). Interestingly, after 24 hours, even in the 
absence of detectable T cell proliferation (Figure 4.14A), αCD3 stimulation was 
sufficient to induce partial upregulation of BST2 expression, on both T cell subsets. 
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Figure 4.16 Frequencies of BST2+ cells in proliferating T cells. 
PBMC from N=3 independent LRSCs were cultured, up to 5 days, in presence or 
absence (CTR) of TLR9L and pre-treated or not with the stimulating αCD3 Ab 
(clone OKT3) or αCD28 Ab. After 24 hours or 5 days the expression of BST2 on 
CD4+/CD8+T cell was evaluated by flow cytometry. The graphs show the 
percentages of BST2+ cells in CD4+/CD8+T cell populations after 24 hours(A) or 5 
days(B). Medians (circles) and interquartile ranges (upper and lower bars) are 
shown. The number of samples was too small to perform Wilcoxon sign rank test.   
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Similar to what observed after TLR9L stimulation, αCD3 caused an increase in the 
frequencies of BST2+ cells to 15% and 21% in CD4+ T cells and CD8+ T cells 
respectively (Figure 4.16A). Moreover, when TLR9L and αCD3 Ab were used 
together, we observed a higher upregulation of BST2 expression by both CD4+ 
and CD8+ T cells after 24h than with either stimulus alone (50% and 65% 
respectively). These data suggest a synergistic effect of TCR stimulation and 
TLR7/9L-induced IFN-I signalling. αCD28 Ab, used as control, did not synergize 
with TLR9L (Figure 4.16A). After 5 days the effect on BST2 expression, of both 
TLR9L and αCD3 Ab used alone, was higher in comparison to 24 hours. Following 
TLR9L stimulation, the frequencies of BST2+ cells increased up to 62% and 70% 
in CD4+T cells and CD8+T cells subset, respectively. Following αCD3 Ab 
stimulation, BST2+ T cells raised up to 39% and 31% in CD4+T cells and CD8+T 
cells, respectively (Figure 4.16B). These increases may be associated to other 
IFNα-independent TLR9-mediated pathways or a consequence of T cell 
proliferation after TCR-engagement.  Nonetheless, when TLR9L and αCD3 Ab 
were used together, they further increased the frequencies of BST2+ cells (70% 
and 84% in CD4+ T cells and CD8+ T cells subset respectively), even though this 
synergic effect was less striking than that observed at 24 hours.  
Collectively these data suggest that TLR9L-mediated BST2 expression is 
enhanced by TCR engagement, as after 24 hours of stimulation we observed a 
synergist effect of TLR9L and αCD3 Ab, resulting in elevated frequencies of BST2+ 
cells in both CD4+ and CD8+ T cells. However, after 5 days of stimulation, it is 
possible that BST2 increases may be also a result of IFNα-independent 
mechanisms. Another possible explanation is that the engagement of TCR may 
accelerate the TLR9L- induced upregulation of BST2. When TLR9L was used 
alone, indeed, we observed an increase up to 62% and 70% in CD4+ T cells and 
CD8+ T cells subset respectively, only after 5 days of culture; comparable levels of 
BST2 upregulation (50% and 65% CD4+ T cells and CD8+ T cells subset, 
respectively) were instead observed already after 24 hours of TLR9L stimulation 
when PBMC were pre-treated with αCD3 Ab 
4.4.2 Enhancement of TLR9L- mediated BST2 expression by T cell 
receptor engagement is not sufficient to suppress IFNα 
production via ILT7 cross-linking 
In order to confirm the synergistic effect of TCR and TLR9 engagement on BST2 
expression on T cells after 24 hours of stimulation, we repeated the previous 
experiment using a different clone of the αCD3 Ab, the clone HIT3a also known for 
its mitogenic properties. Therefore PBMC isolated from N=6 independent donors 
were cultured overnight, in media alone (CTR) or stimulated with TLR9L (0.75 µM 
final concentration) or αCD3 Ab clone HIT3a (1µg/ml final concentration) alone or 
in combination. CD28-specific antibody (αCD28 Ab; 1µg/ml final concentration) 
was used as control. As expected both TLR9L and αCD3 Ab-clone HIT3a used 
alone induced a partial but statistically significant upregulation of BST2 expression 
in both CD4+ and CD8+ T cells compared to unstimulated PBMC (Figure 4.17A). 
The frequencies of the BST2+ cells rose from 1% to 24% and 39% in CD4+ T cells 
and CD8+ T cells respectively following TLR9L stimulation (p=0.028 Wilcoxon sign 
rank test), and up to 36% and 32% in CD4+ T cells and CD8+ T cells subsets 
respectively following αCD3 Ab stimulation (for both p=0.028 Wilcoxon sign rank 
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test) (Figure 4.17A). Moreover when used together, a further upregulation in 
BST2+ cells frequencies was observed, reaching  73% and 78% in CD4+T cell and 
CD8+T cells, respectively. BST2 upregulation in response to TLR9L + αCD3 Ab-
clone HIT3a was significantly higher compared to either TLR9L or αCD3 Ab-clone 
HIT3a used alone (in all p=0.028 Wilcoxon sign rank test); αCD28 Ab did not 
synergize with TLR9L (Figure 4.17A).  
Since we demonstrated that the incubation of PBMC with TLR9L and TCR- 
stimulating αCD3 Ab (clone OKT3 or HIT3a; Figure 4.16A and Figure 4.17A) 
significantly enhanced BST2, we tested whether TLR9L-induced IFNα production 
may be inhibited in these conditions. Consequently, PBMC isolated from N=6 
independent donors were cultured overnight in presence or absence (CTR) of 
TLR9L (0.75 µM final concentration) or αCD3 Ab (clone HIT3a; 1µg/ml final 
concentration) alone or in combination, and pre-treated or not with αBST2 Ab 
(clone 26F8) for 30 minutes before stimulation. The levels of IFNα in culture 
supernatants were tested by ELISA after 24h culture. As shown in Figure 4.17B, 
TLR9L induced a significant increase in IFNα production compared to untreated 
cells (p=0.028 Wilcoxon sign rank test). Surprisingly, a significant increase in IFNα 
secretion, albeit of modest intensity compared to TLR9L, was observed also after 
TCR stimulation by αCD3 Ab (HIT3a) (p=0.027 Wilcoxon sign rank test). However, 
when TLR9L and αCD3 Ab were used together, the effect of TLR9L on IFNα 
production was predominant, and no differences were observed compared to 
TLR9L alone (Figure 4.17B). Moreover the αBST2 Ab did not affect IFNα level, as 
no differences were observed compared to TLR9L alone (Figure 4.17B). These 
data support our previous observations indicating that BST2 is not involved in the 
negative regulation of pDC activation. 
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Figure 4.17 Effect of TCR engagement on BST2 expression in T cells and on 
TLR9L-induced IFNα production. 
A) Box-and-whiskers plots showing the frequencies of BST2+ CD4 (grey bars)and 
CD8 T cells (blue bars) among PBMC cultured overnight in presence or absence 
(CTR) of different combinations of TLR9L, stimulating CD3-specific Ab (αCD3 Ab 
clone HIT3a) and CD28-specific Ab (αCD28); B) ELISA measurement of IFNα 
levels in supernatants from PBMC cultured overnight in presence or absence of 
different combinations of TLR9L, αCD3 Ab (clone HIT3a) and αCD28 Ab, pre-
treated or not with the αBST2 (clone 26F8). In A) and B) medians and IQRs of 
experiments from N=6 independent donors are shown. Whiskers denote: 10
th
 and 
90
th
 percentile. In both panels *P<0.05 (Wilcoxon sign rank test). 
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In summary our data confirm the role of TCR engagement in BST2 expression but, 
as no reduction of IFNα was detected in any condition analyzed (Fig. 4.17B), we 
conclude that even under conditions of maximum BST2 expression, T lymphocytes 
do not downregulate pDC activation by engaging ILT7. 
4.4.3 Summary and discussion  
It has been recently shown that BST2, interacting with ILT7, may play an important 
role in the negative regulation of pDC activation [211, 234]. However, our findings 
collectively ague against this hypothesis, since we were unable to increase IFNα 
production and IDO activity by blocking BST2 with the αBST2 Ab (clone 26F8) as 
described in Section 4.3 of the Results Chapter. We considered the possibility that 
BST2-ILT7 interactions may not be favoured in the in vitro culture system studied. 
However, using a soluble BST2 protein or a co-culture system with BST2-
transfected cells, we were still incapable of detecting changes in IFNα levels 
(Section 4.3.6), supporting the idea that BST2 may not be involved in the 
downregulation of pDC activation. Nevertheless, we wanted to test whether other 
signals may influence BST2 expression on PBMC therefore favouring its interaction 
with ILT7 in a more physiological system. The interaction between pDC and T cells 
plays an important role during the initiation and modulation of the immune 
response. Therefore, we focused our attention on the T cell population, which we 
previously found to express the lowest level of BST2 among PBMC, even after 
TLR7/9 stimulation (Figure 4.5). In particular we verified whether T cell activation 
via TCR engagement affected BST2 expression and favoured its interaction with 
ILT7, therefore suppressing pDC activation. In order to stimulate TCR, we 
incubated total PBMC with either of two clones of αCD3 Ab, OKT3 or HIT3a, both 
well known for their ability to interact with the TCR resulting in cell proliferation 
[265, 267]. Interestingly, we found that the frequency of BST2+ cells significantly 
increased as a consequence of TCR engagement. This effect was amplified in the 
presence of TLR9 stimulation, especially after 24 hours of stimulation, indicating a 
synergic effect between TLR9L-induced IFNα and TCR engagement on BST2 
expression by both CD4+ and CD8+ T cells. After 5 days of stimulation, BST2 
expression was further increased compared to 24h even when TLR9L and αCD3 
Ab were used alone, possibly as a consequence of other TLR9L mediate pathways 
and T cell proliferation. Therefore, the synergistic effect between TLR9L and αCD3 
Ab, even if visible, was less intense. However, although BST2 expression was 
maximum after 24h of stimulation due to the effects of TCR and TLR9 
engagement, αBST2 Ab (clone 26F8) showed no effect IFNα production. Hence, 
BST2 did not downregulate pDC activation by engaging ILT7 even when 
expressed at high levels in T cells in a mixed leukocyte culture. These data provide 
additional argument against the hypothesis suggested by Cao and colleagues 
[211, 234]. 
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4.5 BST2 expression may be modulated by cytokines involved 
in the regulation of inflammatory responses 
Based on the data presented in Section 4.4.1, we hypothesized that signals other 
than IFNα may affect BST2 expression. Therefore, we verified whether the 
suppression of BST2-mediated pDC activation may rely on secondary signals, 
provided by proinflammatory or immunoregulatory cytokines present in the 
microenvironment. Accordingly, we first investigated the direct effects of different 
cytokines on BST2 expression in PBMC and their effects on TLR9L-induced BST2 
upregulation. Second, we tested whether these cytokines influenced IFNα 
production through a BST2-ILT7 mediated pathway. For this purpose we chose 
four cytokines: one involved in the response against virus and intracellular 
pathogen (IFNγ) [268], one promoting the differentiation  of naive CD4
+
 T cells into 
helper Th2 cells (IL4) [269], one proinflammatory (TNFα) [270], and one 
immunosuppressive (IL10) [271] as example of cytokines involved in the regulation 
of inflammatory responses in different conditions.  
4.5.1 Modulation of BST2 expression on PBMC by pro- and anti-
inflammatory cytokines  
In order to test whether BST2 expression may be regulated by signals implicated in 
inflammatory responses, PBMC isolated from 6 independent LRSCs were pre-
incubated for two hours with, or without (none), one of the following cytokines: IFNγ 
(1000 U/ml), IL4 (1000 U/ml), IL10 (10 ng/ml) or TNFα (10 ng/ml). After two hours, 
PBMC were stimulated or not (CTR) with TLR9L (0.75µM final concentration). After 
overnight incubation the frequency of BST2+ cells and BST2 MFI in the different 
cell subsets were evaluated by flow cytometry (Figure 4.18). In the absence of 
TLR9L stimulation we observed significant changes in the frequency of BST2+ 
cells only in the pDC subset. In particular, the frequency of BST2+ pDC 
significantly increased, from a median of 29% (CTR) to median of 62% and 57% in 
presence of IFNγ and TNFα respectively.(p=0.028 for IFNγ and p=0.027 for TNFα, 
Wilcoxon sign rank test; Figure 4.18A). However, these increases were overcome 
by TLR9L stimulation (Figure 4.18A). Indeed, in all the cell types analysed (pDC, 
mDC, monocytes, B and T cells), no significant differences in the frequency of 
BST2+ cells was observed in TLR9L-stimulated PBMC subsets in presence or 
absence (white bars) of different cytokines (Figure 4.18A showing the frequency of 
BST2+ pDC after TLR9L stimulation as a representative example). Nevertheless, 
analysing the MFI of anti-BST2 Ab staining, we noticed significant alterations in the 
number of BST2 proteins per-cell in some of the cell populations that were pre-
incubated with cytokines. In detail, pre-treatment with IL4 significantly reduced the 
TLR9L-induced upregulation of BST2 in mDC by approximately 20% (p=0.028; 
Wilcoxon sign rank test; Figure 4.18B). A similar trend was observed in monocytes, 
in which pre-incubation with IFNγ, IL4 and TNFα significantly reduced the TLR9L-
induced upregulation of BST2 by approximately 50%, 40% and 10% respectively 
(in all p=0.028; Wilcoxon sign rank test ; Figure 4.18B).Surprisingly, pre-incubation 
with IL-10 further enhanced TLR9L-mediated BST2 upregulation on monocytes 
(Figure 4.18B). In all the other considered cell types (pDC, B and T cells), pre-
treatment with any of the cytokines tested did not affect BST2 MFI on TLR9L-
stimulated PBMC subsets (Figure 4.18B). 
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These data suggest that, even though TLR9-stimulated IFN-I remains the most 
potent inducer of BST2 on PBMC, expression of this surface molecule is partially 
modulated by pro- and anti-inflammatory mediators. 
 
 
Figure 4.18 Effects of different cytokines on BST2 expression.  
A) Frequency of BST2+ pDC, among total PBMC, cultured overnight in the 
presence or absence (CTR) of TLR9L and pre-treated or not, for 2 hours before 
TLR9L stimulation, with IFNγ (purple bars), IL-4 (orange bars), IL-10 (green bars) 
or TNFα (blue bars); medians and IQRs of experiments from N=6 independent 
donors are shown; Whiskers denote: 10
th
 to 90
th
 percentiles      *P<0.05 (Wilcoxon 
sign rank test).  B) Fold  changes  in TLR9L-stimulated BST2-PE MFI, induced by 
pre-treatment with IFNγ (purple bars), IL-4 (orange bars), IL-10 (green bars) or 
TNFα (blue bars)  in different PBMC cell populations (pDC, mDC, monocytes, B 
and T cells); data were normalized against TLR9L-stimulated PBMC (in absence of 
cytokines), indicated by the black dashed line; medians and IQRs of experiments 
from N=6 independent donors are shown; Whiskers denote: 10
th
 to 90
th
 percentiles  
*P<0.05 compared to TLR9L-treated PBMC with no cytokines (Wilcoxon sign rank 
test). 
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4.5.2 Inflammatory mediators affect IFNα production but not through 
the BST2/ILT7 pathway 
Since BST2 MFI on monocytes was higher when cells were pre-treated with IL-10 
before TLR9L stimulation compared to TLR9L stimulation alone (Figure 4.18B), we 
questioned whether ILT7/BST2-mediated suppression of IFNα would be favoured 
in presence of IL-10. Consequently, we tested IFNα production in the supernatants 
of the cell cultures described in section 4.5.1; i.e. PBMC isolated from N=6 
independent LRSCs, pre-treated or not with IFNγ, TNFα, IL4 and IL10 and cultured 
overnight in presence or absence of TLR9L. In addition, the same cultures were all 
conducted with PBMC pre-incubated (30 min before TLR9L stimulation) or not with 
the αBST2 Ab (5 µg/ml final concentration) or isotype control antibody (5 µg/ml 
final concentration). At the end of the incubation we measured the levels of IFNα in 
culture supernatants by ELISA (Figure 4.19). As shown in Figure 4.19A, no IFNα 
production was observed in the absence of TLR9L stimulation (below the detection 
threshold of the ELISA kit).  Conversely, stimulation with TLR9L induced 
statistically significant IFNα production in both untreated and cytokines-pre-treated 
PBMC (in all p=0.028 Wilcoxon sign rank test; Figure 4.19A). Interestingly, IFNα 
production in response to TLR9L was significantly lower when PBMC were pre-
treated with IL-10 and TNFα (reduction of approximately 70% and 20% 
respectively, for both p=0.028 Wilcoxon sign rank test) compared to cells that were 
stimulated with TLR9L only (Figure 4.19A and 4.19B). However the inhibitory 
effects of IL10 and TNFα did not appear to be mediated by BST2-ILT7 interaction 
as the levels of IFNα were not restored in presence of αBST2 Ab (Figure 4.19A 
and 4.19B). In detail, no significant differences in IFNα production were observed 
when IL-10 pre-treated PBMC were stimulated with TLR9 alone or pre-incubated 
with αBST2 Ab or the isotype control Ab (Figure 4.19B). Instead, pre-incubation 
with αBST2 Ab and TNFα significantly reduced the levels of IFNα when compared 
to the cells simulated with TLR9L and TNFα only (p=0.028 Wilcoxon sign rank 
test). This effect appeared not to be BST2 specific, because, a similar trend was 
observed in the presence of the isotype control Ab, even though it did not reach 
statistical significance. 
In conclusion, these data indicate that both immunosuppressive and 
proinflammatory cytokines, IL10 and TNFα respectively, exert an inhibitory effect 
on TLR9L-stimulated pDC-mediated IFNα production. However they act through a 
mechanism that is not related to the pathway mediated by BST2 and ILT7. 
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Figure 4.19 Effects of different cytokines on pDC-mediated IFNα production 
A) IFNα ELISA measurement in supernatants from PBMC cultured overnight with 
or without (CTR) TLR9L and pre-treated or not (2 hours before TLR9L stimulation) 
with IFNγ (purple bars), IL-4 (orange bars), IL-10 (green bars) or TNFα (blue bars); 
cells were pre-incubated (30 min before TLR9L stimulation) or not with the BST2-
specific blocking Ab 26F8; B) IFNα levels in supernatants from the same PBMC 
cultured overnight in the presence of TLR9L, and pre-treated or not (white 
bars)with IL-10 (green bars) or TNFα (blue bars), in the presence or absence of  
BST2-specific blocking Ab 26F8 (bars with squares) or Isotype antibody control 
(bars with diagonal lines).In A) and B) Medians and IQRs of experiments from N=6 
different LRSCs are shown; Whiskers denote: 10
th
 to 90
th
 percentiles. In A) *P<0.05 
compared to unstimulated control (CTR) for each cytokine pre-treatment; in B) 
*(blue) P<0.05 compared to TLR9L-stimulated with no cytokine pre-treatment. 
*(red) P<0.05 compared to TLR9L-stimulated with cytokine pre-treatment. 
(Wilcoxon sign rank test). 
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4.5.3 Summary and discussion 
All the data collected and presented in the previous Results sections indicated that 
BST2 may not be involved in the suppression of pDC activation. However it 
remains plausible that secondary signals may be necessary to induce the inhibition 
of pDC activation by BST2/ILT7. In Section 4.4.1, we showed that other IFNα 
independent signals may affect BST2 expression on T cells. Therefore, we tested 
whether inflammatory mediators, involved in the modulation of innate immune 
responses, may provide the secondary signals required for the BST2-mediated 
inhibition of pDC activation. In particular, we selected four cytokines involved in 
different aspects of immune regulation: IL4, a cytokine involved in the 
differentiation and function of CD4+ Th2 cells [269]; IFNγ, produced by NK cells, 
Th1 cells and CD8 cytotoxic T lymphocytes and involved in the immune response 
against viruses and intracellular pathogens [268]; TNFα, a pro-inflammatory 
cytokine which is produced by macrophages, CD4 T cells and NK cells and 
stimulates the acute phase reaction [270]; and IL10, a cytokine mainly produced by 
monocytes and lymphocytes, with pleitropic effects in the immune response but 
known especially for its immunosuppressive properties [271].  We found that BST2 
expression following TLR9L stimulation was partially modulated by the above 
cytokines in some cell subsets. In particular, IL10 enhanced the number of BST2 
molecules per cell in TLR9L-stimulated monocytes. Nonetheless, IFNα produced 
by activated pDC remained the main inducer of BST2 expression on PBMC. 
Moreover, IL10 suppressed IFNα production induced by TLR9L in activated pDC. 
The anti-inflammatory properties of IL10, combined with its ability to increase BST2 
expression on monocytes and suppress IFNα production suggested that the 
BST2/ILT7 pathway might have been involved in the modulation of IFNα 
production. However, the blocking of BST2 using the BST2-specific Ab (clone 
26F8) did not revert the inhibitory effect on IFNα responses mediated by IL10. 
Therefore, it is likely that IL10 inhibits IFNα production through a mechanism that is 
independent of the BST2/ILT7–mediated pathway. TNFα also caused a reduction 
in TLR9L-induced IFNα responses, albeit to a lower degree than what observed for 
IL10. However, different from IL10, TNFα caused a mild reduction in the 
expression of BST2 on monocytes. These data suggest that BST2 is not involved 
in the negative regulation of pDC activation by TNFα, as confirmed by the fact that 
the blocking of BST2 did not affect the TNFα-mediated reduction of IFNα 
production. Finally the inability of BST2 to suppress pDC activation was confirmed 
by the fact that while IFNγ reduced TLR9L-induced BST2 on mDC, and IL4 
reduced BST2 on both mDC and monocytes, none of these cytokines was able to 
inhibit TLR9L-induced production of IFNα.  
In conclusion, our data indicate that even in presence of cytokines which regulate 
immune responses and modulate BST2 expression on PBMC, BST2 was not 
involved in the suppression of pDC activation and IFNα production. These data are 
in clear contrast with the findings reported by Cao and colleagues [234]. 
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5 CONCLUSIONS 
Our data confirmed that ILT7 is exclusively expressed by pDC, among freshly 
isolated PBMC. However, it is rapidly downregulated upon in vitro culture as part of 
the differentiation process of pDC, independently of stimulation with AT-2 HIV or 
TLR7/9L. Indeed, the downregulation of ILT7 coincided with increased 
morphological complexity and upregulation of the homing marker CCR7 in cultured 
pDC; even though their full activation and maturation, epitomized by increased 
CD83 expression, only occurred following TLR stimulation. Thus the differentiation 
of freshly isolated pDC in vitro may be defined as a two step process: a first 
spontaneous step characterized by ILT7 downmodulation, changes in the 
morphology and partial acquisition of lymph node homing properties, leading to the 
generation of immature pDC; and a second step, triggered by TLR7/9 stimulation, 
which promotes full maturation and IFN-α production. 
BST2 expression is not affected by in vitro culture. It is expressed, at different 
degrees, on the surface of all PBMC subsets analyzed and it is mainly modulated 
by TLR7/9-mediate IFNα production. In pDC, BST2 expression peaks at 
intermediate stimuli concentrations but is modestly increased at maximum 
concentrations, following the same profile of CD83 expression and IFNα 
production. This suggests that overstimulation of pDC may result in 
hyporesponsiveness, which we initially hypothesized may be at least in part due to 
BST2-mediated ILT7 cross-linking. Following stimulation with higher HIV doses, 
instead, IDO activity still increased suggesting the involvement of a different 
pathway of modulation or the dysregulation of IDO at high doses of HIV.   
Our data argue against the role of the ILT7/BST2-mediated pathway in the 
negative regulation of activated pDC. On one side we were able to inhibit TLR9L- 
and HIV-induced IFNα production as well as HIV-induced IDO activity by pre-
treating PBMC with an ILT7 cross-linking antibody (17G10.2). On the other side, 
however, we were unable to increase either IFNα production or IDO activity by 
blocking BST2 in the same cell cultures with the αBST2 Ab (clone 26F8). We 
considered and tested different hypotheses for the lack of biological effect of BST2. 
We first discarded the possibility that our negative results were due to poor 
efficiency of αBST2 Ab binding. We verified and confirmed the antibody-binding 
efficiency using PE-labelled 26F8 αBST2 Ab to stain BST2-transfected HEK 293T 
cell lines. In the same experimental setting, we demonstrated that the αBST2 Ab 
binds the extracellular coiled-coil region of the BST2 (the region likely involved in 
the interaction with ILT7). Moreover, when we optimized ILT7-BST2 interactions 
using either a soluble BST2 protein or a co-culture system based on purified pDC 
and BST2
WT
 transfected HEK 293T cells, we were unable to produce any change 
in IFNα production. These results argue against the possibility that the observed 
lack of BST2-mediated regulation of pDC is due to poor or inefficient BST2-ILT7 
interaction in vitro.  
Thus, our data indicated that BST2 is not sufficient to suppress of pDC activation. 
Therefore, we investigated the possibility that complementary signals may be 
involved in the regulation of BST2 expression and activity. During a viral infection, 
pDC may act both as IFN-producing cells and as antigen-presenting cells. When 
antigen specific -T cells come in contact with activated pDC, they may upregulate 
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BST2 following TCR engagement and IFNα signalling, thus suppressing pDC 
activation thought ILT7 interaction. We showed that direct TCR engagement in 
addition to TLR9L-mediated IFNα production, is required to achieve maximum 
BST2 expression on T cells. However, even when BST2 was expressed at high 
levels on T cells, we were unable to enhance IFNα responses using the BST2-
blocking antibody in a mixed leukocyte culture. 
Similarly, we showed that BST2 did not exert negative regulation of pDC activation 
even in the presence of second signals provided by cytokines involved in the 
regulation of innate and adaptive immune responses. Although BST2 expression 
was mildly modulated by IL4, IL10, IFNγ and TNFα, particularly in monocytes, we 
found that only IL10 and, albeit modestly, TNFα, inhibited TLR9L-induced IFNα 
production. However, even in this case, BST2 blockade was ineffective to restore 
IFNα responses. 
We cannot exclude that the interaction between ILT7 and BST2 occurs in vivo, 
maybe in the lymph node compartments, and that this interaction may not be  
reproducible in vitro. However, in light of our finding, it is tempting to speculate that 
ILT7 cross-linking may act as a homeostatic mechanism on circulating pDC rather 
than a negative feedback for activated mature pDC. This could be particularly 
relevant for HIV pathogenesis, during which partial or incomplete pDC maturation 
is observed. Reduction of ILT7 expression as a consequence of partial or 
incomplete pDC maturation could affect BST2-ILT7 homeostasis and favour 
chronic and uncontrolled pDC activation in HIV+ patients. Thus, the exploitation of 
this regulatory system for therapeutic purposes is an intriguing possibility that 
needs to be evaluated. Biological immunotherapy is the treatment of diseases with 
antibodies specific for ligands which modulate immune responses, such as 
infliximab (anti-TFN-a Ab). This approach is showing increasing success in the 
treatment of chronic diseases such as cancers and chronic inflammatory diesease. 
Thus, antibodies promoting the cross-linking of ILT7, which reduce pDC activation, 
may be employed for immunotherapy in HIV+ patients. 
Further studies need to be conducted in order to test the effective role of BST2 in 
regulating pDC activation. It is possible that other unknown ligands may induce the 
cross-linking of ILT7. Other studies are necessary to evaluate whether the 
expression of ILT7 varies among pDC in different anatomic locations, such as 
mucosal and lymphoid tissues, and whether ILT7 cross-linking may differentially 
regulate IFN-α production and IDO activity during HIV infection. Finally, should a 
role for BST2 in cross-linking ILT7 be confirmed in other experimental systems or 
in vivo, it would be important to investigate how the ILT7/BST2 homeostasis may 
be altered during HIV-1 infection by testing the ability of Vpu to prevent BST2- 
mediated pDC downregulation. 
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ABSTRACT 
The immunoglobulin-like transcript (ILT) 7 is a surface molecule selectively expressed by 
human plasmacytoid dendritic cells (pDCs). ILT7 cross-linking suppresses pDC activation 
and type I interferon (IFN-I) secretion following Toll-like receptors (TLR)7/9 engagement. 
The bone marrow stromal cell antigen 2 (BST2, aka HM1.24, tetherin or CD317) is 
expressed by different cell types upon exposure to IFN-I and is a natural ligand for ILT7. 
Here we show that ILT7 expression decreased spontaneously in pDCs upon in vitro culture, 
which correlates with pDC differentiation measured as increased side scatter properties 
and CCR7 expression. TLR7/9 Ligands , as well as HIV, induced BST2 upregulation on all 
tested cell types except T cells, which required TCR stimulation to respond to TLR9L-
induced IFN-I. IFN-, IL-4, IL-10 and TNF- had only marginal effects on BST2 expression in 
blood leukocytes compared to TLR9L.  Pre-incubation with ILT7-crosslinking Ab inhibited 
IFN-I production in PBMCs treated with TLR7/9L or HIV, whereas BST2 blockade did not 
affect IFN-I responses even when BST2 upregulation was further boosted with TCR 
agonists or immunoregulatory cytokines. Our data indicate that BST2-mediated ILT7 cross-
linking may act as a homeostatic regulatory mechanism on immature circulating pDC 
precursors, rather than a negative feedback for activated mature pDCs which have 
downregulated ILT7.  
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INTRODUCTION 
Plasmacytoid dendritic cells (pDCs) are a subpopulation of blood leukocytes which play a 
key role in the innate immune response against viral infections. Blood pDCs are precursors 
of the immature pDCs which patrol tissues and mucosal area for the presence of 
pathogens, and which can mature into fully functional pDCs upon recognition of 
pathogen-associated molecular patterns (PAMPs) (1, 2). Plasmacytoid DCs express 
endosomal toll-like receptors (TLR) 7 and 9 (1, 2). TLR7 and TLR9 are respectively triggered 
by single-stranded RNA and unmethylated CpG-rich DNA, which are characteristic of most 
viral genomes (2). Thus, pDC are directly activated by the engulfed viral pathogens and 
they produce large amounts of type I interferon (IFN-I; IFN- and IFN-) in response to 
viral stimuli (1). IFN-I exert antiviral activity by inducing intracellular restriction factors 
which interfere with viral replication (3), and by promoting apoptosis of potentially 
infected cells (4). Furthermore, IFN-I contribute to shape the adaptive immune response 
by promoting maturation of other antigen-presenting cells (APCs) and favouring the 
differentiation of CD4 T cells toward a T helper type 1 (Th1) phenotype. Activated pDC also 
express high levels of the tryptophan-catabolizing enzyme indoleamine 2,3 dioxygenase 
(IDO), which exerts powerful immunoregulatory activity and plays a critical role in the 
maintenance of immune tolerance (5).  
The tight regulation of pDC responses is critical to allow the smooth transition from an 
innate immune response to an antigen (Ag)-specific T cell-mediated immune response (1, 
6). Studies conducted in murine models have shown that T cell responses to immunization 
can be enhanced if the TLR9 ligand (TLR9L) CpG oligodeoxynucleotide (ODN) is 
administered locally at the site of immunization (7); whereas Ag-specific T cell responses 
are inhibited by an IDO-dependent mechanism upon systemic administration of TLR9L in 
the same immunization setting (7). Furthermore, prolonged pDC stimulation with TLR9L or 
TLR7L had deleterious effects on lymphoid tissue architecture, lymphocyte populations 
and both cell-mediated and humoral immune responses in mice (8, 9). In humans, 
dysregulated pDC activation contributes to suppress immune responses during chronic 
pathologic conditions, such as cancer and chronic infections (10-13). In particular, during 
pathogenic HIV infection, pDC activation is thought to contribute to several aspects of 
chronic immune activation and immune exhaustion, such as T cells apoptosis, dysfunction 
and phenotypic activation (14-18); systemic diffusion of the infection via chemoattraction 
of CCR5+ CD4 T cells (19); and alteration of the Th17/regulatory T cells balance (18, 20, 
21). Additionally, in non-human primate (NHP) models of simian immunodeficiency virus 
(SIV) infection, persistent upregulation of IFN-stimulated genes (ISGs) beyond the acute 
phase is observed only in pathogenic infection of non-natural hosts (Rhesus macaques), 
and not in non-pathogenic infection of natural host NHPs (Sooty mangabeys and African 
green monkeys) (22, 23). Thus, physiologic mechanisms that limit IFN-I production may be 
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dysfunctional during HIV infection, and fail to drive the contraction of innate immune 
responses. 
The immunoglobulin-like transcript 7 (ILT7; CD85g; LILRA4) was identified as a surface 
molecule selectively expressed by pDC (24). ILT7 is expressed in association with the 
FcRI chain, and cross-linking of ILT7 results in a FcRI-transduced circuit, involving Src 
and Syk kinases and activation of ITAM signalling, which limits pDC activation following 
TLR7 or TLR9 engagement (25). The bone marrow stromal cell antigen 2 (BST2, HM1.24, 
tetherin, CD317) has been recently identified as a natural ligand for ILT7 (26). BST2 is a 
homodimeric surface protein encoded by an ISG, and its expression can be induced in 
several different cell types (27, 28). In vivo expression profiling studies have revealed that 
BST2 is expressed at different levels in specialized cells in a variety of human tissues, 
including hepatocytes, pneumocytes, plasma cells, monocytes and vascular endothelium 
(29). BST2 is also known as tetherin, due to its ability to interfere with the release of 
enveloped viruses, such as HIV-1, by binding newly formed virions (tethering action) and 
promoting their endocytosis and degradation in intracellular compartments (30, 31). In 
addition, mouse studies have shown that BST2 can be used as a target for antigen delivery 
to pDC, which can induce efficient T cell immunity after TLR stimulation (32). Engagement 
of ILT7 by BST2 has been suggested to suppress pDC activation (26). Thus, BST2 may play a 
critical role in the physiologic regulation of pDC-mediated IFN-I responses. Upon 
activation, pDCs produce high levels of IFN-I which may induce BST2 upregulation in 
surrounding cells; BST2 may then interact with ILT7-expressing pDCs causing 
downregulation of IFN-I and return to the original resting condition. 
We tested the dynamics of BST2 and ILT7 expression and regulation in primary human 
blood leukocytes and their role in modulating pDC activation. We found that ILT7 is rapidly 
downregulated in pDCs upon in vitro culture and differentiation, and that ILT7 cross-
linking inhibits IFN- production following stimulation with TLR9L or HIV. However, BST2 
blockade did not enhance IFN- responses in vitro, even when BST2 upregulation was 
induced in virtually all circulating leukocytes, raising doubts on the physiologic relevance 
of BST2/ILT7 interactions. Based on our findings we propose that ILT7 may exert its 
immunomodulatory activity only on immature circulating pDCs, therefore providing a 
basic homeostatic mechanism rather than a negative feedback control on activated pDCs. 
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METHODS 
Leukocytes isolation and culture. Leukoreduction system chambers (LRSCs) from healthy 
blood-bank donors were obtained from the North London Blood Transfusion Service. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation using Histopaque-1077 (Sigma-Aldrich, Poole, UK) and cultured at 2x10
6
 
cells/ml in RPMI 1640 (PAA Laboratories GmbH, Pasching, Austria), 10% fetal bovine 
serum (Sigma-Aldrich) and 1% Pen-Strep-Glut (Sigma-Aldrich).  
Stimulation of PBMCs with TLR ligands, HIV, cytokines and T cell receptor agonist. 
PBMCs were cultured in presence or absence of specific stimuli for different periods of 
time, depending on the experimental setting, as described in the Results section. The TLR9 
ligand (TLR9L) CpG oligodeoxyribonucleotide (ODN) type A (Invivogen, San Diego, CA, USA) 
was used at 0.75uM final concentration. The TLR7 ligand (TLR7L) R848 (Imiquimod; 
Invivogen) was used at 5ug/ml final concentration. HIV-1MN/CEMx174 was obtained from 
the AIDS and Cancer Vaccine Program (SAIC-NCI at Frederick). Inactivation of HIV-1MN with 
aldrithiol-2 (AT-2) was performed as previously described (33). AT-2 HIV (referred to as 
HIV from now on) was added to PBMC cultures at 9x10
8
 RNA copies/ml final 
concentration. IFN-, interleukin (IL)-10, tumor necrosis factor (TNF)- (all from Miltenyi 
Biotec, Surrey, UK) and IL-4 (R&D Systems, Abingdon, UK) were used at 10 ng/ml (TNF-, 
IL10) or 1000 U/ml (IFN- and IL-4) final concentrations. The CD3-specific antibody (Ab) 
HIT3a (BD biosciences, Oxford, UK) was used at 1 g/ml final concentration as mitogenic 
stimulus for T cells; the CD28-specifc antibody CD28.2 (BD biosciences) was used as 
control (1 g/ml) final concentration.  
ILT7 cross-linking and BST2 blockade. PBMCs were incubated with the cross-linking ILT7-
specific antibody 17G10.2 (eBioscence, Hatfield, UK) at 10g/ml final concentration or 
with the blocking BST2-specific antibody 26F8 (eBioscence) at 1.25g/ml or 5g/ml final 
concentration for 30 minutes before stimulation with TLR7/9L or HIV.  Blocking antibodies 
against IFN- receptor subunit 2 (IFNAR2; PBL Interferon Source, Piscataway, NJ, USA) and 
IFN- receptor subunit 1 (IFNGR1; R&D Systems) were both used at 10g/ml final 
concentration. 
IFN- and - ELISA. IFN- was quantified in culture supernatants using the human IFN- 
multi subtype ELISA kit (PBL Interferon Source) following manufacturer’s instruction. 
Tryptophan and kynurenine measurement. Tryptophan and kynurenine were detected in 
culture supernatants using high performance liquid chromatography (HPLC) (34). 
Flow cytometry. Cells were incubated for 20 min at room temperature with different 
combinations of the following anti-human antibodies: BST2 (CD317) AlexaFluor 488 clone 
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26F8, CD317 Phycoerythrin (PE) clone 26F8, CD19 Allophycyanin (APC)-eFluor 780 clone 
HIB19, ILT7 (CD85g) Peridinin Chlorophyll Protein Complex (PerCP)-Cy5.5 clone 17G10.2, 
CD3 PE-Cy7 clone UCHT1, BDCA1 (CD1c) PerCP-eFluor 710 clone L161, CD80 Fluorescein 
isothiocyanate (FITC) clone 2D10.4, CD83 PE clone HB15e, CD8 APC clone SK1, CD40 PE 
clone 5c3 all purchased from eBioscence;- CD123 PE-Cy7 clone 6H6, CD4 Pacific blue clone 
SK3, CD86 pacific blue IT2.2 purchased from Biolegend, London, UK; CD14 APC-H7 clone 
6MPφ9, CD14 APC clone 6MPφ9 purchased from BD Bioscience; BDCA3 (CD141) FITC 
clone AD5-14H12, BDCA2 (CD303) APC clone AC144 purchased from Miltenyi Biotec. Cells 
were washed twice with staining buffer (BD Bioscience) and fixed with BD cytofix buffer 
(BD Bioscience). FACS analysis was performed on a LSR-II flow cytometer using FACSDiva 
software (BD Bioscience). FlowJo software (Treestar, Ashland, OR) was used for data 
analysis. Fluorescence minus one (FMO) controls were used to establish positivity 
thresholds. 
BST2 staining of IFN--treated and BST2-transfected 293T cells. To verify the specificity 
of the 26F8 antibody for BST2, we used PE-conjugated 26F8 to stain confluent 293T cells 
which had been treated or not with recombinant IFN- (PBL Interferon Source) overnight 
and 293T cells which were stably transfected with the human wild-type bst2 gene or bst2 
bearing the following mutations: a) L123P, disrupted in the third heptad repeat in the 
extracellular coiled; b) ΔGPI, mutated in the extracellular anchor; c) 3CA, lacking the 
dimerization site; and d) Y6,8A and 10-12A, both mutated in the intracellular region. Cells 
were cultured in 24 well cell culture clusters until confluence in DMEM high glucose (PAA), 
10% fetal bovine serum (Sigma-Aldrich) and 1% Pen-Strep (Sigma-Aldrich). Transfected 
cells were maintained by adding  Hygromycin B (invitrogen, Paisley, UK) diluited 1:500 in 
media. Confluent cells were treated with trypsin (Invitrogen) and washed twice. Staining 
and flow cytometry analysis were performed as described above. 
Statistical analysis. Statistical analyses were performed using SPSS 19.0 software (SPSS 
Inc., Chicago, IL, USA). Pairwise comparisons between control and stimulated cells were 
performed using non-parametric Wilcoxon sign rank test. Changes in measured 
parameters over time in kinetic experiments were analyzed using Friedman’s two-way 
analysis of variance (ANOVA) by ranks, and pairwise comparisons were subjected to 
Dunn’s post-hoc correction for multiple analyses. P values lower than 0.05 were 
considered statistically significant. 
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RESULTS 
ILT7 expression is limited to pDCs and is downregulated during in vitro culture. As 
expected, overnight culture resulted in partial loss of pDCs (Supplemental Fig. 1A), and 
reduction of BDCA2 expression (Supplemental Fig. 1A).  Expression of ILT7 has been 
reported to be strictly limited to pDCs (24). Our analysis of freshly isolated primary PBMCs 
from healthy donors confirmed the selective expression of ILT7 by pDCs (Fig. 1A and 1B). 
ILT7 expression decreased progressively during in vitro culture, following a linear profile 
during the first six hours of culture (R
2
=0.9625; Fig. 1C), and was dramatically reduced 
after overnight culture (Fig. 1D). The decrease in ILT7 was observed both when the 
frequency of ILT7+ pDCs (Fig. 1C and 1D) and ILT7 MFI (Supplemental Fig. 1B and 1C) were 
considered. ILT7 downregulation appeared to be due to a generalized decrease of surface 
expression on all pDCs, rather than the selective reduction in one subpopulation of pDCs 
(Supplemental Fig. 1B). Stimulation with TLR9L or HIV did not prevent ILT7 
downregulation, despite promoting pDC activation as measured by upregulation of the 
activation marker CD83 (Fig. 1D). 
ILT7 downregulation is associated with morphologic and phenotypic changes consistent 
with differentiation of blood pDC precursors. In vitro culture results in spontaneous 
differentiation of pDC precursors into immature pDCs, which can be activated in presence 
of adequate stimulation. We tested whether ILT7 downregulation was associated with 
changes in the morphology and surface molecule expression pattern of pDCs. The 
reduction in ILT7 expression was associated with an increase in side scatter properties 
(SSC) of pDCs after overnight culture of unsorted PBMCs (Fig. 2A and 2B), indicating 
augmented intracellular complexity, granularity and dendritic morphology. TLR7L 
appeared to induce a more rapid downregulation of ILT7 which was expressed at 
significantly lower levels compare to untreated and TLR9L- and HIV-treated cells after 6 
hours culture. Conversely, TLR9L and HIV, but not TLR7L, induced a more rapid increase in 
SSC compared to media alone, as indicated by significantly higher SSC after 6 hours 
culture.  The change in pDC morphology occurred independent of whether PBMCs were 
cultured in media only or with TLR7/9L or HIV (Fig. 2A and 2B). Furthermore, expression of 
the chemokine receptor CCR7, associated with homing to secondary lymphoid tissues such 
as lymph nodes, spontaneously increased in pDCs during in vitro culture (Fig. 2B) in media 
alone, and was further enhanced when PBMCs were cultured in presence of TLR7/9L or 
HIV (Fig. 2B). Conversely, a mild increase in the expression of the pDC activation marker 
CD83 was observed only transiently at 6 hours culture in unstimulated PBMCs, whereas it 
was higher and persistent in pDCs from TLR7/9L- or HIV-treated PBMCs (Fig. 2A and 2B). 
ILT7 downregulation was also associated with increased expression of the costimulatory 
molecules CD40, CD80 and CD86 in pDCs after overnight incubation with TLR9L, but not in 
media alone (Supplemental Fig. 1D and 1E). 
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These data collectively suggest that ILT7 downregulation is associated with a process of 
pDC differentiation, characterized by increased morphological complexity and CCR7 
expression, but not with activation and full maturation, epitomized by increased 
expression of the activation marker CD83 and costimulatory molecules (CD80, CD86 and 
CD40), which occurred only following TLR stimulation. 
BST2 expression is upregulated following PBMC incubation with TLR7/9L, but is not 
sufficient to suppress IFN- production via ILT7 cross-linking. We tested the expression 
of BST2 on freshly isolated PBMCs and on leukocytes cultured overnight in presence or 
absence of TLR7/9L or HIV. TLR9L, TLR7L and HIV directly activate pDC and induce IFN- 
production, which is a known inducer of BST2 (28). Among freshly isolated PBMCs, only 
monocytes (CD14+) expressed constitutively high levels of BST2, intermediate levels were 
observed in mDCs and B cells, whereas a minor portion of pDCs and T cells tested positive 
for BST2 (Fig. 3A and Supplemental Fig. 2A). In vitro overnight culture of PBMCs with 
TLR7L, TLR9L or HIV induced different degrees of BST2 upregulation depending on the cell 
types analyzed (Fig. 3B and Supplemental Fig. 2B). Thus, pDCs became highly positive for 
BST2 when PBMCs were cultured with TLR7L, TLR9L or HIV (Fig. 3B and Supplemental Fig. 
2B). Myeloid DC showed a reduction of BST2 expression after overnight culture in the 
absence of stimuli (p=0.0001; compare Fig. 3A and 3B), but treatment of PBMCs with 
TLR7/9L or HIV resulted in a significant upregulation of BST2 on mDCs compared to 
untreated control (Fig. 3B and Supplemental Fig. 2B). B cells partially upregulated BST2 
when PBMCs were treated with either TLR7/9L or HIV (Fig. 3B and Supplemental Fig. 2B). T 
cells showed minor alterations of BST2 expression, which tested significant only after 
stimulation with TLR7L or HIV (Fig. 3B and Supplemental Fig. 2B). Because the frequency 
of BST2+ monocytes approached 100% even in the absence of stimulation (Fig. 3A, 3B and 
Supplemental Fig. 2A, 2B), we investigated whether BST2 expression was upregulated on 
monocytes on a per-cell basis by analyzing the mean fluorescence intensity (MFI) of anti-
BST2 Ab staining. BST2 expression was increased in monocytes following PBMCs 
treatment with TLR7/9L or HIV (Fig. 3C and Supplemental Fig. 2B). As expected, BST2 
upregulation was inhibited on all cell types when the subunit 2 of the IFN- receptor 
(IFNAR2) was blocked by pre-incubation of PBMCs with 5g/ml anti-IFNAR2 Ab for 30min 
before stimulation with TLR7/9L or HIV (data not shown). These data are consistent with 
the regulation of BST2 expression by IFN-I produced by TLR7/9-stimulated pDC,  and 
corroborate the findings by Homann et al. and Bego et al. showing BST2 regulation by TLR 
agonists and IRF7, respectively (35, 36). 
We tested the effect of one ILT7-specific (17G10.2) and one BST2-specific Ab (26F8) on 
TLR9L-induced IFN- production in PBMCs. Clone 17G10.2 has been used in plate-bound 
form to cross-link ILT7 and suppress pDC activation (25), whereas 26F8 was reported to 
block BST2-ILT7 interaction (26). Based on the observed upregulation of BST2 on different 
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cell types upon exposure of PBMCs to TLR7/9L and HIV, we expected 26F8 to increase IFN-
 responses by inhibiting BST2-ILT7 interactions. Stimulation with TLR9L, TLR7L and HIV 
induced statistically significant increases in IFN- measured in culture supernatants after 
overnight culture (Fig. 3D). Pre-incubation (30 minutes before stimulation) with the ILT7-
cross-linking Ab 17G10.2 significantly inhibited TLR9L- and HIV-induced IFN- production, 
but did not affect the already low levels of TLR7L-induced IFN-. Conversely, the BST2-
blocking Ab 26F8 had no detectable effect on IFN- production (Fig. 3D). The inhibitory 
effect of 17G10.2 was detectable already 6 hours after stimulation of PBMCs with TLR9L, 
whereas 26F8 did not show any effect on TLR9L-induced IFN- production at any of the 
time points considered (Fig. 3E). 26F8 and 17G10.2 are both mouse IgG1 isotype, and no 
effect was observed when isotype control antibodies were used (data not shown). 
Because pDC activation leads to upregulation of the immunosuppressive enzyme 
indoleamine 2,3 dioxygenase (IDO) and increased catabolism of the essential amino acid 
tryptophan (Trp) into the kynurenine (Kyn) pathways (5, 12, 20), we tested whether ILT7 
cross-linking or BST2 blockade influenced TLR7/9L- and HIV-induced IDO activity. The ratio 
between Kyn and Trp (Kyn:Trp), a well accepted marker of IDO activity (34), was measured 
by HPLC in culture supernatants. Similar to IFN-, TLR9L, TLR7L and HIV all induced 
statistically significant increases in Kyn:Trp (Fig. 3F). Interestingly, cross-linking of ILT7 by 
pre-incubation with 17G10.2 did not reduce TLR9/7L-induced Kyn:Trp, but resulted in a 
statistically significant inhibition of HIV-induced IDO activity. 
No effect on IFN- production or IDO activity was observed after pre-incubation with 26F8 
even when the antibody was used at concentrations up to 10g/ml. 
The complete lack of biologic effect of 26F8 prompted us to test its reactivity with the 
extracellular portion of BST2 in a controlled in vitro system. We used fluorescently-
labelled (PE) 26F8 to detect BST2 expression by flow cytometry on 293T cells which were 
transfected or not with wild-type (wt) BST2 or BST2 bearing specific mutations, as well as 
mock-transfected 293T cells which were treated with rIFN-. Efficient staining was 
observed using as little as 3g/ml 26F8-PE in rIFN--treated 293T cells and 293T cells 
transfected with wild-type BST2 (BST2
WT
), but not in mock-transfected untreated cells (Fig. 
3G). Furthermore, 26F8-PE efficiently stained 293T cells transfected with BST2
10-12A
 and 
BST2
Y6,8A
, which bear mutations in the intracellular region of BST2, as well as BST2
GPI
, 
which lacks the extracellular membrane anchor (Fig. 3G). 293T cells transfected with 
monomeric BST2
3CA
 also stained positive for 26F8-PE, albeit showing reduced staining on a 
per cell basis as measured by MFI. Finally, BST2
L123P
 mutated in the coiled-coil extracellular 
region, presumably the region responsible for ILT7 binding, showed no reactivity 
whatsoever with 26F8-PE. 
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Collectively, these data indicate that BST2 blockade does not affect pDC activation in 
unsorted PBMC cultures stimulated with either TLR7/9L or HIV, and that this 
ineffectiveness is not due to lack of reactivity of the 26F8 antibody with the extracellular 
portion of BST2. 
T cell receptor engagement enhances TLR9L-induced BST2 expression on T cells, but is 
not sufficient to suppress IFN- production via ILT7 cross-linking. To test whether BST2 
expression on T cells could be upregulated following direct TCR-dependent stimulation, 
we cultured PBMCs with stimulating anti-CD3 Ab (HIT3a) in presence or absence of TLR9L. 
When used alone, TLR9L and HIT3a induced a limited increase in BST2 expression on CD4 
and CD8 T cells, which tested statistically significant only for CD4 T cells (Fig. 4A). 
Interestingly, when TLR9L and HIT3a were used together, we observed a significant 
upregulation of BST2 expression by both CD4 and CD8 T cells, indicating a synergistic 
effect of TCR stimulation and TLR7/9L-induced IFN-I signalling (Fig. 4A). Activating Ab 
specific for CD28 (CD28.2), used as control, did not synergize with TLR9L. 
We investigated the mechanism responsible for the synergy between HIT3a and TLR9L. 
We first tested whether PBMC stimulation with HIT3a increased the expression of IFNAR2 
on T cells, and found no increase in the receptor’s expression following TCR stimulation 
(data not shown). Because TCR stimulation activates cytokine production by T cells, we 
tested whether the combination of IFN- and IFN- contributed to the upregulation of 
BST2 observed on T cells in presence of HIT3a and TLR9L. Preincubation (30min before 
stimulation) of PBMCs with anti-IFNAR2 partially prevented TLR9L-induced BST2 
upregulation on both CD4 and CD8 T cells, whereas anti-IFNGR1 interfered with the 
modest increase in BST2 induced by HIT3a alone (Fig. 4B). When used separately, both 
anti-IFNAR2 and anti-IFNGR1 partially inhibited BST2 upregulation on T cells in PBMCs 
simultaneously stimulated with TLR9L and HIT3a, and a more potent inhibition was 
observed when the two antibodies were used together (Fig. 4B). These data suggest that 
both IFN- and IFN- participate to BST2 upregulation on TCR-stimulated T cells in 
presence of TLR9L, but do not exclude the contribution of other immune mediators.  
Because incubation of PBMCs with TLR9L and TCR-activating HIT3a antibodies induced 
high BST2 expression on T cells (Fig. 4C), we tested whether TLR9L-induced IFN- 
production may be inhibited in these conditions. PBMCs were cultured overnight with 
different combinations of HIT3a, TLR9L and 26F8 (CD28.2 was used as a control for HIT3a), 
and IFN- was measured in culture supernatants by ELISA. No reduction of TLR9L-induced 
IFN- was observed in any condition analyzed (Fig. 4C), suggesting that even under 
conditions of maximum BST2 expression, T lymphocytes do not downregulate pDC 
activation by engaging ILT7. 
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IL-10 downregulates IFN- production in response to TLR9L in a BST2/ILT7-independent 
manner. We investigated the effect of a panel of cytokines on BST2 expression on 
different cell types and their effect on TLR9L-induced BST upregulation. We chose IFN-, 
IL-4, IL-10 and TNF- as examples of Th1, Th2, immunosuppressive and proinflammatory 
cytokines, respectively. PBMCs from healthy donors were incubated with each cytokine 
and cultured overnight; TLR9L was added 2 hours after the cytokine. Incubation with IFN- 
or TNF- induced a statistically significant increase in BST2+ pDC even in the absence of 
TLR9L (Fig. 5A). IFN- induced a modest, yet significant increase in BST2+ T cells even in 
the absence of TLR9L (control median 0.7%, IQR 0.5%-1.2% vs. IFN- median 1.1%, IQR 
0.8%-2.2%; P=0.027). No significant increase in BST2 expression was observed in other cell 
types after incubation of PBMCs with any cytokine in the absence of TLR9L (data not 
shown). Pre-incubation with IL-4 reduced TLR9L-induced upregulation of BST2 in mDC of 
approximately 20% (Fig. 5B). Significant reductions of TLR9L-induced upregulation of BST2 
were also observed in monocytes after incubation with IFN-, IL-4 and TNF- 
(approximately 50%, 40% and 10%, respectively; Fig. 5B). Unexpectedly, pre-incubation 
with IL-10 further enhanced the positive effect of TLR9L on BST2 upregulation on 
monocytes (Fig. 5B). Pre-incubation of PBMCs with any of the cytokines tested did not 
affect BST2 upregulation in other cell types after stimulation of PBMCs with TLR9L (Fig. 
5B).  
Because we observed an enhancement of TLR9L-mediated BST2 upregulation in 
monocytes after pre-treatment with IL-10, we tested whether BST2/ILT7-mediated 
suppression of IFN- production would be favoured in presence of IL-10. Stimulation with 
TLR9L induced statistically significant IFN- production in untreated PBMCs or PBMCs 
which were pre-treated with IFN-, IL-4 or TNF-, but not IL-10 (Fig. 5C). In addition, IFN- 
production in response to TLR9L was significantly lower in cells pre-treated with IL-10 or 
TNF- compared to untreated cells, but the defects were not corrected by pre-incubation 
with 26F8 (Fig. 5C). These data indicated that both the immunosuppressive cytokine IL-10 
and the proinflammatory TNF- exert inhibitory activity on IFN- production by TLR9L-
stimulated pDC, but this inhibitory activity is not mediated by BST2-ILT7 interaction. 
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DISCUSSION 
The critical function played by pDCs in the early phases of antiviral immune responses 
bears the risk of an excessive and uncontrolled activation of IFN-I and IDO, and 
subsequent immune dysregulation. Persistent pDC overactivation has been shown to have 
deleterious effects on the immune function in murine models (8, 9), and is thought to be a 
key contributor to the immunopathogenesis of HIV infection (11). ILT7 is a pDC-specific 
surface receptor which, when cross-linked, exerts potent inhibitory activity on pDC 
activation (25). The only known natural ligand for ILT7 is the IFN-I-regulated surface 
protein BST2, better known for its ability to prevent the release of HIV particles from 
infected cells, which is counteracted by the HIV-1 accessory protein Vpu (26, 31). It has 
been hypothesized that, upon production of IFN-I by pDCs, surrounding cells may 
upregulate BST2 which may in turn suppress pDC activation by cross-linking ILT7, providing 
the negative feedback necessary to prevent potentially deleterious pDC overactivation 
(26, 27). 
Our data collectively argue against a role for BST2 in regulating pDC activity, particularly 
IFN- production. Thus, we were unable to enhance pDC responses by blocking BST2 using 
the 26F8 antibody. This same antibody has been used to successfully inhibit BST2/ILT7 
interactions in other experimental settings, such as ILT7-reporter systems (26), but not in 
unsorted human PBMCs, which represent a more physiologically relevant setting. 
Conversely, our data indicate that pre-incubation with the ILT7 cross-linking antibody 
17G10.2 exerted inhibitory activity on TLR9L- and HIV-induced IFN- production, as well as 
HIV-induced IDO activity. One possible explanation for the lack of biologic effect of 26F8 
may be the incomplete blocking of BST2. However, in BST2-transfected HEK 293T cell 
lines, fluorescently-labelled 26F8 stained 96% of cells, indicating efficient binding to the 
vast majority of expressed protein. Furthermore, by using HEK 293T cells transfected with 
a panel of BST2 mutants, we confirmed that 26F8 binds to the extracellular coiled-coil 
region of the molecule, which is likely the region of interaction with ILT7.  
An alternative explanation for the inability of 26F8 to enhance IFN- responses is that 
BST2 expression levels in PBMCs are insufficient to cause ILT7 cross-linking. Ligand-
receptor interaction involving pDCs are more likely to occur either in trans with T cells or 
in cis within the pDC itself, rather than with other APCs. However, we found that only 
monocytes, among freshly isolated PBMCs, express constitutively high levels of BST2. 
Upon stimulation of IFN- production with TLR7/9L or HIV, all cell types analyzed, showed 
upregulation of BST2 to high levels, with the exception of T cells. Conversely, T cells 
required direct TCR engagement and subsequent IFN- production in addition to TLR9L-
induced IFN- to achieve maximum BST2 expression. However, even in conditions in 
which BST2 expression was induced in virtually all major cell types, we were unable to 
enhance IFN- responses using the BST2-blocking antibody 26F8.  
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Because innate immune responses may be modulated by secreted cytokines present in 
the environment, we tested whether BST2-mediated inhibition of pDC activation may rely 
on secondary signals provided by proinflammatory or immunoregulatory cytokines. We 
found that only IL-10 and, to a much lesser extent, TNF- exerted inhibitory activity on 
TLR9L-induced IFN- production. This effect was consistent with both the well known anti-
inflammatory activity of IL-10 (37-39), and with our surprising observation that IL-10 
enhanced TLR9L-induced upregulation of BST2 on monocytes. However, BST2 blockade 
with 26F8 was ineffective at either improving or fully restoring IL-10-inhibited IFN- 
responses. The lack of BST2-mediated pDC regulation in this setting is also supported by 
the fact that IFN- inhibited BST2 expression on monocytes, whereas IL-4 inhibited BST2 
expression on both monocytes and mDC. However, neither IFN- nor IL-4 affected TLR9L-
induced IFN- production. Finally, TNF- inhibited IFN- production, albeit very mildly, 
despite causing a slight reduction in BST2 expression in monocytes. 
We cannot exclude that ILT7/BST2 interactions occur in vivo, possibly in lymphoid tissues, 
and that such interactions are simply not reproducible in culture in vitro. However, our 
data showed that ILT7, albeit exclusively expressed by pDCs among freshly isolated 
PBMCs, is rapidly downregulated upon in vitro culture, independently of stimulation with 
HIV or TLR7/9L. Our results only partially resemble the decrease in ILT7 expression 
observed by Cao et al., who described a slow reduction in ILT7 MFI in human pDCs, even in 
presence of IL-3 or TLR9L, but retention of a large population of ILT7+ pDCs after up to 72 
hours of in vitro culture (25). Conversely, we found that ILT7 downregulation is extremely 
rapid, and results in a pDC population which is homogeneously negative for ILT7, 
independent of whether pDC were activated or not. The reasons for this discrepancy 
remain unclear. However, our data suggest that ILT7 downregulation is not a consequence 
of pDC activation, but rather a spontaneous change occurring during blood pDC 
differentiation. Thus, circulating blood pDCs are in an immature state and have the 
potential to differentiate into the mature pDCs with full antigen-presenting function which 
can be found in lymphoid tissues (40, 41). When cultured in vitro, freshly isolated blood 
pDCs differentiate into immature pDCs, which can then mature into fully competent APCs 
in response to adequate stimulation (1, 2, 40, 41). Furthermore, pDCs can directly migrate 
from blood to inflamed lymph nodes through high endothelial venules (42). The observed 
downregulation of ILT7 appears to be part of the blood pDCs differentiation process and 
was indeed accompanied by an increase in the cellular morphological complexity, 
epitomized by augmented side scatter properties, and by increased expression of the 
lymph node homing marker CCR7. Conversely, expression of the activation marker CD83 
showed only a modest and transient increase after 6 hours of culture in media alone, and 
returned to the original level unless the pDC activating stimuli TLR7/9L or HIV were added 
to the culture. Thus, the differentiation of freshly isolated blood pDCs in vitro appears to 
occur in two phases: an initial spontaneous step characterized by a morphological change, 
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expression of homing receptors and ILT7 downregulation, and a second step triggered by 
TLR7/9 stimulation which promotes full maturation and IFN- production. In light of these 
findings, it is tempting to speculate that ILT7 may act as a control mechanism to prevent 
or limit the activation of immature pDCs in the peripheral blood, rather than as a negative 
feedback on mature activated pDCs.  
Benlahrech and colleagues have recently shown that ILT7 expression is reduced in pDCs 
from HIV-infected patients when viral replication is not efficiently controlled by therapy 
(43). Based on our findings, it is possible that the downregulation of ILT7 observed during 
HIV infection is symptomatic of partial or incomplete pDC differentiation due to chronic 
stimulation. Consistent with this hypothesis, Sabado and colleagues reported that pDC and 
mDC relocation to lymphoid tissues may occur already during primary HIV infection, and 
persists throughout the course of disease (44). However, reports on IFN- secretion by 
pDCs in lymphoid tissues during chronic HIV infection showed contrasting results. For 
example,  although IFN- and upregulation of ISGs has been reported in tissues from HIV+ 
patients (45, 46), Nascimbeni and colleagues showed that pDCs in the spleen of HIV-
infected patients have an immature phenotype and do not contribute to the increased 
IFN- production (47). The question may be raised as to whether ILT7 downregulation 
may contribute to chronic pDC activation during HIV infection by allowing a lower 
activation threshold or an enhanced response to chronic stimulation. 
A number of questions arise and remain to be answered. Further studies are required to 
test whether ILT7 expression varies among pDCs in different anatomic locations, including 
mucosal and lymphoid tissues. Also, the role of BST2 in regulating pDC activation via ILT7 
remains unclear, and it is possible that other unidentified ligands promote ILT7 cross-
linking on circulating pDCs. Finally, the potential contribution of the ILT7 impairment to 
chronic viral infections or inflammatory disease, as well as the exploitation of this 
regulatory system for therapeutic purposes needs to be further evaluated. 
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FIGURE LEGENDS 
Figure 1. ILT7 expression is limited to pDCs and is downregulated following in vitro 
culture. A) Flow cytometry dot-plots showing the gating strategy used to identify pDC 
(CD14- BDCA2+ CD123+), monocytes (CD14+), mDC (CD19- CD14- CD3- BDCA1/BDCA3+), B 
cells (CD14- CD3- CD19+) and T cells (CD14- CD19- CD3+). B) Flow cytometry histograms 
showing ILT7 expression on different cell populations gated as in panel A; thin lines 
indicated fluorescence minus one (FMO) controls and thick lines indicate ILT7 staining; for 
both panels A and B one example of experiments performed on N=6 independent donors 
is shown. C) Frequency of ILT7+ pDCs in function of time; each dot represents median of 
N=5 donors for a specific time point; lines indicate linear regressions of medians and IQRs; 
** P<0.01 compared to 0 hours (Friedman’s test with Dunn’s correction for multiple 
pairwise comparisons). D) Change in the frequency of ILT7+ pDCs (circles) and CD83+ pDCs 
(triangles) overtime in presence or absence of the TLR9L CpG ODN or HIV; medians and 
IQRs are shown (N=3); P values in legend indicate Friedman’s test results for changes 
overtime in each condition. 
Figure 2. ILT7 downregulation is associated with pDC precursors differentiation. A) Flow 
cytometry contour plots showing ILT7 expression in comparison to side scatter properties 
(SSC; upper panels) and CD83 expression (lower panels) of pDCs in freshly isolated PBMCs 
(black contours in all plots) and in PBMCs cultured overnight (SSC: red contours; CD83: 
blue contours) in presence or absence of TLR9L, TLR7L or HIV; one example of 
experiments performed on N=6 independent donors is shown. B) Summary graphs 
showing (from top to bottom) frequency of ILT7+ pDCs, fold change in side scatter (SSC), 
frequency of CCR7+ pDCs and frequency of CD83+ pDCs in freshly isolated PBMCs and 
PBMCs cultured in control media alone or in presence of TLR9L, TLR7L or HIV; SSC were 
normalized against measurements on fresh cells; medians and IQRs are shown (N=6); * 
P<0.05 and ** P<0.01 (Friedman’s test with Dunn’s correction for multiple pairwise 
comparisons); § P<0.05 compared to ntreated control at the same time point (Wilcoxon 
sign rank test). 
Figure 3. TLR7/9L- and HIV-mediated induction of BST2 in PBMCs and ILT7/BST2 pDC-
regulatory activity. A) Frequencies of BST2+ cells among different subsets of freshly 
isolated PBMCs, gated as in Figure 1A; medians and IQRs from at least N=5 independent 
donors are shown. B) Frequencies of BST2+ cells among different subsets of PBMCs 
cultured overnight in presence or absence of TLR9L (CpG ODN), TLR7L (R848) or HIV; 
medians and IQRs of experiments from at least N=5 independent donors are shown. C) 
BST2-PE MFI in monocytes from PBMCs cultured overnight in presence or absence of 
TLR9L, TLR7L or HIV; medians and IQRs of experiments from N=5 independent donors are 
shown. D) IFN- was measured by ELISA in culture supernatants from PBMCs cultured 
overnight in presence or absence of TLR9L, TLR7L or HIV and pre-treated or not with the 
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cross-linking ILT7-specific Ab 17G10.2 or the BST2-specific blocking Ab 26F8; medians and 
IQRs of experiments from N=11 independent donors are shown. E) Fold change in TLR9L-
induced IFN- in PBMC cultures after pre-treatment with 17G10.2 or 26F8 over time (6, 9, 
18 or 48 hours); all values were normalized against TLR9L-stimulated cells, indicated by 
the grey dashed line; medians and IQRs of experiments from N=3 independent donors are 
shown; P values indicate Friedman’s test results for changes overtime in each condition. F) 
Kyn:Trp was measured by HPLC in supernatants from PBMCs cultured overnight in 
presence or absence of TLR9L, TLR7L or HIV and pre-treated or not with the cross-linking 
ILT7-specific Ab 17G10.2 or the BST2-specific blocking Ab 26F8; medians and IQRs of 
experiments from N=11 independent donors are shown. G) HEK 293T cells were stained 
with PE-labelled 26F8 anti-BST2 antibody; leftmost panel shows forward and side scatter 
properties of 293T cells; all other panels show staining of untreated and rIFN--treated 
mock-transfect 293T, as well as 293T cells transfected with wild-type or mutated BST2; 
details of mutations are given in the text; numbers in the plots indicate % BST2+ cells 
(upper figure) and BST2-PE MFI (lower figure). In panels B, C, D and F, * P<0.05, ** P<0.01, 
*** P<0.001. 
Figure 4. Effect of TCR engagement on BST2 expression in T cells and effect on TLR9L-
induced IFN- production. A) Frequencies of BST2+ CD4 and CD8 T cells among PBMCs 
cultured overnight in presence or absence of different combinations of TLR9L, stimulating 
CD3-specific Ab (HIT3a) and stimulating CD28-specific Ab (CD28.2); medians and IQRs of 
experiments from N=6 independent donors are shown. B) Frequencies of BST2+ CD4 and 
CD8 T cells among PBMCs cultured overnight in presence or absence of TLR9L and/or 
stimulating CD3-specific Ab (HIT3a) and pre-treated or not with blocking antibodies 
against the subunit 2 of the IFN- receptor (IFNAR2) and/or against the subunit 1 of the 
IFN- receptor (IFNGR1); each symbol represents results from one independent donor 
(N=3) for both CD4 and CD8 T cells (empty and solid symbols, respectively). C) IFN- was 
measured by ELISA in supernatants from PBMCs cultured overnight in presence or 
absence of different combinations of TLR9L, HIT3a and CD28.2, pre-treated or not with the 
BST2-specific blocking Ab 26F8; medians and IQRs of experiments from N=6 independent 
donors are shown. In both panels, * P<0.05, ** P<0.01 compared to control. 
Figure 5. Effect of cytokines on BST2 expression, regulation and effect on TLR9L-induced 
IFN- production. A) Frequency of BST2+ pDC among PBMCs cultured overnight in 
presence or absence of TLR9L and pre-treated or not (2 hours before TLR9L stimulation) 
with IFN-, IL-4, IL-10 or TNF-; medians and IQRs of experiments from N=6 independent 
donors are shown; * P<0.05. B) Change in TLR9L-stimulated BST2-PE MFI induced by pre-
treatment with IFN-, IL-4, IL-10 or TNF- in different subsets of PBMCs; all results were 
normalized against TLR9L-treated PBMCs with no cytokines, indicated by grey dashed line; 
medians and IQRs of experiments from N=6 independent donors are shown; * P<0.05 
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compared to TLR9L-treated PBMCs with no cytokines. C) IFN- was measured by ELISA in 
supernatants from PBMCs cultured overnight in presence or absence of TLR9L and pre-
treated or not (2 hours before TLR9L stimulation) with IFN-, IL-4, IL-10 or TNF-; cells 
were pre-incubated (30 min before TLR9L stimulation) or not with the BST2-specific 
blocking Ab 26F8 or isotype control antibody; medians and IQRs of experiments from N=6 
independent donors are shown; dark grey dashed line and light grey shaded area indicate 
median and IQR of TLR9L-stimulated PBMCs without cytoikine pre-treatment (first data 
set on the left); * P<0.05 compared to unstimulated control (no TLR9L) for each cytokine 
pre-treatment; § P<0.05 compared to TLR9L-stimulated with no cytokine pretreatment. 
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Supplemental Figure Legends 
 
Supplemental Figure 1. Details of pDC gating strategy and ILT7 staining overtime. A) 
Flow cytometry pseudocolour dot plots showing one example of BDCA2 and CD123 
staining on CD14- cells (pDC gating strategy) among freshly isolated PBLs and PBLs 
cultured overnight (O/N) with or without TLR9L, TLR7L or HIV;rRed squares indicate pDC 
gating; numbers within plots indicate the frequency of pDCs within the total live PBLs 
(defined by SSC/FSC gating as in Fig. 1A). B) Flow cytometry histograms showing ILT7 
staining on pDCs (CD14-BDCA2+CD123+) in freshly isolated PBLs and PBLs cultured in 
media alone for 3h, 6h or 18h; one example of N=3 independent experiments is shown. C) 
Change in the MFI of ILT7 staining overtime in presence or absence of the TLR9L CpG ODN 
or HIV; medians and IQRs are shown (N=3); P values in legend indicate Friedman’s test 
results for changes overtime in each condition. D) Flow cytometry contour plots showing 
ILT7 expression in comparison to CD40 (upper panels), CD80 (middle panels) and CD86 
(lower panels) of pDCs in freshly isolated PBMCs (black contours in all plots) and in PBMCs 
cultured overnight (CD40: green contours; CD80: orange contours; CD86: purple contours) 
in presence or absence of TLR9L; one example of experiments performed on N=3 
independent donors is shown. E) Summary graphs showing (from top to bottom) 
expression of ILT7, CD40, CD80 and CD86 on pDCs, expressed both as frequency of 
positive pDCs (left panels) and MFI (right panels) in freshly isolated PBMCs (empty 
symbols) and PBMCs cultured in presence or absence of TLR9L (blue and grey symbols, 
respectively) from N=3 donors tested; each symbol represents one individual donor.   
Supplemental Figure 2. BST2 expression and regulation in PBLs. A) Flow cytometry 
histograms showing BST2 expression on different cell populations among freshly isolated 
PBLs, gated as in Figure 1A; black lines indicated fluorescence minus one (FMO) controls 
and orange lines indicate BST2 staining; one example of experiments performed on at 
least N=5 independent donors is shown. B) Flow cytometry histograms showing BST2 
expression on different cell types among PBLs cultured overnight in control media (black) 
or stimulated with TLR9L (blue), TLR7L (green) or HIV (red); grey lines indicate 
fluorescence minus one (FMO) controls; one example of experiments performed on at 
least N=5 independent donors is shown. 
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APPENDIX 3 
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Immunoglobulin like transcript (ILT) 7 is a surface molecule selectively expressed 
by human pDC. ILT7 cross-linking suppresses plasmacytoid dendritic cells (pDC) 
activation and type I interferon (IFN-I) secretion following Toll-like receptors (TLR) 
7/9 engagement. The bone marrow stromal cell antigen 2 (BST2, tetherin) is 
expressed by different cell types upon exposure to IFN-I and has been recently 
identified as a natural ligand for ILT7.  
We investigated BST2/ILT7 expression in peripheral blood leukocytes (PBL) 
following HIV- or TLR7/9 ligand (TLR7/9L)-mediated pDC activation, and tested 
whether HIV-induced pDC activation is modulated by ILT7 cross-linking. Our data 
confirmed that ILT7 expression is specific to pDC, however the frequency of ILT7-
positive pDC halved within 6 hours of in vitro culture, a kinetic which was only 
modestly modified by HIV or TLR7/9L. BST2 expression was not affected by in 
vitro culture and was highest in monocytes, myeloid DC and B cells compared to 
pDC and T cells. BST2 upregulation in response to HIV-1 and TLR7/9L was 
observed only in pDC and monocyte and peaked in pDC at intermediate stimuli 
concentration, being only modestly increased at maximum stimuli concentration. 
This upregulation profile correlated with that of CD83 on pDC and IFN-alpha 
secretion. Finally, ILT7 cross-linking using a specific Ab inhibited IFN-alpha 
production in HIV and TLR7/9L-exposed PBL.  
Our data suggests that pDC over-stimulation results in hyporesponsiveness or 
altered kinetics of pDC responses, and points at the BST2/ILT7 system as a 
regulator of pDC activation in response to HIV. 
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Background: The immunoglobulin-like transcript (ILT) 7 is a surface molecule 
selectively expressed by human plasmacytoid dendritic cells (pDC). ILT7 cross-
linking suppresses pDC activation and type I interferon (IFN-I) secretion following 
Toll-like receptors (TLR) 7/9 engagement. The bone marrow stromal cell antigen 2 
(BST2, tetherin) is expressed by different cell types upon exposure to IFN-I and is 
a natural ligand for ILT7. We investigated BST2/ILT7 expression and regulation by 
HIV or TLR7/9 ligands (TLR7/9L) in peripheral blood leukocytes (PBL). We then 
tested whether ILT7/BST2 modulates HIV-induced pDC activation. 
Methods: PBL from healthy donors were cultured with different concentrations of 
imiquimod, CpG ODN or AT-2 HIV-1MN. The effect of BST2 blockade and ILT7 
cross-linking were tested using anti-BST2 monoclonal antibodies (mAb; clones: 
26F8, RS38E) or cross linking-ILT7 mAb (clone 17G10.2). Expression of ILT7, 
BST2 and CD83 was analyzed in different cell types by flow cytometry. IFN-α 
production was quantified by ELISA. Statistical analysis was performed using non-
parametric Wilcoxon sign rank test. 
Results: Our data confirmed that ILT7 expression is specific to pDC. However the 
frequency of ILT7-positive pDC halved within 6 hours of in vitro culture. BST2 
expression was not affected by in vitro culture and was highest in monocytes, mDC 
and B cells compared to pDC and T cells. A significant upregulation of BST2 was 
observed in all cell types after culture with HIV or TLR7/9L. BST2 and CD83 
expression peaked in pDC at intermediate stimuli concentration but were only 
modestly increased at maximum stimuli concentration, which correlated with IFN-α 
production. ILT7 cross-linking inhibited IFN-α production in HIV- and TLR7/9L-
exposed PBL while BST2 blockade showed different results depending on the mAb 
used. Clone RS38E significantly reduced IFN-α secretion whilst no changes were 
observed when clone 26F8 was used. Thus, the two clones may have different 
binding sites and clone RS38E may induce clustering of BST2 resulting in cross-
linking of its receptor ILT7. 
Conclusions: Our data indicate that BST2-mediated ILT7 cross-linking negatively 
regulates pDC activation, possibly resulting in hyporesponsiveness and/or 
extensive alterations of the kinetic of pDC responses. This negative feed-back 
mechanism may be exploited to prevent HIV-induced immune-hyperactivation.  
